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Epithelial ovarian cancer (EOC) is often characterized by defects in DNA repair pathways, 
which partially explain its sensitivity to platinum compounds and to poly (ADP-ribose) 
polymerase inhibitors (PARPi). However, EOC almost invariably relapses with a drug 
resistant, incurable disease. Biomarkers able to predict the response to therapy could 
ameliorate the management of EOC patients.  
The studies herein reported aimed to elucidate the role of different DNA repair pathways as 
possible determinants of cisplatin (DDP) and olaparib (a PARPi) response in a collection of 
patient-derived xenografts (PDXs) characterized for their response to both drugs. We 
analysed the expression of 35 different DNA repair genes involved in DDP and olaparib 
response, and found CDK12, XPF, PALB2, USP28, ARTEMIS, ARID1A and MDR1 
associated with DDP response. In particular, CDK12 expression was significantly higher in 
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DDP resistant PDXs and associated with higher recurrence rate in EOC patients with low 
residual tumour. We analysed the basal level of RAD51 foci in proliferating cells of 
formalin-fixed paraffin-embedded PDX tumours, as possible readout of homologous 
recombination pathway, and found that the percentage of RAD51 foci-positive cells 
predicted olaparib, but not DDP response. 
As DDP adducts can be repaired by multiple pathways including nucleotide excision repair 
(NER) and base excision repair (BER), we studied POLB, ERCC1, XPF and ERCC1/XPF 
complex as read out of NER and BER activity, but no correlation with DDP response was 
found.  
These findings support the role of CDK12 and RAD51 foci expressed in untreated tumours 
in the response to DDP and olaparib, respectively, in our EOC PDX models and warrant the 
setup of DNA repair functional assays able to capture the complexity of factors determining 
DDP and PARPi response, that could be easily translated in the clinical practice to prioritize 




















“Considerate la vostra semenza: 
fatti non foste a viver come bruti 
ma per seguir virtute e canoscenza” 
 
“Consider well the seed that gave you birth:  
you were not made to live as brutes,  
but to follow virtue and knowledge” 
 






I have a long list of marvellous persons to thank, who helped and supported me along these 
latest four years. 
My sincere gratitude to the Istituto di Ricerche Farmacologiche Mario Negri IRCCS that 
gave me the opportunity to obtain the PhD. 
The first thank to my internal supervisor Giovanna Damia, and Massimo Broggini, Head of 
the Molecular Pharmacology Laboratory at the Mario Negri Institute, my first mentors, that 
every day along these years, gave me the passion for this incredible job.  
I would like to thank my external supervisors, Prof Simon Langdon and Dr Helen Coley, for 
their guidance, professionalism and competence demonstrated through these years.  
A special thanks to all my colleagues, especially Elisa, Francesca, Roberta and Sara, for their 
friendship, the support received in any moments, and their incredible capacity to make easier 
any difficulties, I wish all of them the brilliant future that they deserve. 
To my family, all my gratitude for having supported me in any moment and decision. 
To Vincenzo, the love of my life. 








The work described herein was performed at the Istituto di Ricerche Farmacologiche Mario 
Negri IRCCS in Milan, Italy from 2016 to 2020. 
This work was performed under the supervision of Dr Giovanna Damia (director of studies), 
and Dr Helen Coley and Dr Simon Langdon (external supervisors). 
 
DECLARATION 
This thesis has not been submitted in whole or in part for a degree or diploma or other 
qualifications to any other university. 
The experimental work described herein was performed by myself, Federica Guffanti. 
Collaborations to perform specific parts of the project (xenobank characterization, 
histopathological analyses, statistical analyses and genomic studies) are clearly indicated in 




TABLE OF CONTENTS 
ABSTRACT ....................................................................................................................... I 
AKNOWLEDGEMENTS ............................................................................................... IV 
TABLE OF CONTENTS ................................................................................................ VI 
LIST OF FIGURES AND TABLES ............................................................................... XI 
1. INTRODUCTION ....................................................................................................... 1 
1.1 OVARIAN CANCER .................................................................................................. 2 
1.1.1 Incidence and mortality rates in epithelial ovarian cancer ................................... 3 
1.1.2 Risk and preventive factors for epithelial ovarian cancer .................................... 5 
1.1.3 Pathology of ovarian carcinoma ........................................................................... 8 
1.1.3.1 Anatomy of the ovaries and Fallopian tubes ................................................. 8 
1.1.3.2 EOC: origin and pathogenesis ....................................................................... 9 
1.1.3.3 Symptoms and diagnosis ............................................................................. 20 
1.1.3.4 Classification and staging ............................................................................ 22 
1.1.3.5 Molecular profile associated with different EOC histotypes ....................... 24 
1.1.4 Management of EOC .......................................................................................... 31 
1.1.4.1 Primary treatment ........................................................................................ 31 
1.1.4.2 Treatment of relapses ................................................................................... 36 
1.1.4.3 Targeted therapies and new drugs ............................................................... 37 
1.2 DNA REPAIR ........................................................................................................... 44 
1.2.1 DNA repair and cancer ....................................................................................... 44 
1.2.2 DNA repair pathways ......................................................................................... 46 
1.2.2.1 Base excision repair ..................................................................................... 46 
1.2.2.2 Mismatch repair ........................................................................................... 48 
VII 
 
1.2.2.3 Nucleotide excision repair............................................................................ 49 
1.2.2.4 Homologous recombination ......................................................................... 52 
1.2.2.5 Non-homologous end joining ....................................................................... 54 
1.2.2.6 Fanconi anemia ............................................................................................ 56 
1.2.2.7 Translesion synthesis repair ......................................................................... 57 
1.3 MECHANISM OF ACTION OF PLATINUM AGENTS......................................... 58 
1.3.1 Cisplatin and carboplatin .................................................................................... 58 
1.3.2 Mechanism of action ........................................................................................... 59 
1.4 MECHANISM OF ACTION OF PARP INHIBITORS ............................................ 65 
1.4.1 PARP inhibitors .................................................................................................. 65 
1.4.2 Mechanism of action ........................................................................................... 66 
1.5 DETERMINANTS OF RESPONSE TO PLATINUM AGENTS AND PARP 
INHIBITORS THERAPY IN EOC ................................................................................. 71 
1.5.1 Determinants of response to platinum compounds ............................................. 72 
1.5.1.1 DNA repair as determinant for platinum-response ...................................... 72 
1.5.1.2 Determinants of response to platinum-based therapy beyond DNA repair 
pathways ................................................................................................................... 83 
1.5.2 Determinants of response to PARPi .................................................................... 88 
1.5.2.1 DNA repair as determinant of response to PARPi ....................................... 89 
1.5.2.2 Determinants of response to PARPi beyond DNA repair .......................... 100 
1.6 DNA REPAIR FUNCTIONAL ASSAYS ............................................................... 103 
1.7 PATIENT-DERIVED XENOGRAFT MODELS ................................................... 108 
2. AIMS ............................................................................................................................. 110 
3. MATERIALS AND METHODS ............................................................................ 113 
3.1 IN VIVO STUDIES ................................................................................................. 114 
VIII 
 
3.1.1 Patient specimen collection and clinical data ................................................... 114 
3.1.2 Compliance with guidelines and laws regulating animal research ................... 114 
3.1.3 Animals and establishment of patient-derived xenografts ................................ 115 
3.1.4 PDX samples storage ........................................................................................ 116 
3.1.5 Antitumour pharmacological activities............................................................. 117 
3.2 HISTOPATHOLOGICAL ANALYSIS .................................................................. 118 
3.3 MOLECULAR ANALYSES................................................................................... 119 
3.3.1 DNA extraction and purification ...................................................................... 119 
3.3.2 STR analysis ..................................................................................................... 119 
3.3.3 Mutational status analysis ................................................................................. 120 
3.3.3.1 Sanger method ........................................................................................... 120 
3.3.4 Promoter methylation status analysis ............................................................... 122 
3.3.4.1 Sodium bisulfite conversion ...................................................................... 122 
3.3.4.2 Pyrosequencing technology ....................................................................... 123 
3.3.4.3 MS-PCR ..................................................................................................... 125 
3.3.5 Gene expression analysis .................................................................................. 126 
3.3.5.1 RNA extraction and retrotranscription ...................................................... 126 
3.3.5.2 Real time-PCR reaction ............................................................................. 127 
3.3.6 HRDetect assay ................................................................................................. 131 
3.3.7 Nuclear foci immunofluorescence-based assays .............................................. 132 
3.3.7.1 IF detection of RAD51 foci on TMA ........................................................ 132 
3.3.7.2 IF detection of RAD51 foci on FFPE samples (PARPiPred test) ............. 133 
3.3.8 Immunohistochemical analysis ......................................................................... 135 
3.3.9 Proximity Ligation Assay ................................................................................. 136 
3.3.9.1 PLA on TMA (brightfield technology)...................................................... 137 
IX 
 
3.3.9.2 Cell culture conditions and in vitro treatment ............................................ 138 
3.3.9.3 PLA on A2780 DDP-treated cells (IF technology) .................................... 139 
3.4 STATISTICAL METHODS .................................................................................... 140 
4. RESULTS ................................................................................................................. 142 
4.1 THE EOC XENOBANK.......................................................................................... 143 
4.1.1 Clinical-pathological characteristics of the patient tumours from which the EOC-
PDXs derived ............................................................................................................. 146 
4.1.2 The EOC-PDXs well resemble the tumour of origin ........................................ 148 
4.1.3 Mutational profile of the EOC-PDXs ............................................................... 152 
4.1.4 Promoter methylation status .............................................................................. 155 
4.1.5 Pharmacological characterization of the EOC-PDXs ....................................... 160 
4.1.6 Discussion I ....................................................................................................... 164 
4.2 EXPRESSION OF DNA REPAIR GENES AND HR MUTATIONAL STATUS OF 
THE EOC-PDXS IN RESPONSE TO THERAPY ....................................................... 167 
4.2.1 Gene expression levels ...................................................................................... 168 
4.2.2 Correlation between gene promoter methylation status and mRNA expression
 .................................................................................................................................... 174 
4.2.3 HRDetect score ................................................................................................. 175 
4.2.4 DNA repair gene expression levels and HR mutational status associated with 
response to therapy in EOC-PDX tumours ................................................................ 177 
4.2.5 Discussion II ..................................................................................................... 182 
4.3 STUDY OF RAD51 FOCI AS PREDICTIVE BIOMARKER FOR RESPONSE TO 
PLATINUM AND PARPI THERAPY .......................................................................... 186 
4.3.1 Quantitative immunofluorescence assay to evaluate RAD51 foci in a tissue 
microarray representative of the xenobank ................................................................ 186 
X 
 
4.3.2 Evaluation of RAD51, BRCA1 and γH2AX nuclear foci in geminin positive FFPE 
EOC-PDX tumours .................................................................................................... 190 
4.3.3 Discussion III .................................................................................................... 194 
4.4 FOCUS ON NER AND BER PATHWAYS AND RESPONSE TO PLATINUM 
THERAPY ..................................................................................................................... 197 
4.4.1 Relationship among ERCC1, XPF, POLB and ERCC1/XPF complex expression 
levels in the xenobank ............................................................................................... 197 
4.4.2 Analysis of ERCC1, XPF, POLB and ERCC1/XPF complex as possible 
predictive biomarkers for platinum response in EOC-PDX TMA ............................ 202 
4.4.3 Discussion IV .................................................................................................... 204 
5. GENERAL DISCUSSION ...................................................................................... 207 
6. REFERENCES ........................................................................................................ 217 
7.     APPENDIX ............................................................................................................... 264 
LIST OF PUBLICATIONS ........................................................................................... 265 
Works by the candidate emanating from the work described in this thesis ............... 265 
Work not pertaining, or previous, to the work described in this thesis ..................... 265 




LIST OF FIGURES AND TABLES 
Figure 1.1 The most diffuse histological subtypes of epithelial ovarian cancer .................... 3 
Figure 1.2 EOC incidence (grey curve) and mortality (green curve) estimated trends (period 
2003-2018) ............................................................................................................................. 4 
Figure 1.3 Anatomy of the female reproductive apparatus .................................................... 9 
Figure 1.4 EOC origin: the theory of OSE ........................................................................... 10 
Figure 1.5 EOC origin: the theory of secondary Müllerian system ..................................... 12 
Figure 1.6 EOC origin: the theory of imported disease ....................................................... 14 
Figure 1.7 Dualistic model of EOC carcinogenesis ............................................................. 16 
Figure 1.8 Model of endometriosis-related ovarian cancers formation ............................... 18 
Figure 1.9 Model of low grade serous (LGSOC) and high grade serous (HGSOC) carcinoma 
formation .............................................................................................................................. 20 
Table 1.1 2014 FIGO ovarian cancer staging system .......................................................... 24 
Figure 1.10 The most common genetic and epigenetic abnormalities occurring in the ovarian 
cancer subtypes .................................................................................................................... 29 
Table 1.2 Time scale of PARPi approvals in Europe and USA and therapeutic indications
 .............................................................................................................................................. 41 
Table 1.3 Results of PARPi maintenance therapy in HGSOC............................................. 43 
Figure 1.11 Schematic representation of base excision repair pathway. ............................. 48 
Figure1.12 Schematic representation of mismatch repair pathway ..................................... 49 
Figure 1.13 Schematic view of nucleotide excision repair pathway .................................... 51 
 .............................................................................................................................................. 53 
Figure 1.14. Schematic view of homologous recombination repair .................................... 53 
Figure 1.15 Overview of DNA repair pathways involved in the repair of DNA double strand 
breaks (DSBs) ...................................................................................................................... 55 
Figure 1.17 Chemical structures of cisplatin (left) and carboplatin (right).......................... 59 
XII 
 
Figure 1.18 Intracellular trafficking of platinum compounds (cisplatin and carboplatin) .. 62 
Figure 1.19 The most common intra-strand and inter-strand Pt-DNA adducts on DNA and 
their frequency ..................................................................................................................... 63 
Figure 1.20 PARP activity and role of PARP inhibition in DNA repair and synthetic lethality
 ............................................................................................................................................. 69 
Figure 1.21 Schematic summary of the most studied pathways and tumour conditions able 
to influence the anti-tumour effect of platinum compounds in ovarian carcinoma ............. 72 
Figure 1.22 Schematic overview of the mechanisms leading to restoration of replication fork 
protection ............................................................................................................................. 98 
Table 1.4 Mechanisms and molecular alterations associated with PARPi resistance and 
eventually, cross-resistance with cisplatin ......................................................................... 102 
Figure 3.1 Chromosomal location of the PyromarkCpG assays (Qiagen) used to analyse the 
methylation status of BRCA1, ERCC1, MLH1 and XPA through Pyromark PCR and 
Pyrosequencing (Qiagen) ................................................................................................... 124 
Table 3.1 List of the PyromarkCpG Assays (Qiagen) used for Pyrosequencing .............. 124 
Figure 3.2 Maxwell® RSC cartridge system (Promega) employed for automated RNA 
extraction from tissues or cells .......................................................................................... 127 
Figure 3.3 Duolink® PLA workflow .................................................................................. 137 
Figure 4.1 Establishment, characterization and application of the Mario Negri’s EOC 
xenobank ............................................................................................................................ 145 
Table 4.1 Clinical-pathological characteristics of the original EOC from which PDXs 
derived ............................................................................................................................... 147 
Figure 4.2 Comparative histological and immunohistochemical (IHC) analyses of tumours 
deriving from EOC-PDXs at different in vivo passages and the original patient tumour it 
derived from ....................................................................................................................... 149 
Figure 4.3 Allele report of MNHOC124 STR analysis ..................................................... 151 
Table 4.2. Mutational profile of the most common mutated genes in EOC ...................... 154 
XIII 
 
Table 4.3 Quantification of the % of CpG islands methylated in different promoter regions 
of six DNA repair genes in the EOC-PDXs ....................................................................... 157 
Figure 4.4 Methylation status of BRCA1 promoter in the EOC-PDXs .............................. 158 
Figure 4.5 Methylation status of XPG and FANCF promoters .......................................... 159 
Table 4.4 Classification of EOC-PDXs based on their response to DDP and olaparib therapy
 ............................................................................................................................................ 162 
Figure 4.6 Best treatment response to DDP and olaparib of EOC-PDXs pharmacologically 
characterized ...................................................................................................................... 163 
Table 4.5 Lists of genes analysed and pathways in which they are involved .................... 168 
Figure 4.7 Expression pattern of DNA repair genes in all the EOC-PDXs analysed ........ 169 
Table 4.6 Correlations between single gene expressions of DNA repair genes analysed in the 
high grade EOC-PDXs ....................................................................................................... 170 
Table 4.7. Correlation of CDK12 with other DNA repair genes from two TCGA databases
 ............................................................................................................................................ 171 
Figure 4.8 Expression pattern of the genes involved in platinum and PARPi response studied 
in all the EOC-PDXs .......................................................................................................... 172 
Table 4.8 Significant correlations between single gene expression in all the PDXs and in the 
subgroup of high grade PDXs ............................................................................................ 173 
Table 4.9 Comparison between methylation status and gene expression in PDXs resulted 
hypermethylated in selected genes ..................................................................................... 175 
Figure 4.9 HRDetect assay ................................................................................................. 176 
Figure 4.10 DNA repair gene expression levels and DDP response in high grade PDXs . 178 
Figure 4.11 mRNA expression levels of genes significantly associated with DDP response 
in all the EOC-PDXs .......................................................................................................... 179 
Figure 4.12 Overview of the best treatment response to DDP and olaparib and HR related 
profile of the EOC-PDXs under study ............................................................................... 181 
Table 4.10 List of the EOC-PDXs included in the TMA ................................................... 187 
XIV 
 
Figure 4.13 RAD51 foci at baseline in EOC-PDXs .......................................................... 189 
Figure 4.14 RAD51 foci expression at the basal level and response to therapy ............... 189 
Figure 4.15. Percentage of cells positive for both nuclear foci and geminin in all the PDXs 
studied ................................................................................................................................ 191 
Figure 4.16 Correlation between RAD51 and BRCA1 foci .............................................. 192 
Figure 4.17 RAD51 and BRCA1 foci positive cells and response to DDP treatment in FFPE 
EOC-PDXs ........................................................................................................................ 193 
Figure 4.18 RAD51 and BRCA1 foci positive cells and response to olaparib treatment in 
FFPE EOC-PDXs .............................................................................................................. 194 
Table 4.11 Descriptive analysis of ERCC1 and POLB IHC, ERCC1/XPF foci (PLA) and 
ERCC1, XPF and POLB mRNA expression levels in the EOC-PDXs studied ................. 198 
Figure 4.19 ERCC1 and POLB proteins expression on the TMA visible in IHC ............. 199 
Figure 4.20 ERCC1/XPF protein complexes detected by PLA in IHC in FFPE EOC-PDXs
 ........................................................................................................................................... 200 
Table 4.12 Correlations between ERCC1 and POLB IHC score, ERCC1/XPF foci and 
ERCC1, XPF and POLB gene expression data in the EOC-PDXs under study ................ 201 
Figure 4.21 ERCC1 IHC score, POLβ IHC score and DDP response in high grade EOC 
PDXs .................................................................................................................................. 202 
Figure 4.22 ERCC1/XPF foci number per nucleus and response to DDP in high grade EOC-
PDXs .................................................................................................................................. 203 
Figure 4.23 Detection by IF and quantification of ERCC1/XPF foci per nucleus in A2780 












1.1 OVARIAN CANCER 
Ovarian cancer, also named the “silent killer”, is the most lethal gynaecological malignancy 
in the Western countries and the fifth most lethal cancer worldwide among women (Bray et 
al., 2018). The adjective “silent” is due to the absence of specific symptoms in its early 
phases of development leading to late diagnosis and a dismal prognosis. Depending on the 
cells of origin, ovarian cancers can be classified into ovarian carcinomas, deriving from 
epithelial cells, sex cord-stromal tumours, originating from the hormone-producing cells in 
the cortex of the ovary, or germ cell tumours, deriving from the granulosa cells localized 
inside the ovarian follicles.  
Epithelial ovarian carcinoma (EOC) is the most common type, accounting for 90% of 
tumours (Cho and Shih, 2009). It is clinically and pathologically distinct from the non-
epithelial ovarian cancers and will be the subject of this thesis. EOC is a broad term gathering 
heterogeneous types of cancers, sharing the same anatomical position (all disseminate to the 
ovaries and related pelvic organs), but few molecular features. In fact, they have different 
origins, mutational profiles and sensitivity to pharmacological therapies. Based on 
histopathology and genomic analyses and on the cells of origin (all these aspects will be 
discussed in the following chapters), the four most relevant and currently identified EOC 
sub-types are serous carcinoma (divided into high grade serous (HGSOC, ~70% of total 
EOC) and low grade serous (LGSOC, ~3%) carcinomas), endometrioid carcinoma (divided 
into high grade endometrioid (HGEOC, ~3%) and low grade endometrioid (LGEOC, ~10%) 
carcinomas), mucinous carcinoma (MC, ~3%) and clear cell carcinoma (CCC, ~10%) 




Figure 1.1 The most diffuse histological subtypes of epithelial ovarian cancer  
In this schematic figure are reported the incidence rate (in percentage) and histological 
representative images for each of the most diffuse subtypes of epithelial ovarian cancer 
(adapted from (Karst and Drapkin, 2010)).  
 
1.1.1 Incidence and mortality rates in epithelial ovarian cancer 
Globally, 295,414 new cases of ovarian carcinoma were diagnosed in 2018, while 184,799 
women died from this disease in the same year (Bray et al., 2018; Gaona-Luviano et al., 
2020). Based on these statistics, ovarian carcinoma is the seventh most common cancer 
diagnosed among women (3.4% of oncology diagnosis) and the fifth cause of death from 
cancer in women in the world (4.4% of the entire cancer-related mortality) (Bray et al., 
2018). Reported incidence and mortality rates slightly differ depending on geographical 
areas and ethnic origins (Momenimovahed et al., 2019). African and Asiatic populations 
register a mild lower incidence, in part due to the variability of cancer registration that could 
lead to an underestimation of the incidence rate, while the mortality rate in African women 
is higher than in women in Europe and in Asia, who tend to have the better survival (La 
Vecchia, 2017). Worldwide differences in mortality rates can be attributed to disparities in 
the access of sanitary care and treatments, and in part due to a different incidence of the 
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ovarian carcinoma histotypes across ethnic groups (i.e. clear cell carcinoma is more diffuse 
in Asia  
than in Europe and USA, where more aggressive histotypes, such as high grade serous and 
endometrioid cancers are more frequent) (Jemal et al., 2017). Considering incidence and 
mortality trends of ovarian carcinoma in Italy, as an example of a Western country, the 
Italian Association of Oncology Medicine (AIOM) estimated a slow decreasing in incidence 
for the period 2003-2018 (-0.9%), while the mortality rate was stable (-0.1%) (figure 1.2) 
(Cancer Genome Atlas Research Network, 2011; “https://www.aiom.it/wp-
content/uploads/2018/10/2018_NumeriCancro-operatori.pdf,” n.d.). It has been reported 
that the incidence rate would decrease in parallel with the increasing use of contraceptive 
pill, which seems to reduce the risk of ovarian carcinoma (Collaborative Group on 
Epidemiological Studies of Ovarian Cancer et al., 2008), while the lack of new effective 
therapies may be one explanation for the un-improved mortality rate.  
Figure 1.2 EOC incidence (grey curve) and mortality (green curve) estimated 
trends (period 2003-2018) 
Rates are normalized for the European population in 2013.  
 
At the time of diagnosis, almost 75% of patients show distant/metastatic disease and this is 
associated with a 5-year survival rate of 29% (Reid et al., 2017). On the contrary, when 
diagnosed as local disease, ovarian carcinoma patients have a 5-year survival rate of 92% 
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(Reid et al., 2017). These statistics highlight the lack of pre-symptomatic diagnostic tools 
and effective early detection strategies, that should have an important role in a much earlier 
diagnosis. Furthermore, a better understanding of the biology of EOC is warranted to find 
new biomarkers and new therapeutic strategies.  
1.1.2 Risk and preventive factors for epithelial ovarian cancer 
The estimated lifetime risk of developing ovarian carcinoma is 1 in 80 women 
(“https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-
web.pdf,” n.d.; Torre et al., 2018). EOC may affect all women, but especially those who 
have already had their menopause; in fact, the incidence rate rises after 40-years of age, the 
peak of diagnosis is in women aged 55 to 64 and the curve drops slowly over 80-years old, 
suggesting an age-related risk (Doubeni et al., 2016). 
Epidemiological research has identified several hormonal factors implicated in the 
pathogenesis of EOC. The “incessant ovulation hypothesis” proposes that after the ovulation 
process, the rupture of the ovarian surface epithelium undergoes rounds of repair and cellular 
proliferation processes that might facilitate the onset of spontaneous mutations (Fathalla, 
1971). Consequently, situations that increase the number of lifetime ovulations (i.e. 
nulliparity, post-menopausal hormone therapies for more than 5 years, early age at menarche 
or late age at menopause) favor the risk of developing cancer. On the contrary, oral-
contraceptive pill use for at least 10 years, has a significant protective effect on the risk of 
ovarian carcinoma, as well as multiparity, fallopian tubal ligation, late age at menarche and 
early age at menopause (Mallen et al., 2018). Some environmental and life-style risk factors 
have been reported, but the risk correlated with EOC is less evident and still controversial. 
The most discussed factors are obesity, high body mass index, smoking and the prolonged 
use of genital talcum powder (Cannistra, 2004; Penninkilampi and Eslick, 2018). 
Endometriosis, polycystic ovary syndrome and pelvic inflammatory disease are benign 
gynecological conditions may degenerate in the development of ovarian tumours. In 
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particular, during endometriosis, which is a chronic-inflammatory condition, the retrograde 
menstrual flux causes the deposition of endometrioid cells in other areas, like the ovaries 
and pelvic peritoneum, that may evolve to malignant lesions (especially endometrioid and 
clear cell ovarian carcinomas (Reid et al., 2017).  
Even if sporadic tumours are the majority of cases, genomic predisposition and familiar 
history are the strongest risk factors associated with EOC, especially for the high grade 
serous/endometrioid ovarian carcinoma (HGOC) histotype, the most aggressive and diffuse 
ovarian cancer subtype. It was observed that 15% to 20% of patients with HGOC have 
germline mutations in the breast cancer-associated genes (BRCA1 or BRCA2) (Jones et al., 
2017). BRCA1 and BRCA2-mutated genes are high-penetrant susceptibility genes that 
encode for tumour suppressor proteins and their mutational status is actually used as a 
biomarker to detect women with high-risk to develop EOC and breast cancer. BRCA1 or 
BRCA2 mutation carriers have an overall risk of developing EOC by the age of 70 of 39% 
and 11% respectively, while the cumulative risk for breast cancer is 65% for BRCA1 
mutation carriers and 45% for BRCA2, depending on the type and location of the mutations 
along the gene sequence (Antoniou et al., 2003). Several studies focusing on hereditary 
gynaecologic tumours and BRCA1/2 mutation carriers have led to the identification of the 
Hereditary Breast and Ovarian Cancer (HBOC) syndrome. It is an autosomal dominantly 
inherited disease characterized by a three-fold lifetime risk of developing breast and/or 
ovarian carcinomas before 40-years of age. BRCA1 and BRCA2 have a causative role in 
~70% of hereditary EOC and other intermediate-risk susceptibility genes have been 
identified. These include Fanconi anemia (FA) pathway (FANCD2, FANCC, FANCA, 
FANCM), RAD51C, RAD51D, BRIP1, ATM and ATR, all involved in the DNA repair cluster. 
Also mutated DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) are 
associated with the autosomal dominant hereditary syndrome, Lynch syndrome, which 
accounts for 10-15% of inherited EOC, typically endometrioid and clear cell ovarian 
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carcinomas (Kobayashi et al., 2013; Mallen et al., 2018). The identification of women with 
high risk of developing EOC may help to prevent or delay the cancer onset through different  
strategies. Patients should be supported by personalized programs of medical screening and 
genetic counseling, according to their cancer risk type. The use of the oral-contraceptive pill 
should be supported when pregnancy is not demanded, since it reduces the risk of ovarian 
cancer also in BRCA1/2 mutation carriers. Prophylactic surgery is the most preventive 
treatment option. Prophylactic bilateral salpingo-oophorectomy (BSO) (surgical removal of 
fallopian tubes and ovaries) lowers the ovarian cancer risk by 80% and, if performed before 
age of 50, exhibits a 50% reduction in subsequent breast cancer risk, leading to reduction of 
mortality-risk related to cancer. On the other hand, BSO causes an anticipated menopause 
and consequently exposes women to higher risk for osteoporosis and cardiovascular 
diseases. These side effects should be taken into consideration to decide when BSO is 
suggested (Chang and Bristow, 2012; Clarke-Pearson, 2009; Collaborative Group on 
Epidemiological Studies of Ovarian Cancer et al., 2008). For these reasons, clinical trials are 
evaluating if a two-step prophylactic surgery could delay the onset of anticipated menopause. 
The two-step strategy consists of bilateral salpingectomy followed by oopherectomy after 
some years, based on more recent pathogenesis studies that point to the fallopian tubes as 
the primary site of origin for HGOC (Pérez-López and Chedraui, 2016). A personalized and 
routine screening program in BRCA1/2 mutated patients might help to postpone the BSO as 
much as possible, and at the same time, lead to an early detection of ovarian malignancy. 
For sporadic EOC, the knowledge of risk and preventive factors, especially those related to 
life-style habits and hormonal therapies, may help to lower the lifetime risk to develop EOC, 




1.1.3 Pathology of ovarian carcinoma 
1.1.3.1 Anatomy of the ovaries and Fallopian tubes 
The ovaries are the female gonads whose main functions are the production of gametes and 
the secretion of hormones estrogen and progesterone. Each ovary has an ovoid structure, 
sized 4 cm x 2 cm. They are located one on each side of the uterus, in the pelvic cavity and 
are linked to the uterus by peritoneal ligaments. The ovaries surface is covered by flat 
epithelial cells, which form a layer named the germinal epithelium or ovarian surface 
epithelium (OSE). Above the epithelium, a fibrotic connective tissue, named the cortex 
includes the follicular structures. Each follicle contains a single oocyte and cooperates for 
its development. The inner part of the ovary is the medulla, a dense connective tissue full of 
blood and lymphatic vessels and nerve fibers.  
The fallopian tubes or uterine tubes are part of the reproductive tract together with the uterus, 
cervix and vagina. Each tube is directly associated with each ovary and, even if there is no 
direct contact between these two parts, the last part of the tube (infundibulum) expands 
through finger-like structures named fimbriae and surrounds the ovary. After the ovulation, 
the mature oocyte is released from the ovary in the pelvic cavity and enters into the Fallopian 
tube to get into the uterus, facilitated by cilia that cover the inner surface of the tubes and by 
peristaltic movements.  








Figure 1.3 Anatomy of the female reproductive apparatus  
Ovaries are connected to the uterus by ligaments and are surrounded by the terminal 
parts of Fallopian tubes, named fimbriae. These structures collect the mature oocytes 




1.1.3.2 EOC: origin and pathogenesis 
The development of effective early-screening strategies, new therapeutic options and in 
general, improvements in understanding the biology of ovarian carcinoma, have long been 
hampered by the lack of knowledge of the site of origin and carcinogenesis process of these 
tumours.  
The ovarian surface epithelium (OSE) has been traditionally considered the site of origin of 
all EOC histotypes. OSE originates from the coelomic epithelium and is composed of cells 
morphologically similar to the mesothelium, lining the peritoneal cavity. The OSE was 
assumed to invaginate into the underlying stroma forming the so-termed cortical inclusion 
cysts (CICs). CICs are thought to acquire by metaplastic change a Müllerian phenotype, 
resembling the epithelia of fallopian tubes, endometrium, endocervical or gastrointestinal 
tract (Park et al., 2018). Ultimately, these epithelial cells may degenerate into a neoplastic 
formation giving rise to borderline malignancies that may evolve into high-grade and low-
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grade carcinomas, according to the cellular phenotype acquired previously (figure 1.4) 
(Fleszar et al., 2018; Okamura and Katabuchi, 2005). This theory was supported by the 
“theory of incessant ovulation” suggested by Fathalla in 1971 (Fathalla, 1971) in which the 
OSE, exposed to repeated damage and repair processes during the ovulatory cycles, could 
undergo metaplastic transformation and form CICs. The Müllerian epithelium lining the 
CICs is exposed to hormones and inflammatory factors present in the ovarian stroma, which 
may facilitate the onset of deleterious mutations resulting in neoplastic transformation 
(Fathalla, 1971).  
 
Figure 1.4 EOC origin: the theory of OSE 
Epithelial cells forming the ovarian surface epithelium (OSE), may invaginate into the 
stroma of the ovary forming cortical inclusion cysts (CICs). CICs are lined by epithelial 
cells with a Müllerian phenotype acquired through a metaplastic process that resembles 
epithelia of fallopian tubes or that of other Müllerian tissues. Under hormonal or 
inflammatory factors present in the stroma, CICs could then undergo malignant 
transformation forming low grade and high grade EOCs, whose histology reflects the 
previously acquired phenotype (schematic illustration modified from (Aggarwal et al., 
2016)). 
 
Some limitations in the “theory of OSE” have been put forward, since none of the 
constitutive elements of EOCs, nor biomarkers, such as PAX8 or CA125 extensively 
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expressed in carcinomas, have ever been found in the normal ovaries. Moreover, EOC 
subtypes are more similar to other tumours of extra-ovarian tissues in the female 
gynaecologic apparatus. For example, serous, endometrioid and mucinous carcinomas 
histologically reflect fallopian tube, endometrium or endocervical tumours, respectively. 
Considering also the embryonic development, the doubts against the “theory of OSE” were 
reinforced since tissues and organs deriving from the Müllerian ducts (i.e. fallopian tubes 
and endometrium) are notably distinct and separate from those like ovaries, deriving from 
the mesothelial layer of the peritoneum, which lines all the pelvic and abdominal organs (Li 
et al., 2012; Prat, 2012). The Müllerian ducts, also named paramesonephric ducts, are paired 
ducts of the embryo parallel to the lateral side of the urogenital ridge. In the female they 
develop to form the fallopian tubes, uterus, cervix and the upper one-third of the vagina. 
Although the model described for the “theory of OSE” could be sustained by features 
associated with the onset of some borderline, endometrioid, clear cell and mucinous ovarian 
tumours (Kroeger and Drapkin, 2017; Levanon et al., 2008), the third argument against the 
traditional theory of EOC pathogenesis is the fact that no precancerous lesions of EOCs have 
been found in a reproducible manner in normal ovaries. In fact, the transition from the CICs 
to high-grade EOC has never been reported and gene expression studies have revealed that 
the majority of EOCs (serous, endometrioid and mucinous) little resemble the genomic 
profile of the proposed cells of origin (the OSE) (Kurman and Shih, 2010).  
With the aim to explain the origin of tumours not directly involving the OSE, a second theory 
was proposed in 1972, named “secondary Müllerian system theory” (Lauchlan, 1972). The 
secondary Müllerian system refers to those Müllerian-type epithelia like CICs, paraovarian 
and paratubal cysts, endometriosis, endosalpingiosis and endocervicosis, outside the primary 
Müllerian system (i.e. uterus, cervix and fallopian tubes). According to this theory, tumours 
with a Müllerian phenotype found in the pelvis probably derived from these secondary 
structures, either directly or by metaplastic transformation (figure 1.5). As the tumour 
enlarges, it comprises the ovary resulting in an adnexal ovarian tumour, that appears to  
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develop from the ovary itself. This theory provides a clear explanation for the presence of 
ovarian-like cancers arising outside the primary Müllerian system and could also explain 
why women who have already undergone prophylactic surgery, might develop peritoneal 
carcinomas later on (Aggarwal et al., 2016). However, this theory does not explain why the 
majority of mucinous tumours morphologically reflect the gastrointestinal tract rather than 
the endocervical epithelium and consequently they cannot be considered part of the 
Müllerian-type tumours (Kurman and Shih, 2010). 
 
 
Figure 1.5 EOC origin: the theory of secondary Müllerian system  
In addition to the primary Müllerian system (i.e. fallopian tubes, uterus and cervix) it is 
possible to observe in the pelvis secondary Müllerian epithelia, such as paratubal and 
paraovarian cysts, endometriosis, endosalpingiosis and endocervicosis formations that 
could directly or through metaplastic process give rise to tumours with a Müllerian 
phenotype like serous, endometrioid and clear cell carcinomas (adapted from (Aggarwal 




The most relevant point against the “theory of OSE” and the “secondary Müllerian system 
theory” is that precancerous lesions have never been found in OSE, nor in the paratubal or 
paraovarian cysts.  
In the late 1990s and early 2000s, prophylactic salpingo-oopherectomy was recommended 
for women with familiar history of ovarian cancer and/or germline mutations in BRCA or 
BRCA2 genes and pathologists began to evaluate these specimens more carefully. They did 
not find any precancerous lesion in the ovary, but, interestingly, they found occult non-
invasive or invasive neoplastic lesions in the fimbria of the fallopian tubes with a frequency 
ranging from 42% to 100% in patients BRCA-mutated diagnosed with HGSOC (Reade et 
al., 2014). In 1999, Dubeau firstly suggested that serous ovarian carcinoma might originate 
from the Müllerian system, including the fallopian tubes (Dubeau, 1999). He reported that 
the vast majority of epithelial ovarian cancer specimens histologically recapitulated the tubal 
epithelium, but not that of normal ovaries, where no precancerous lesions had ever been 
observed (Dubeau, 1999). Afterwards, in 2003, it was proposed that occult lesions localized 
in the tubal fimbriated ends might spread their benign or malignant epithelial cells to the 
ovary, then these cells could implant on the OSE and start to growth into the ovarian stroma 
as CICs (Kuhn et al., 2012). Corroborating this so-called “theory of imported disease”, 
several studies identified and named these precancerous lesions as tubal intraepithelial 
cancers (TICs) and subsequently serous tubal intraepithelial cancers (STICs) since they were 
observed in specimens deriving from both women having a great familiar risk to develop 
HGSOC and from women affected by sporadic (non-hereditary) HGSOC (Morrison et al., 
2015; Rabban et al., 2014). STICs were described as the precancerous lesions localized in 
the fallopian tubes able to give origin to HGSOC, the most diffuse and aggressive subtype. 
Even if STICs have not been associated with endometrioid carcinomas (EMCs), clear cell 
(CCCs) and mucinous cancers (MCs), this theory was adapted to explain the origin of EMCs 
and CCCs, where endometrial-type cells coming from endometriosis would be able to move  
14 
 
from the uterus through the fallopian tubes, to form endometriotic cysts, whose cells could 
shed and implant on the close ovary (figure 1.6) (Giudice, 2010; Piek et al., 2003). 
According to the “theory of imported disease” EOC does not originate from 
the ovary, but represents an “imported disease”, distinct from the real primary ovarian cancer 
(i.e. the sex cord-stromal tumours and germ cell ovarian cancer). 
 
Figure 1.6 EOC origin: the theory of imported disease  
The terminal part of fallopian tube (fimbria) is the site of origin of serous tubal 
intraepithelial carcinomas (STICs) and endometrioic cysts (in women affected by 
endometriosis). Cells from these lesions are hypothesized to spread to the ovary, implant 
on the OSE and then forming cortical inclusion cysts (CICs) from which may derive 
low grade or high grade serous ovarian carcinomas (LGSOC/HGSOC) from STICs or 
endometrioid or clear cell carcinomas (EMC/CCC) from endometrioic cysts (modified 
from (Kurman and Shih, 2011)). 
 
In the ensuing years, different morphologic and molecular genetic studies elucidated that 
EOC is not a single disease, but is a heterogeneous group of different entities having peculiar 
clinic-pathologic features and biological behaviours. This concept led to a paradigm shift 
regarding the EOC carcinogenesis based on a new “dualistic model”. It divides the ovarian 
surface epithelial tumours into two categories termed “type I” and “type II”, first described 
in 2008 and then reviewed in 2016 by Kurman and Shih (Kurman and Shih, 2016, 2008). 
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The Type I group includes low grade serous, low grade endometrioid, clear cell and 
mucinous carcinomas, Müllerian-mixed tumours, also named sero-mucinous carcinomas 
(they comprise cystadenomas, atypical proliferative (borderline) tumours and carcinomas), 
and malignant Brenner tumours. They usually appear as a large, cystic malignant mass, 
confined in one ovary, and are typically diagnosed at an early stage and low grade, with the 
exception of CCCs which are considered high grade. The detection of low-grade tumours is 
generally accompanied with a favourable prognosis, but when type I tumours are diagnosed 
in an advanced stage, they have a poor outcome due to their poor sensitivity to the standard 
chemotherapy. The Type II group is largely composed of high grade serous and 
endometrioid carcinomas and in a minor part, of carcinosarcomas and undifferentiated 
carcinomas. They account for 90% of EOC-related deaths, because their early detection is 
still challenging as they are usually diagnosed at advanced stage, evolve rapidly and are 
highly aggressive. Type II tumours usually involve both the ovaries and extra-ovarian sites, 
like omentum and mesentery, and ascites formation is common. However, cytoreductive 
surgery and standard chemotherapy based on platinum agents combined with paclitaxel 
provide lengthened progression free survival because initially most patients respond. 
Unfortunately, 70% of cases will recur with drug resistant disease (Kurman and Shih, 2016, 
2010, 2008; Vang et al., 2013). 
One of the main features of the dualistic model was the relation of the different histologic 
subtypes to their precursor lesion. Type I tumours were found to develop from benign 
precursor lesions, notably atypical proliferative (borderline) tumours (APTs), characterized 
by specific mutations (the mutational profiles will be broadly discussed in the chapter 1.3.5 
“Molecular profile associated to different EOC histotypes”) able to induce morphologic 
changes evolving in a step-wise fashion manner from benign to invasive low-grade tumours. 
In contrast, type II was thought to develop mostly from STICs in fallopian tubes and 
subsequently disseminating to the ovaries, and a minor percentage was thought to evolve  
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probably de novo from CICs deriving from tubal epithelium cells implanted on the OSE, that 
undergo metaplastic malignant transformation (Vang et al., 2013). Now, the revised and 
expanded dualistic model considers the new histopathologic classification integrating it with 
the emerging molecular/genetic studies and better elucidates the morphologic and molecular 




Figure 1.7 Dualistic model of EOC carcinogenesis  
EOC include different histological subtypes that can be divided into type I and type II. 
Type I includes low grade serous (LGSOC), low grade endometrioid (LGEMC), 
mucinous (MC), clear cells carcinomas (CCC), Müllerian mixed and Brenner tumours. 
Their sites of origin as well as their precursor lesions, is different for each ovarian 
subtypes, ranging from endometriosis and fallopian tube epithelium for LGSOC, 
LGEMC, CCC and Müllerian mixed tumours, to transitional epithelium or germ cells 
for Brenner tumours and MC. Type II comprises high grade serous (HGSOC) and 
endometrioid (HGEMC), carcinosarcomas and undifferentiated tumours, all of which 
have a tubal origin and main of them derive directly from serous tubal intraepithelial 
cancers (STICs). 
 
The site of origin of low grade serous tumour (LGSOC) is localized in the fallopian tubes, 
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hyperplasia, that evolves to APTs, often characterized by mutations affecting KRAS, BRAF 
and ERBB2, which constitutively activate the MAP-kinase pathway and drive neoplastic 
transformation. Endometrioid carcinoma (EMC), clear cell carcinoma (CCC) and Müllerian 
mixed carcinoma are defined endometriosis-related carcinomas, since they are derived from 
epithelial cells of endometrial origin, passed through the fallopian tubes and arrived at the 
ovary through endometriosis. This association, hypothesized for decades, has now been 
proven by genetic studies. Mutations in ARID1A, a tumour suppressor gene involved in 
switch/sucrose non-fermentable (SWI/SNF) chromatin remodelling, were detected in up to 
50% of CCC, in 30% of EMC and in the epithelial cells forming the endometriomas, the 
APT that, as in LGSOCs, is often found adjacent to EMC and CCC, but not in the 
endometriotic cysts, which are located more distant from cancer. Somatic mutations in 
PTEN, another tumour suppressor gene, are observed in EMC and CCC and in endometriotic 
cysts, supporting these latter as possible precursor lesions for edometriosis-related 
carcinomas (Kurman and Shih, 2016) (figure 1.8). The origin of primary mucinous 
carcinomas (MC) is still unknown. MC typically displays foci of mucinous cystoadenoma, 
mixed with APTs and epithelial malignant cells. Mutational profiling of these sections 
revealed the same KRAS somatic mutations in all the three areas, supporting the idea of 
clonal evolution (Simons et al., 2020). Recently, it was hypothesized that MC might derive 
from either teratomas (cancers from germ cells) or Brenner tumours that give rise to different 
subtypes of MC. It was argued that Brenner tumours could derive from groups of epithelial 
cells, named Walthard cell nests, which can be found adjacent to the fallopian tubes and 
ovaries (tuboperitoneal junctions) and have been observed to undergo metaplasia processes. 
However, subsequent transformation pathways are similar regardless of the cell of origin 





Figure 1.8 Model of endometriosis-related ovarian cancers formation  
Endometriosis determines a retrograde menstrual flux from the uterus through fallopian 
tubes that leads the deposition on ovarian surface of endometrioid cells. These could form 
endometrioic cysts and atypical proliferative tumours, thought to be the precursor lesions 
for low grade EMC, CCC and Müllerian mixed tumours (adapted from (Kurman and Shih, 
2011)). 
 
Regarding HGSOC, the predominant histotype, many of these tumours may develop from 
STICs in the fimbriated ends of the fallopian tubes. STICs were found in BRCA1/2 mutation 
carries, but also in 50% to 60% of women with sporadic HGSOC. Several data support their 
role as precursor lesions and now their clonal relationship has been reported. STICs are often 
found in the absence of carcinoma in women with higher familiar risk for EOC. When STIC 
and HGSOC are both present, they usually show the identical TP53 mutation. In addition, 
STICs have shorter telomeres compared to the concomitant HGSOC, and this condition is 
one of the earliest events in carcinogenesis. In engineered mouse models, the inactivation of 
TP53, PTEN and BRCA1/2 genes leads to the development of STICs and HGSOC (Karst 
and Drapkin, 2010). Because STIC is a carcinoma more or less confined to the fallopian tube  
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epithelium, it would be expected that the existence of a STIC’s precursor lesion would be 
found there too. Serous tubal intraepithelial lesions in transition were found close to STICs 
and normal tube cells expressing higher levels of p53 (termed p53 signature) were reported, 
but their effective relation with STIC has yet clearly to be established. It is likely that the 
p53 signature cells undergo subsequent molecular events, such as loss of BRCA function, 
leading to malignant STICs. In a recent study (Wu et al., 2019), the genomic landscape of 
tubal precursor lesions including p53 signature, dormant or proliferative STICs, have been 
analysed in specimens from women without any cancer diagnosis using whole-exome 
sequencing and amplicon sequencing. The results showed that p53 signature and dormant 
STICs have less somatic mutations and allelic imbalance than tubal lesions associated with 
ovarian cancer, indicative of their earlier onset in tumour development process, and a low 
Ki-67 proliferative index (<10%), in line with the fact that it could take two or more decades 
to develop into STIC, whereas proliferative STIC could progress to carcinoma in a much 
shorter time (~6 years), suggesting an acceleration from this stage towards tumour formation 
(Wu et al., 2019). However, not all HGSOC are associated with STIC and directly to 
fallopian tubes. It has also been suggested that a small proportion of HGSOC may develop 







Figure 1.9 Model of low grade serous (LGSOC) and high grade serous 
(HGSOC) carcinoma formation 
 LGSOC and HGSOC can develop from cortical inclusion cysts (CICs) of tubal origin and 
cystadenomas (1) or from serous tubal intraepithelial cancers (STICs) implanting directly 
on ovarian surface and giving origin to HGSOC (2) (adapted from (Kurman and Shih, 
2011)).  
 
In aggregate, there is mounting evidence suggesting that HGSOC, LGSOC, EMC, MC and 
CCC should be considered different diseases, deriving from different sites of origin, with 
different molecular events during oncogenesis, and characterized by peculiar molecular 
profiles and patterns of spread.  
 
1.1.3.3 Symptoms and diagnosis 
EOC prodromic symptoms are shared by many common gynaecological and gastrointestinal 
conditions, such as irritable bowel syndrome, and include constipation, vague pelvic 
pressure, abdominal distension, early satiety, fatigue, nausea, change in bowel and urinary 
function, body weight loss and back pain (Lheureux et al., 2019b; Orr and Edwards, 2018a). 
They usually appear when the presence of the tumour mass produces abdominal distension,  
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pelvic pressure and when malignant nodules spread in the peritoneal cavity, affecting 
abdominal organs function. However, since the pain is minimal and symptoms are 
misleading, typically, EOC diagnosis is delayed by months from their onset (Goff et al., 
2004). Symptom presentation and duration differ significantly by tumour histology. Women 
with serous tumours are significantly more likely to report bowel symptoms than women 
with other histological subtypes; women with endometrioid carcinoma are three times more 
likely to report abnormal bleeding, while MC are usually diagnosed as large primary tumours 
(>15cm in diameter) that cause symptoms when the disease is still confined to the ovary. 
Women with MC are likely to have a better prognosis since this subtype is easily detected 
in an early stage than women with HGSOC, whose symptoms have a short duration, but it 
is diagnosed at advanced stage (Morice et al., 2019).   
Ovarian cancer, due its anatomic position, is characterized by pelvic dissemination, since 
small clusters of cells shed from fallopian tube epithelium and OSE into the intraperitoneal 
fluid, which transports cancer cells all over the abdomen, favouring a diffuse tumour 
peritoneal diffusion. In addition, tumour cells can move through lymphatic or blood vessels 
to form metastasis in distant organs, such as kidney, parenchyma of the liver or lungs (Bast 
et al., 2009).  
Generally, when the diagnosis is suspected, the diagnostic pathway includes the 
measurement of cancer antigen 125 (CA125) blood concentration and transvaginal 
sonography (TVS). CA125 is a membrane-spanning mucin glycoprotein whose extracellular 
domain is cleaved, releasing CA125 in the extracellular environment and in blood, where it 
can be measured with an immunoassay. Increase of serum CA125 levels is strongly 
associated with ovarian cancer, being detected in 90% of patients with advanced stage (III-
IV) and in 50%-60% with stage I disease (Elias et al., 2018). However, CA125 alone lacks 
sensitivity and specificity. Greater specificity can be achieved by the combination of CA125 




by pelvic ultrasound check and, if lesions are detected, by laparoscopy to assess the disease  
stage. Alternatively, CA125 assay and TVS can be performed concomitantly. The United 
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has been one of the 
latest clinical trials focused on the diagnostic value of the two-stage screening strategy 
(Jacobs et al., 2016). More than 200.000 postmenopausal women at average risk have been 
allocated in three groups: control (no screening), annual TVS, and the use of an ovarian 
cancer algorithm (ROCA) to interpret the impact of CA125 to prompt TVS. The primary 
end point was not reached (mortality reduction); however, subsequent analyses suggested a 
late survival advantage from the two-stage screening, but longer follow-up will be needed 
(Jacobs et al., 2016).  
Effective screening tools are not yet available. In fact, owing to the relatively low incidence 
and prevalence of EOC, to achieve a good predictive value screening tests should have a 
very high specificity (>99%) and sensitivity (>75%), to be effective in detecting early 
curable stages, cost-effective and to improve the overall survival (Elias et al., 2018). Thus, 
early detection of EOC remains an unmet health need. The discovery and validation of novel 
biomarkers and cost-effective strategies should be explored in new randomized clinical 
trials, alone or in combination. 
 
1.1.3.4 Classification and staging  
When EOC has been diagnosed, histological classification and staging of the tumour are 
pivotal steps to provide the most appropriate clinical care and therapeutic strategy. 
In 2014 the histologic and staging classifications of EOC has been reviewed and updated 
(Zeppernick and Meinhold-Heerlein, 2014). The World Health Organization (WHO) and the 
International Federation of Gynecology and Obstetrics (FIGO) revised their guidelines in 
light of the most recent scientific studies, that underscored the heterogeneous nature and 
biological behavior of ovarian carcinoma. The WHO Classification divides epithelial 
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ovarian tumours by cell type (serous, endometrioid, clear cell, mucinous and transitional 
tumours), by grade (I to IV), and by atypia (benign, borderline -atypical proliferation, low 
malignant potential- and malignant); malignant may be invasive or non-invasive) 
(Meinhold-Heerlein et al., 2016). In addition, high grade tumours with 
serous/endometrioid/transitional histology with p53 mutations are all considered high grade 
serous ovarian cancers (HGSOC), serous tumours are divided into low and high grade based 
on p53 lack (IHC assessment) or mutations, and the requirement for p53 testing for grade 2 
tumours will appropriately re-classify a percentage of grade 2 tumours to high grade (Duska 
and Kohn, 2017). 
The FIGO staging system is used to identify the spread of ovarian cancer (table 1.1). Stage 
I tumours are confined to the ovaries with different degrees of spread (IA, IB, IC) and no 
peritoneal involvement. Stage II defines tumours localized to one or both the ovaries and 
with some pelvic organ involvement. Stage II may include curable tumours as well as 
tumours that have seeded the pelvic peritoneum and, therefore, have a poor prognosis. 
Following recent advice, these tumours should undergo p53 immunostaining and if positive, 
they should be considered high grade (Duska and Kohn, 2017). The vast majority of HGSOC 
present at stage III with different degrees of spread (IIIA, IIIB, IIIC), and involve one or 
both the ovaries, with microscopic metastasis affecting pelvic and abdominal peritoneum 
surfaces and/or regional lymph node metastasis. Finally, tumours that involve distant 
metastasis beyond the peritoneal cavity, as liver/splenic parenchymal metastasis and extra-
abdominal metastasis, are classified as stage IV (Mutch and Prat, 2014; Prat and FIGO 
Committee on Gynecologic Oncology, 2015). The presence of ascites is also an important 
factor in the FIGO classification. Ascites fluid in early-stage disease is a poor prognostic 
factor, with smaller tumour volume and absence of ascites in advanced disease are associated 




Table 1.1 2014 FIGO ovarian cancer staging system 
Adapted from (Mutch and Prat, 2014). 
 
1.1.3.5 Molecular profile associated with different EOC histotypes 
In the last decade, a deep knowledge of EOC-molecular characterization was obtained by 
advanced sequencing techniques. In particular, the identification of specific mutational 
profiles led to the division in two categories (type I and II) of ovarian carcinomas, and at the 
same time, revealed the heterogeneous nature of each single histotype.  
Generally, type I tumours are relatively genetically stable, without TP53 mutations (except 
for MC, where TP53 mutations may occur as a late event (Palmirotta et al., 2017)). Type I 
tumours are often characterized by activating mutations of KRAS, BRAF and amplifications 
in ERBB2, all involved in the mitogen-activated protein kinase (MAPK) pathway, which 
regulates cellular proliferation, differentiation and survival mechanisms (Hunter et al., 2015; 
Jones et al., 2012). Somatic mutations of KRAS at codons 12 and 13 are the most common 
Stage I: Tumour is confined to the ovary.
IA: tumour confined to one ovary; capsule intact; no malignant cells in the ascites or peritoneal washing.
IB: tumour limited to both ovaries; capsule intact;  no malignant cells in the ascites or peritoneal washing.
IC: tumour limited to one or both ovaries with any of the following:
IC-1: surgical spill during  intervention;
IC-2: capsule ruptured before surgery or tumour on ovarian surface;
IC-3: malignant cells present in the ascites or peritoneal washing.
Stage II: Tumour involves one or both ovaries with pelvic extension or primary peritoenal cancer.
IIA: extension and/or implants on the uterus/fallopian tubes/ovaries.
IIB: extension to other pelvic intraperitoneal tissues.
Stage III: Tumour spread to the peritoneum outside of the pelvis and/or metastasis to the retro-peritoneal lymph 
nodes.
IIIA-1: metastasis to retroperitoneal lymph nodes with or without microscopic peritoneal involvement beyond the 
pelvic.
IIIA-2: microscopic peritoneal involvement with or without nodes.
IIIB: macroscopic peritoneal <2 cm above the pelvic brim.
IIIC: macroscopic peritoneal >2 cm above the pelvic brim.
Stage IV: Distant metastasis excluding peritoneal metastases.
IVA: pleural effusion with malignant cells
IVB: metastases to extra-abdominal organs and lymph nodes  outside abdomen and parenchymal metastases.
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(Dobrzycka et al., 2009) and lead to a constitutive activation of the GTPases, which 
phosphorylate its downstream targets and effectors (Burotto et al., 2014). The majority of 
BRAF mutations occur from a substitution of valine to glutamic acid at position 600 in the 
exome 15 (V600E) and seem to be mutually exclusive with KRAS mutations (Ilenkovan and 
Gourley, 2018; Romero et al., 2013). KRAS somatic mutations are the most frequent 
alterations in mucinous subtype (40% to 65% of MC (Morice et al., 2019)) and are found in 
>20% of LGSOC and EMC, while BRAFV600E is observed in less than 5% of type I EOC 
(Geyer et al., 2009; Romero et al., 2013). Amplification of ERBB2 (gene encoding for 
HER2) has been revealed in 19% of MC and 14% of CCC (Anglesio et al., 2013). Other 
well-identified and diffused mutations include PIK3CA, PTEN and ARID1A. The PIK3CA 
gene encoding the catalytic subunit (p110α) of PI3K protein, is an oncogene whose 
phosphorylation activates AKT. The PI3K/AKT signaling pathway controls many cellular 
processes, such as cell proliferation, apoptosis and motility (Ediriweera et al., 2019). The 
region containing PIK3CA is amplified in 50% of ovarian carcinomas (Bader et al., 2005) 
but its mutations, mostly missense, are observed mainly in the small subset of EMC and 
CCC subtypes, in which their frequency is approximately of 20% (Levine et al., 2005; Wang 
et al., 2005). PTEN is an oncosuppressor gene and inactivating somatic mutations are 
uncommon in sporadic EOC. PTEN is inactivated by loss of heterozygosity (LOH), which 
means the loss of the second wild type allele containing the gene of interest when the first 
allele was already mutated, in only 3-8% of cancers largely EMC, CCC and LGSOC, while 
PTEN promoter hypermethylation causes loss of expression in >20% of CCC (Bast et al., 
2009; Ilenkovan and Gourley, 2018). Another oncosuppressor gene is ARID1A, whose 
inactivating mutations (somatic truncating or missense mutations) are the most frequently 
observed in CCC subtype, accounting for 46% of cases and in 30% of EMC (Wiegand et al., 
2010).  
In 2011 The Cancer Genome Atlas (TCGA) Research Network employed whole exome 
sequencing and a variety of other high-throughput technologies to analyze 489 HGSOC 
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samples and catalog their exome sequences, DNA copy number, mRNA and microRNA 
expression, from which emerged the main HGSOC’s molecular alterations (Cancer Genome 
Atlas Research Network, 2011). HGSOC, which is the predominant and most representative 
subtype for type II ovarian cancers, usually evolves rapidly and is characterized by 
aggressive biological behavior and genomic instability, which is clearly associated with the 
mutational profile. HGSOC shows a simple mutational profile: tumours harbor TP53 
mutations in almost all cases, making evident its role as an essential driver mutation in the 
pathogenesis of HGSOC (Ahmed et al., 2010; Cancer Genome Atlas Research Network, 
2011; Cole et al., 2016). TP53 mutations are usually missense and tend to cluster in the DNA 
binding domain region (exon 5 to 9), but also non- sense or frameshift mutations may be 
observed all over the coding region (Ahmed et al., 2010; Silwal-Pandit et al., 2014). Such 
mutations can cause both loss-of-function or gain-of-function effects on p53 protein (Silwal-
Pandit et al., 2017).  
Beside TP53, the TCGA study registered mutations in other genes albeit with a low 
prevalence, but which were statistically significant: BRCA1, BRCA2, NF1, RB1, PTEN and 
CDK12. In the TCGA cohort, BRCA1 and BRCA2 harbor germline mutations in 8% and 6% 
of samples respectively, and somatic mutations in an additional 3% of sporadic tumours, 
making them the second most mutated genes in HGSOC (Cancer Genome Atlas Research 
Network, 2011; Hennessy et al., 2010). BRCA1 and BRCA2 mutations are largely frameshift 
insertions or deletions in different genetic regions coding for the protein functional domains. 
In general, it has been assessed that 81% of BRCA1 and 72% of BRCA2 mutations are 
followed by LOH indicating a biallelic inactivation, while promoter hypermethylation 
constitutes an alternative mechanism also leading to loss of BRCA1 expression (not BRCA2), 
observed in 10% to 20% of HGSOC (Cancer Genome Atlas Research Network, 2011; 
Ceccaldi et al., 2015). Of note, genetic or epigenetic silencing of BRCA1 are mutually 
exclusive, both contributing to BRCA silencing (Konstantinopoulos et al., 2015). BRCA1 
and BRCA2 proteins act in the homologous recombination (HR) pathway involved in the 
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DNA repair mechanism and later studies showed that more than a half of HGSOC presented 
HR deficiencies, a condition determined not only by BRCA1/2 alterations, but also by 
mutations in FA genes (mainly PALB2, FANCA, FANCI, FANCF, FANCD2 and FANCC), 
in core HR restriction site associated DNA (RAD) genes (RAD50, RAD51 and RAD51C), 
and in DNA damage response genes involved in HR (ATM, ATR, CHEK1, and CHEK2) 
found mutated or silenced with a low prevalence in HGSOC (Ceccaldi et al., 2015; 
Mittempergher, 2016). Globally, all the alterations that affect HR genes or related genes 
induce a HR deficiency, a condition termed "BRCAness” phenotype, one of the hallmarks 
of HGSOC (Konstantinopoulos et al., 2015; Turner et al., 2004). However, other genes 
involved in different DNA repair pathways, such as nucleotide excision repair (NER) and 
MMR, can be found mutated in HGSOC, albeit with a low frequency (<10%) (Cancer 
Genome Atlas Research Network, 2011; Konstantinopoulos et al., 2015).  
CDK12 has emerged as a possible new hit in ovarian cancer, where it has been found mutated 
in 3% of cases (Cancer Genome Atlas Research Network, 2011). CDK12 belongs to the 
cyclin-dependent kinases family, it is classified as an oncosuppressor and its role consists in 
the transcriptional regulation of several genes, included some involved in the HR, such as 
ATM, ATR, CHK1, FANCI, MDC1 and RAD51C (Chilà et al., 2016). Cells expressing 
inactive CDK12 have been reported to contain functional defects in HR repair and display a 
tandem duplication phenotype (Vanderstichele et al., 2017). 
High grade serous ovarian cancer is mostly characterized by chromosomal instability, in 
particular copy number alterations (CNA), gain or loss of DNA sequences. Heterozygous or 
homozygous loss are determinants for oncosuppressor inactivation. PTEN has been found 
deleted in 7% of HGSOC (Konstantinopoulos et al., 2015) with possible consequences on 
HR activity. Mendes-Pereira and colleagues proposed that PTEN deficiency could be linked 
to transcriptional downregulation of RAD51 and therefore cause a HR defective (HRD) 
phenotype (Mendes-Pereira et al., 2009). Also, RB1 and NF1 are tumour suppressors located 
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in regions affected by homozygous deletions in at least 2% of HGSOC (Cancer Genome 
Atlas Research Network, 2011). 
The most common amplified genes are CCNE1, EMSY and MYC in more than 20% of 
HGSOC (Cancer Genome Atlas Research Network, 2011). 14% of HGSOC shows an 
amplification of CCNE1, which is mutually exclusive with BRCA1/2 loss (Cancer Genome 
Atlas Research Network, 2011). CCNE1 overexpression promotes uncontrolled proliferation 
and increases genomic instability. Moreover, CCNE1-amplified tumours represent a well-
studied group since they are associated with poor overall survival and primary treatment 
failure (Mittempergher, 2016). EMSY amplification is reported in 17% of HGSOCs and 
represents another mechanism of HR deficiency. This could be due to the interaction of 
EMSY with BRCA2, leading to inhibition of its transcriptional activity (Hughes-Davies et 
al., 2003). However, the exact role of EMSY alterations in HR deficiency is still controversial 
(Mittempergher, 2016).  
Genomic instability in type II EOC reflects the global effect of TP53 alterations and DNA-
repair deficiency, which make the tumour more susceptible to DNA breaks and 
chromosomal rearrangements. Furthermore, aberrations that occur in type I tumours are not 
observed in type II and vice versa, and this may in part explain the deep differences between 
these groups, assessing even more the concept of EOC as a heterogeneous group of diseases. 





Figure 1.10 The most common genetic and epigenetic abnormalities 
occurring in the ovarian cancer subtypes 
The graph on the left shows the main abnormalities occurring in the different type I 
tumour-subtypes. On the right side are highlighted the main alterations and their 
frequencies found in type II tumours (high grade serous and endometrioid carcinomas).  
 
Other attempts to classify EOC took into consideration tumour gene expression 
profiles. Tothill et al. (Tothill et al., 2008), as well as Tan et al. (Tan et al., 2013) 
through microarray gene expression profiling identified distinct biological subtypes of 
ovarian carcinoma. In the first study 285 serous and endometrioid tumours of the 
ovary, fallopian tubes and peritoneum, low grade and high grade, were analysed and 
their expression profiles correlated with clinical outcomes. Six molecular signatures 
were identified and validated in an independent dataset; two mainly represented low 
grade serous and endometrioid tumours, respectively, while the other four subtypes 
included high grade serous and endometrioid tumours, confirming that high grade 
serous and endometrioid are molecularly similar. These subtypes were named: C1 
(high stromal response), C2 (high immune signature), C4 (low stromal response) and 
C5 (mesenchymal, low immune signature).  C1 showed a significant trend toward early 
relapse and short overall survival, and overexpression of stromal response biomarkers; 
C2 was particularly enriched in tumour infiltrating T-cells; C4, unlike C1, had higher 
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level of E-cadherin, an epithelial marker, and low stromal associated factors; C5 was 
firstly described, and particularly reflects epithelial to mesenchymal transition (EMT) 
tracts, such as low E-cadherin levels, activation of WNT/β catenin pathway and 
overexpression of vimentin and N-cadherin, markers of mesenchymal cells (Tothill et 
al., 2008). Subsequently, Tan et al. (Tan et al., 2013) using a cohort of 1538 EOC 
including all the histotypes, identified five molecular subtypes: Epithelia-A (Epi-A), 
Epithelia-B (Epi-B), Mesenchymal, Stem-like-A (Stem-A) and Stem-like-B (Stem-B), 
and correlated them with clinicopathological information. The aim of this study was 
to better explore the potential of gene expression profiles as predictive biomarker and 
to find specific vulnerabilities that could be exploited during treatment decision. For 
instance, the Stem-A subtype was associated with poor prognosis, but was sensitive to 
vincristine and vinorelbine, two microtubule polymerization inhibitor drugs, leading 
to the possibility of tailoring personalized treatment for ovarian cancer patients based 




1.1.4 Management of EOC 
1.1.4.1 Primary treatment  
Primary treatment of newly diagnosed EOC has evolved over the last 50 years on an 
evidence-based approach and integrates surgical intervention with systemic chemotherapy 
(adjuvant and neoadjuvant, whether necessary), followed by an appropriate follow-up.  
The main goal of surgical intervention besides establishing the FIGO stage, is to achieve 
complete resection, consisting in the removal of all visible macroscopic disease, with no 
residual tumour (R0). In fact, residual tumour after cytoreductive surgery is one of the most 
important determinants of long-term survival, with the amount of residual tumour being 
inversely proportional to patient survival (du Bois et al., 2009; Griffiths, 1975). Du Bois et 
al. reported that even if the preoperative tumour burden (as indicated by different FIGO 
stages) maintained an important prognostic role, complete surgical debulking significantly 
improved prognosis in any FIGO stage in HGSOC. In particular, the median survival in the 
group of complete debulking surgery was 99.1 months (95% CI, 83.5 to 100) compared to 
those of small residual tumour burden after surgery (1-10mm) group (36.2 months, 95% CI, 
34.6 to 39.4) and macroscopic residual tumour burden (>1cm diameter) group (29.6 months, 
95% CI, 27.4 to 32.2) (du Bois et al., 2009). 
Surgery includes, whenever possible, complete hysterectomy, bilateral salpingo-
oophorectomy, complete tumour debulking, omentectomy, diaphragm resection and bulky 
lymph node removal (Jayson et al., 2014). It is important to distinguish surgical approaches 
used in early stage and those for advanced disease. Once optimal staging laparoscopy 
assesses the presence of low-risk early EOC (FIGO stage IA-IB, non-clear cell carcinoma or 
borderline tumours, grade 1) and does not detect occult disease, fertility conservative surgery 
is indicated in young women, with the aim of preserving the remaining ovary and uterus 
(Komiyama et al., 2016; Trimbos, 2017). For early stage disease, there is no indication for 
adjuvant chemotherapy, since it does not improve overall survival (OS) or progression free 
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survival (PFS) (Trimbos, 2017). On the contrary, maximal debulking surgery is always 
recommended for advanced EOC, even if not always feasible. It has been estimated that in 
30% to 60% of high-grade EOC, it is possible to obtain an optimal debulking surgery, with 
a residual tumour ≤ 1 cm in diameter, or suboptimal surgery (residual tumours >1 cm) (Orr 
and Edwards, 2018b). Interval debulking surgery (IDS) should be considered as a treatment 
option if primary surgery is not possible due to extensive disease, metastasis or poor patient 
condition (Komiyama et al., 2016). IDS has the same aim of complete resection and is 
generally performed after 3 or 6 cycles of neoadjuvant chemotherapy (NACT), and followed 
by additional adjuvant chemotherapy cycles (Lheureux et al., 2019a). EORTC 55971 and 
CHORUS randomized clinical trials have demonstrated a non-inferior prognosis for patients 
treated with NACT + IDS, respect those treated with primary debulking surgery followed 
by chemotherapy (Kehoe et al., 2015; Vergote et al., 2010) leading to increased use of NACT 
+ IDS over the past decade in EOC patients.  
Together with surgery, adjuvant chemotherapy has a central role in the treatment of 
advanced EOC (FIGO stages II-IV). The standard frontline therapy is a combination of 
platinum and taxane doublet, typically administered both intravenously, every 3 weeks, for 
6 cycles of treatment, even if over the last decades, several variations have been explored 
(Marth et al., 2017). The introduction of cisplatin (DDP) in 1976 as front-line therapy 
significantly improved PFS in the first clinical trial (Wiltshaw and Kroner, 1976). In 1979 
FDA approved the use of DDP for the treatment of EOC, but only in the late ‘80s, when anti-
emetic drugs were introduced, DDP became the treatment of choice (Muggia, 2009). Clinical 
trials by the Gynaecologic Oncology Group (GOG) later explored DDP in combination with 
cyclophosphamide, which became the reference regimen for subsequent trials until the 
randomized trial GOG111, comparing DDP/paclitaxel regimen with the standard 
DDP/cyclophosphamide, showed a superior survival outcome in the new combination arm 
(McGuire et al., 1996). Afterwards, GOG158 trial reported less toxicity and the same 
efficacy using carboplatin than DDP, with paclitaxel (Ozols et al., 2003), defining 
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carboplatin/paclitaxel as the best tolerated doublet and that has been the standard regiment 
for first-line treatment in advanced EOC over the last 20 years.  
During this period, several studies have tried to address some questions on different 
platinum/taxane schedule, dose density, mode of administration (intravenous and/or 
intraperitoneal), role of hyperthermia, and additional chemotherapeutic agents. GOG132 and 
ICON3 trials investigated the potential of platinum monotherapy, showing that platinum had 
the dominant effect on outcome, but subsequent treatment with paclitaxel upon recurrence, 
extended survival (International Collaborative Ovarian Neoplasm Group, 2002; Muggia et 
al., 2000). When paclitaxel was combined with a platinum compound, the combination 
extended PFS longer than monotherapy (Parmar et al., 2003). Platinum monotherapy has not 
been completely excluded, and is recommended for frail and elderly patients, who may not 
tolerate the combination regimen (Komiyama et al., 2016). Alternative schedules of 
administration of platinum and paclitaxel include the dose-dense carboplatin/paclitaxel 
regimen, based on the Norton-Simon hypothesis, in which shorter interval between doses of 
cytotoxic agents should be more effective in reducing tumour burden than dose escalation 
(Simon and Norton, 2006). Dose-dense therapy has been applied in EOC patients receiving 
paclitaxel (1h intravenous, at 80 mg/ml on days 1, 8, and 15) plus carboplatin (1h 
intravenous, at an AUC of 6 on day 1), every 3 weeks for 6 cycles (Lheureux et al., 2019a). 
The Japanese trial JGOG3016 revealed a significant improvement in survival outcomes in 
patients who received dose-dense regimen than the standard ones (Harano et al., 2014), but 
the ICON8 study, performed in a European population, did not confirm any PFS 
improvement and reported several cases of toxicity, which led to premature trial stop (Clamp 
et al., 2019). In the absence of confirmatory data, dose-dense administration of paclitaxel 
currently can be considered an option, but not a standard of care.  
Intraperitoneal (IP) chemotherapy uses an intra-abdominal device to locally administer, 
usually platinum agents, directly into the abdominal cavity leading to a higher drug exposure 
in cancer cells than after intravenous injection. It has been found to significantly prolong 
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PFS and OS in three studies (GOG104, 114 and 172) (Alberts et al., 1996; Armstrong et al., 
2006; Markman et al., 2001): however, the regimen was poorly tolerated, due to toxicity 
related to chemotherapy itself, infections and abdominal discomfort, as only 42% of patients 
were able to finish all 6 cycles. For these reasons, IP chemotherapy has not been adopted as 
a standard of care in the majority of countries.  
A second complementary therapeutic strategy is Hyperthermic Intraperitoneal 
Chemotherapy (HIPEC), already applied with efficacy in other peritoneal diseases, such as 
peritoneal carcinomatosis from colon and gastric cancer (Esquivel, 2016). HIPEC is done at 
the completion of cytoreductive surgery. No clear-cut efficacy data exist for HIPEC in EOC; 
HIPEC was used in different regimens and in heterogeneous patients, with discordant results 
in terms of survival improvement (Chiva and Gonzalez-Martin, 2015; van Driel et al., 2018).  
The role of other cytotoxic drugs in combination with DDP and/or the doublet 
DDP/paclitaxel has been investigated. Pegylated liposomal formulation of doxorubicin 
(PLD) is a new formulation of doxorubicin characterized by a better toxicological profile, in 
particular with less cardiotoxicity, and improved efficacy. PLD in combination with 
carboplatin was evaluated in first-line chemotherapy for women with advanced EOC in a 
large randomized clinical trial MITO-2 (Pignata et al., 2011) and in a subsequent large 
Cochrane meta-analysis (Lawrie et al., 2013). These studies reported that PLD/carboplatin 
was as effective as the standard doublet regimen regarding PFS and OS outcomes in first-
line chemotherapy; however, women treated with PLD experienced more toxicity (anemia 
and thrombocytopenia) leading to a higher % of treatment discontinuation (Lawrie et al., 
2013). Based on these results, the platinum/PLD combination cannot be considered among 
the best therapeutic options, but it may be used in patients who do not tolerate or are allergic 
to paclitaxel. Topotecan and gemcitabine treatments, which have reproducible activity and  
reasonable therapeutic index, have been tested in EOC frontline treatment in combination 
with DDP/paclitaxel; however, their addition to DDP/paclitaxel (triplet regimen) in the five-
arm phase III randomized trial GOG182-ICON5 was not better than the standard doublet 
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(Bookman et al., 2009), confirming doublet carboplatin/paclitaxel chemotherapy as the 
optimal therapeutic option, despite its side effects (nausea, vomiting, myelosuppression, 
peripheral neuropathy, and alopecia) (Lheureux et al., 2019a). 
It is important to note that treatment guidelines are mainly driven by response rates of high-
grade serous carcinoma, the predominant advanced EOC subtype and the most sensitive to 
this chemotherapy regimen. Nevertheless, rarer tumours like low-grade serous carcinoma, 
clear cell carcinoma, mucinous carcinoma and undifferentiated cancers are much less 
responsive to the platinum-based chemotherapy (Lheureux et al., 2019a). Based on EOC 
cumulating biological knowledge, the management of ovarian cancer is evolving from a one-
size-fits all approach towards a personalized one, that considers both histology and 
molecular characteristics. For example, based on LGSOC’s biology, MEK-inhibitor 
treatment has been evaluated in recurrent tumours and hormonal therapy in LGSOC frontline 
treatment, as well as immunotherapy is being assessed in CCC (Lheureux et al., 2019a).  
Treatment response after first-line therapy is monitored through follow-up visits, in which 
pelvic examination and CA125 measurement are considered [113]. Even single evaluation 
of elevated CA125 levels did not demonstrate the capacity to predict the onset of tumour 
recurrences, CA125 levels considered together with clinical pelvic examination through 





1.1.4.2 Treatment of relapses 
Despite ~80% of women with advanced ovarian carcinoma having a good response to first-
line treatment, more than 70% of them will experience recurrent disease within the first 3 
years (Bowtell et al., 2015). Recurrent ovarian cancer (ROC) is rarely, if ever, curable so the 
main treatment aim in this setting is to prolong patient survival maintaining a good quality 
of life. While the leading approach is chemotherapy, as surgery is indicated for few selected 
patients, actually there is no standard treatment. Even if the number of available therapies 
has increased, the selection of the most appropriate regimen remains challenging. 
Considerable efforts have been undertaken to find biomarkers able to predict tumour 
sensitivity to therapy and to overcome treatment failure.  
The prognosis and probability of ROC’s response are based on progression-free interval 
(PFI), the interval from the last dose of platinum-based chemotherapy and the onset of ROC, 
which defines different platinum sensitive patients, and guides the subsequent therapy. Ten 
to 15% of patients are considered “platinum-refractory”, when they experience progression 
or stable disease during first-line chemotherapy, or when ROC appears within one months 
from the end of first-line chemotherapy. In these cases, the tumour is considered intrinsically 
resistant and the median survival is < 9 months (Lheureux et al., 2019a). “Platinum-resistant” 
disease responds to primary treatment, but recurrence occurs within 6 months, and this 
condition affects 20% to 30% of patients (Lheureux et al., 2019a). Platinum-
refractory/resistant population has a poor prognosis and a null or poor response rate to 
platinum-based chemotherapy (<10%), even if some attempts to overcome platinum 
resistance have evaluated dose-dense chemotherapy or a dose-fractionated weekly therapy 
(Armbruster et al., 2018). Platinum-refractory and resistant EOC are usually treated with a 
single-agent chemotherapy based on topotecan, paclitaxel, PLD or gemcitabine, which have 
different objective response rate (ORR) and toxicity (Armbruster et al., 2018). Treatment of 
platinum-refractory or resistant EOC should be mainly focused on maintaining quality of 
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life and controlling symptoms, since the efficacy of pharmacological treatments decreases 
after each line.  
Patients with a durable response to first-line platinum therapy are a heterogeneous group, 
which includes platinum-partially sensitive patients with a PFI between 6 and 12 months and 
platinum-sensitive patients, who experience a PFI ≥12 months. Partially sensitive and 
sensitive patients show a better response to a second platinum-containing regimen than to 
alternative non-platinum therapies (Lheureux et al., 2019a). Several therapeutic options are 
available for this group: platinum can be combined with paclitaxel, PLD or gemcitabine, and 
all these combinations are associated with better outcomes, so the choice will rely on side 
effects and hypersensitivity to the selected drugs. Treatment is usually administered for 
many cycles, until resistance or toxic side-effects appear.  
An important “evolution” regarding the PFI concept is underway starting from the proposal 
during the fifth Ovarian Cancer Consensus Conference in Tokyo to reflect a wider range of 
treatments by replacing PFI with “treatment free interval” (TFI), which takes into 
consideration the period starting from the last dose of any treatment, not only platinum 
(TFIp), but also non-platinum agents (TFInp) or other biological agents (TFIb) (Wilson et 
al., 2017). 
1.1.4.3 Targeted therapies and new drugs 
The standard of care of EOC takes into little consideration the histological subtype or the 
genomic profile of the single case, but in the era of precision medicine, there is mounting 
interest for molecular-targeted therapies able to hit driver mutations or molecular targets, 
such as angiogenic mechanisms, DNA repair and signal transduction pathways (Rojas et al., 
2016). At the moment, only two targeted therapies are approved by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for the maintenance 
therapy of EOC and treatment of ROC. These are anti-angiogenic agents, such as 
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bevacizumab, and poly-adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitors 
(PARPi), such as olaparib, niraparib and rucaparib.  
Bevacizumab is a humanized monoclonal antibody specifically directed against vascular 
endothelial growth factor A (VEGF-A) and the most studied anti-angiogenic agent. VEGF 
is a family of key regulators of angiogenesis, involved in endothelial cell survival, 
proliferation and vascular permeability. Increasing levels of VEGF in EOC promote tumour 
vascularization and vascular permeability which favor metastatic spread and ascites 
formation (Garcia et al., 2020). The rational for the use of anti-angiogenic therapy is based 
on evidence, where increased levels of VEGF in EOC were associated with poor prognosis 
and platinum resistance (Siddiqui et al., 2011). Bevacizumab in combination with 
chemotherapy, was studied in several phase III trials in platinum-sensitive and platinum-
resistant recurrence settings. The OCEANS and GOG213 phase III randomized studies 
investigated the association of standard chemotherapy (carboplatin/gemcitabine or 
carboplatin/paclitaxel, respectively) in patients with platinum-sensitive ROC, who received 
one prior line of therapy. These studies compared chemotherapy with or without 
bevacizumab, followed by maintenance with or without bevacizumab (Aghajanian et al., 
2012; Coleman et al., 2017). Both reported a significant increment in PFS in the arm treated 
with bevacizumab (12.4 vs 8.4 months in OCEANS and 13.8 vs 10.4 months in GOG213), 
and GOG213 also reported a higher OS (42.2 vs 37.3 months in chemotherapy + 
bevacizumab versus chemotherapy alone) (Coleman et al., 2017). The AURELIA phase III 
open-label trial demonstrated higher efficacy in terms of PFS of bevacizumab associated 
with single-agent chemotherapy (PTX or PLD or topotecan) than chemotherapy alone, in 
women with platinum-resistant ROC (PFS: 6.7 vs 3.4 months, respectively). Bevacizumab 
also improved quality of life in these patients and a retrospective analysis of AURELIA trial 
showed that the sub-group of patients with ascites had a major benefit from bevacizumab 
treatment, suggesting ascites as a phenotypic marker for anti-angiogenic therapy (Rojas et 
al., 2016). All these results were recently confirmed with cediranib, a tyrosine kinase 
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inhibitor that specifically target VEGF receptor (VEGFR) (Rojas et al., 2016). Cediranib and 
bevacizumab displayed similar efficacy and similar side effects (Lheureux et al., 2019a; 
Monk et al., 2016). However, benefits derived from anti-angiogenic therapy in EOC should 
be balanced with toxicity and related-costs, and although these agents are widely used, the 
lack of molecular biomarkers is a drawback in their use (Monk et al., 2016).  
PARPi, whose mechanisms of action and determinants of response will be discussed in detail 
in the following chapters, are the most active and interesting class of agents recently 
approved for the treatment of EOC. Briefly, PARP is a large family of multifunctional 
proteins, where PARP1 is the prevalent isoform. PARP1 is involved in the base excision 
repair (BER) pathway, able to repair DNA single-strand breaks (SSBs). PARP1 inhibition 
causes an accumulation of un-repaired SSBs and stalled replication fork (RF), which in turn 
degenerate into the most lethal DNA double-strand breaks (DSBs). Cancer cells with defects 
in the DBS-repair pathways, such as HR, accumulate a great number of DSBs which 
determine the block of RF and enhance genomic instability, leading to cancer cell death. The 
rationale of the use of PARPi relies on the concept of synthetic lethality that was firstly 
introduced in biology by C. Bridges during his studies on Drosophila Melanogaster, then 
taken forward for the development of new cancer therapeutic approaches by Hartwell and 
colleagues (reviewed by (Ashworth and Lord, 2018; Hartwell et al., 1997)). The concept of 
“synthetic lethality” describes the situation whereby a combination of two defective genes 
or proteins induce severe effects or death, whereas the single defective gene/protein is not 
dangerous per se. This concept was further applied to explain the results reported in 2005 in 
two preclinical seminal studies, which demonstrated the extreme sensitivity of BRCA1 and 
BRCA2 mutated tumours to PARPi (Bryant et al., 2005; Farmer et al., 2005), laying the 
foundations for their clinical development. In the case of EOC, where half of the HGSOCs 
are HRD, the synthetic lethality approach aims to hit a second DNA repair pathway (i.e. 
BER) on which the HRD cancer cells rely on to repair DNA damage and survive. Olaparib 
was the first PARPi introduced into clinical practice and from 2014 and the end of 2017, 
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other PARPi, rucaparib and niraparib respectively, were approved in Europe and USA for 
the treatment of EOC, but with different clinical indications. Briefly, the most recent 
guidelines released from EMA (“www.esmo.org/guidelines/gynaecological-cancers/newly-
diagnosed-and-relapsed-epithelial-ovarian-carcinoma/eupdate-ovarian-cancer-treatment-
recommendations,” n.d.) indicate the use of all the PARPi (olaparib, rucaparib and niraparib) 
as monotherapy in the maintenance setting, following platinum-based chemotherapy in 
relapsed, platinum sensitive, HGSOC adult patients, who are in complete or partial response 
to platinum-based therapy, regardless of BRCA status. Moreover, EMA approved 
monotherapy with rucaparib for patients with germline or somatic BRCA1/2-mutations who 
have received at least two lines of platinum-based chemotherapy, but are unable to receive 
again platinum due to toxicity (Oza et al., 2017).  
Currently, FDA has approved olaparib, rucaparib and niraparib as monotherapy in the 
maintenance setting of advanced recurrent HGSOC patients, in complete or partial response 
to platinum-based therapy. Olaparib was also extended to 4th line monotherapy in germline 
or somatic BRCA-mutated patients and rucaparib as 3rd line monotherapy also in germline 
or somatic BRCA-mutated carriers. Even in the USA the tendency is to extend as much as 
possible the population of patients that could benefit from PARPi therapy, also in HRD not 
established patients.    
The time scale approvals of PARPi by EMA and FDA, and their clinical indications are 





Table 1.2 Time scale of PARPi approvals in Europe and USA and therapeutic indications 
Drug 
Year of 









FDA Advanced OC g BRCA1/2 mut 
4th line monotherapy 
treatment 
Olaparib (tablets) 
2017 FDA Recurrent OC, in CR or PR to DDP therapy g BRCA1/2 mut Monotherapy maintenance 
2018/19 
EMA 
DDP sensitive, relapsed HGSOC, post CR or PR to 
DDP therapy 













Advanced OC / progressive disease 
g/s BRCA1/2 
mut 
3rd line monotherapy 
treatment 
Recurrent OC, in CR or PR to DDP therapy - Monotherapy maintenance 
2018 
EMA 
DDP sensitive, relapsed or progressive HGSOC 
g/s BRCA1/2 
mut 
3rd line monotherapy 
treatment 
2019 DDP sensitive, relapsed HGSOC, in CR or PR to DDP 
therapy 
- Monotherapy maintenance 
Niraparib 2017 
FDA Recurrent OC, post CR or PR to DDP therapy - Monotherapy maintenance 
EMA DDP sensitive, relapsed HGSOC, in CR or PR to DDP 
therapy 
- Monotherapy maintenance 
Abbreviations: FDA= Food and Drug Administration; EMA= European Medicine Agency; EOC= epithelial ovarian cancer; Advanced= FIGO stage III or IV; 
DDP= platinum; CR= complete response; PR= partial response; g= germline; s= somatic; mut= mutation.
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The use of PARPi in the maintenance setting was investigated in phase II and phase III trials. 
STUDY19 and SOLO-2 (phase II and III respectively) for olaparib, NOVA for niraparib and 
ARIEL-3 for rucaparib (Coleman et al., 2017; Ledermann et al., 2012, 2014; Mirza et al., 
2016a; Pujade-Lauraine et al., 2017). Survival has been evaluated in treated arms compared 
with placebo arm, in recurrent, platinum-sensitive HGSOC patients. PFS was significantly 
improved in PARPi-treated arms (median PFS ranging from 16.6 to 21.0 months considering 
the different trials) than in the placebo arm (median PFS ranging from 5.4 to 5.5 months) 
(table 1.3). BRCA-mutated patients had the major benefit in terms of median PFS (hazard 
ratio (HzR) ranging from 0.18 to 0.27 in the different trials), respect those classified as HRD-
positive (HzR ranging from 0.38 to 0.44). However, analyses of PFS in intention to treat 
population or in BRCA-wild type patients have demonstrated a significant increase in PFS 
in treated patients irrespective of BRCA or HRD status. In particular, niraparib in non-
germline BRCA-mutated group showed a median PFS of 9.3 vs 3.9 months in placebo (HzR 
0.45, 95% CI, 0.34-0.61) (Mirza et al., 2016a); in rucaparib trial the intention-to-treat 
population had a median PFS of 10.8 vs 5.4 months of placebo (HzR 0.36, 95% CI, 0.30-
0.45) (Coleman et al., 2017); data obtained analyzing a subgroup of non-BRCA mutated 
tumours in STUDY 19 treated with olaparib, showed a median PFS of 7.4 vs 5.5 months in 
placebo (HzR 0.54, 95% CI, 0.34-0.85) (Friedlander et al., 2018; Ledermann et al., 2014; 
Pujade-Lauraine et al., 2017) (table 1.3). Taken together these results lead to the latest EMA 
approval for PARPi regardless of the BRCA status of tumours.  
Data regarding OS are not yet completed apart for the first STUDY 19, where patients treated 
with olaparib did not experience a significant increment in OS (HzR 0.73, 95% CI, 0.55-
0.95). It has been reported in this study 11% of long-term survival (PFS >6 years) of treated 





Table 1.3 Results of PARPi maintenance therapy in HGSOC 
 
Abbreviations: EOC= epithelial ovarian cancer; PFS= median progression free survival; HzR= hazard ratio; LOH= loss of heterozygosity; HRD= homologous recombination deficiency.  
*PFS in intention to treat population, including all patients recruited in ARIEL3. 
   PFS depending on specific biomarkers considered in each trial 
Clinical trial Patient 
Population 
Study design BRCA-mutated 
BRCA-wild 
type 
HRD +  HRD –  
Olaparib/Study 19 
[Ledermann et al., 2012, 





Randomized 1:1, double blind, 
placebo controlled, phase II. 
PFS: 11.2 months 
vs 4.3; 
HzR= 0.18 
PFS: 7.4 months 
vs 5.5; 
HzR=0.54 
Not considered Not considered 
Olaparib/SOLO2 
[Pujade-Lauraine et al., 
2017] 
Randomized 2:1, double blind, 
placebo controlled, phase III. 
PFS: 19.1 months 
vs 5.5; 
HzR= 0.3 
Not included Not considered Not considered 
Niraparib/NOVA 
[Mirza, et al., 2016] 
Randomized 2:1, double blind, 
placebo controlled, phase III. 
PFS: 21.0 months 
vs 5.5; 
HzR= 0.27 
PFS: 9.3 months 
vs 3.9; 
HzR= 0.45 
PFS: 12.9 months vs 3.8; 
HzR= 0.38 
*HRD defined by Myriad assay 
PFS: 6.9 months vs 3.8; 
HzR= 0.58 
Rucaparib/ARIEL3 
[Coleman et al., 2017] 
Randomized 2:1, double blind, 
placebo controlled, phase III. 




 months vs 5.4; 
HzR= 0.36 
PFS: 9.7 months vs 5.4; 
HzR= 0.44 
 
*HRD defined by Foundation 
Medicine ’s T5 NGS assay 




1.2 DNA REPAIR  
1.2.1 DNA repair and cancer 
In normal cells, genomic integrity is the result of high-fidelity replication processes 
associated with mechanisms that recognize and actively repair DNA lesions induced by 
endogenous or exogenous insults (Ganai and Johansson, 2016). The articulated signalling 
network responsible for DNA integrity is defined as DNA damage response (DDR) and 
DNA repair pathways are part of this network (Carrassa and Damia, 2017). DDR actively 
monitors the genomic integrity, and, in the presence of DNA lesions, it suspends cell cycle 
progression and activates the appropriate DNA repair pathway to solve each kind of lesion 
to preserve genomic integrity. Different types of DNA lesions are known: single base 
modifications, mismatches, intra- or inter-strand cross links (ICLs) and DNA single- (SSB) 
or double-strand breaks (DSB), and for each kind of damage detected on DNA, one or more 
specific DNA repair pathways are activated by DDR sensors in order to remove the lesion 
and replace the original sequence (Abbotts and Wilson, 2017; Hashimoto et al., 2016; 
Kinsella, 2009; Wright et al., 2018). Once the lesion has been repaired, the cell cycle 
progresses, or, in the alternative, DDR activates apoptosis to avoid an accumulation of 
dangerous DNA alterations (Carrassa and Damia, 2017). In fact, genetic or epigenetic 
alterations affecting DDR activity enhance the number of genomic mutations, and if they 
affect oncogenes or oncosuppressor genes, may induce malignant transformation and drive 
tumorigenesis (Kiwerska and Szyfter, 2019). Impaired DDR is one of the hallmarks of 
cancer (Hanahan and Weinberg, 2000), but also a “double-edged sword” because besides 
favouring carcinogenesis, DDR deficiency generally makes cancer cells more sensitive to 
DNA damaging chemotherapies (Ceccaldi et al., 2015; Kiwerska and Szyfter, 2019). In fact, 
DNA repair activity is able to modulate the effect of chemotherapy, since one of the main 
mechanisms of action of standard anti-tumour agents is the induction of severe inter-strand 
cross-links (ICLs), and/or double-strand breaks (DSBs) (Kitao et al., 2018) that if not 
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repaired, increase replication stress, mutational burden and chromosomal instability, finally 
inducing apoptosis (Kiwerska and Szyfter, 2019). 
The progressive characterization of DNA repair pathways and proteins involved in DDR 
elucidated how these pathways interplay with each other and led to identifying targets for 
therapy and new therapeutic strategies. For instance, inhibition of critical genes can be 
exploited to improve responsiveness to standard chemotherapy, or in DDR defective 
tumours target the alternative remaining pathway, which the mutated cell relies on to survive 
has demonstrated the selective efficacy of the synthetic lethality approach. For instance, the 
extreme sensitivity of BRCA1/2 mutated tumours, which have a defective HR pathway, to 
inhibition of PARP1/2 enzymes, involved in the SSB repair, became the paradigm of 
synthetic lethality concept applied to cancer therapy (Bryant et al., 2005; Farmer et al., 
2005).  
Moreover, several DNA repair genes, including ATM, ATR, CHK1 and WEE1 are interesting 
proteins acting between DDR and downstream activation of DNA repair, and are studied as 
therapeutic targets (Carrassa and Damia, 2017). Briefly, ATM and ATR are two kinases 
leading to activation of DDR once DNA damage has been created. In particular, ATM is 
activated in the presence of DSBs, activating then the deputy DNA repair pathway through 
BRCA1/53BP1 proteins to repair the DSB, which promote HR and non-homologous end 
joining (NHEJ) respectively, and regulates the checkpoint in G1/S phase. ATR is activated 
following DNA single-strand breaks (SSB), often a pre-lesion before DSB formation, and 
mediates its activity through CHK1, its downstream effector, which can be phosphorylated 
also by ATM. ATR/CHK1 regulate the checkpoint during the S phase, and in G2/M, 
regulating access in mitosis, and phosphorylate a number of proteins involved in HR and 
ICL repair (Carrassa and Damia, 2017; Maréchal and Zou, 2013). WEE1 is a kinase, which 
also regulates the checkpoint in G2/S cell cycle phases and may activates HR (Carrassa and 
Damia, 2017). ATM, ATR, CHK1 and WEE1 genes can be found mutated in approximately 
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2% of HGSOC, with consequences on DNA repair efficiency (Cancer Genome Atlas 
Research Network, 2011).     
Due to their early and critical activity in inducing the activation of DNA repair, in particular 
HR, regulating the cell cycle phases and apoptosis, several inhibitors are currently being 
tested, alone exploiting the synthetic lethality approach in HR-deficient tumours, or in 
combination with chemotherapy (Carrassa and Damia, 2017; Cleary et al., 2020). 
1.2.2 DNA repair pathways 
Usually, all the DNA pathways are multistep processes, with many proteins involved in the 
same pathways (Abbotts and Wilson, 2017; Hashimoto et al., 2016; Kinsella, 2009; Wright 
et al., 2018).  
DNA repair activity is generally structured in three phases regardless of the type of damage 
or pathway activated: 1) recognition of the damage by specific sensor proteins; 2) activation 
of the suitable effectors to remove DNA damage; 3) restoration of DNA strand integrity.   
The mechanism of action and proteins involved in the seven major cellular DNA repair 
pathways will be described here. In particular, they participate to various extent in the 
removal of platinum adducts (i.e. NER, HR, FA, translesion synthesis (TLS) and MMR) or 
can influence PARPi activity (i.e. HR, FA, non-homologous end joining (NHEJ), BER) with 
consequences on EOC therapy and patient outcome. 
1.2.2.1 Base excision repair  
The base excision repair (BER) is responsible for the repair of aberrant bases on DNA, 
caused by a wide range of endogenous and exogenous insults and it is involved in repair of 
single strand breaks (SSB) (Dianov and Hübscher, 2013) (figure 1.11). The BER process 
consists of different enzymatic steps and is able to repair one or up to 12 nucleotides. In the 
presence of a single damaged nucleotide (the most frequent condition), the short patch BER 
pathway is generally activated, or alternatively, the long patch BER, which mainly involved  
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different glycosylases with respect to the short patch pathway (Kim and Wilson, 2012). The 
damage is recognized and removed by a damage-specific DNA glycosylase, which creates 
an apurinic or apyrimidinic (AP) site, then is processed by AP endonuclease (APE1), with 
the generation of SSB. Replacement of the damaged base and re-ligation of the DNA involve 
binding of poly(ADP-ribose) polymerases (PARP), DNA polymerase β (POLB) and ligase 
I or III (Damia and D’Incalci, 2007). PARP1, following auto-modification, can interact with 
other BER proteins such as XRCC1 and POLB, enabling their recruitment to the damage 
site (El-Khamisy et al., 2003; Mortusewicz and Leonhardt, 2007). In addition, PAR 
polymers formed by PARP-1 at the damaged site have a net negative charge which promotes 
chromatin loosening and facilitates the access to DNA of repair proteins (Weaver and Yang, 
2013). POLB is a small polymerase, which replaces the single damaged nucleotide (Beard 
and Wilson, 2019). Completion of the BER pathway can be performed by either DNA ligase 
I or the DNA ligase IIIα/XRCC1 complex, where XRCC1 acts as a fundamental scaffold to 
bridge polymerase and ligase activity (Sleeth et al., 2004). Proteins acting at different levels 
in the BER pathway have been found dysregulated in different tumours (germline and 
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Figure 1.11 Schematic representation of base excision repair pathway. 
Short patch BER removes and substitutes single damaged nucleotide; long patch BER removes 
and substitutes up to 12 nucleotides; BER through PARP enzyme repairs DNA single strand 
breaks. 
 
1.2.2.2 Mismatch repair 
The mismatch repair (MMR) (figure 1.12) recognizes and corrects the wrong incorporation 
of single nucleotide (mismatch), or erroneous insertion and deletion loops occurring during 
DNA replication (Kunkel and Erie, 2015). MMR involves different well-conserved proteins, 
that detect the mismatches (MSH2-MSH6) forming the heterodimer complex hMutSα, or 
the indel loops (MSH2-MSH3) forming the heterodimer complex hMutSβ. When hMutS 
slides along the newly replicated strand and finds a mismatch to repair, it recruits PMS2 and 
MLH1 proteins, together forming the hMutLα complex. The next steps are not completely 
elucidated in eukaryotic cells, but DNA is unwound, excised by the exonuclease I (Exo1), 
that removes the short sequence (up to 4 nucleotides) containing the error, correctly re-
synthesizes the DNA sequence by polymerase δ or polymerase ε and finally ligates the nick 
(Hsieh and Zhang, 2017; Kunkel and Erie, 2015). MMR can also induce apoptosis recruiting 
ATM/ATR by hMutLα (Gee et al., 2018). Mutations in MMR genes can destabilize the 
genome increasing the mutational rate and inducing microsatellite instability, which favour 
cancer development (Curtin, 2012). Inherited mutations in MMR represent the second most 
common cause of hereditary ovarian cancer, after BRCA1/2 mutations, and are the cause of 
Lynch Syndrome that predisposes to colorectal, endometrial and ovarian cancer (Backes and 
Cohn, 2011). However, MMR alterations can occur in sporadic cancers, usually through 
epigenetic mechanism, such as hypermethylation of hMLH1 promoter leading to lack of 
protein expression (Leskela et al., 2020). 
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Figure1.12 Schematic representation of mismatch repair pathway  
MSH complex slides along the newly replicate DNA strand looking for eventually 
mismatches or indel loops. In proximity of the mismatch, MSH recruits the complex MLHα 
(MLH1+PMS2), unwinding the DNA and activating the nuclease EXO1 for the 5’ to 3’ 
excision of the sequence including the mismatch (up to 4 pb). Finally, the high-fidelity 
polymerase δ or ε re-synthesizes the correct sequence and ligase I completes the ligation. 
 
1.2.2.3 Nucleotide excision repair  
Nucleotide excision repair (NER) is a highly conserved and versatile pathway that 
repairs a broad range of helix-distorting and bulky DNA lesions, mostly induced by 
exogenous sources. This system is one of the major players involved in the removal of 
all cisplatin DNA lesions, including intra-strand and inter-strand crosslinks (ICLs), 
and is almost entirely responsible for the removal of pyrimidine dimers caused by UV 
radiation (Damia and D’Incalci, 2007). It is a multistep process in which at least 20-
30 proteins are involved. Two major NER pathways can be recognized: the global 
genome repair (GGR) pathway, which participates in the context of a non-replicating 
DNA and slowly controls and repairs the entire genome, preventing mutations to be 
passed on to the next generation and keeping genomic integrity; the transcription 

















polymerase is stalled for the presence of DNA damage (Tian et al., 2015). The basic 
steps of NER are: damage recognition; excision and release of the 24-32 nucleotides 
oligomer; synthesis of the excised sequence and ligation. DNA damage is recognized 
by the co-operation of replication protein A (RPA), Xeroderma pigmentosum group A 
(XPA), XPC and TFIIH, which assemble at the damaged site. TCR-NER requires also 
Cockayne syndrome WD repeat protein A (CSA) and CSB to detect the damage, while 
in GGR-NER XPC-RAD23B and DNA damage-binding protein (DDB) participate in 
the process. Therefore, while the two sub-pathways differ in the initial steps of 
recognition of DNA lesions, they converge into a common molecular mechanism. The 
complex formed at the damaged site unwinds the double helix by 25 nucleotides 
around the lesion (thanks to XPB and XPD helicases of TFIIH complex). The 3’ 
endonuclease XPG then replaces XPC in the complex, which gains more stability and 
recruits the 5’ nuclease XPF-ERCC1. These two enzymes are responsible for the 
incision of DNA around the lesion and for the removal of the damaged sequence, the 
limiting step of the process. The gap is then filled by POL δ or POL ε, with the aid of 
the accessory proteins proliferating cell nuclear antigen (PCNA) and replication factor 
C (RFC), and by DNA ligase III (figure 1.13) (Dijk et al., 2014).  
51 
 
Figure 1.13 Schematic view of nucleotide excision repair pathway 
Global NER (GG-NER) repairs overall the genome, while transcription-coupled NER (TC-
NER) quickly acts during transcription. The recognition players are different between GG-
NER and TC-NER. In the first, XPC–RAD23B and DDB are required, while TC-NER 
involves CSA and CSB. XPA, RPA and TFIIH are involved in both pathways. Thereafter 
the steps are common, with unwinding of DNA helix, excision of the damaged 
oligonucleotide by XPG and ERCC1–XPF nuclease, which represent the critical step of the 
process, then synthesis of the oligonucleotide by POLs δ/ε and ligation by DNA ligase III 




1.2.2.4 Homologous recombination 
The homologous recombination (HR) pathway is a multistep, error-free mechanism (figure 
1.14) involved in DNA double strand breaks (DSB), acting during the S and G2 phases of 
the cell cycle (figure 1.15). It relies on the presence of the sister chromatid as a template for 
the DNA sequence to be repaired. First, the MRE11, RAD50 and NSB1 (MRN) complex 
detects and binds the broken ends of DSBs (step 1, fig 1.14), recruiting ataxia telangiectasia 
kinase (ATM). ATM phosphorylates and activates BRCA1 on the DSB site, promoting end 
resection through the MRN-BRCA1–CtIP complex, after CtIP cyclin-dependent-kinase 
(CDK)-mediated phosphorylation leading to the exposure of two ssDNA regions, which 
overhang on either side of the DSB (step 2, fig 1.14). Following, the BRCA2 protein is then 
recruited at the damaged site by BRCA1 and their interaction is mediated by PALB2, which 
is the essential link between BRCA1 and BRCA2 (step 3, fig 1.14). The central player of 
HR repair, the single strand binding protein RAD51, which forms visible nuclear foci, is 
loaded onto the 3’single-strand overhangs by BRCA2 and RAD51, and guides strand 
invasion and copying to homologous sequences in the intact sister chromatid to repair the 
lesion without lack of genetic material (step 3 and 4, fig 1.14). DNA polymerase uses the 
homologous sister chromatid as a template, and uses the ssDNA as a primer to synthesize 
new DNA sequence (step 5, fig 1.14). The final steps involve endonuclease MUS81 and 
ligase IV to solve this complex structure (step 6, fig 1.14) and complete the solution of DSB 
(step 7, fig 1.14) (Lord and Ashworth, 2016).   
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1.2.2.5 Non-homologous end joining 
Classical non-homologous end joining (NHEJ) is also involved in DSB repair predominantly 
during G0/G1 phases or as an alternative to HR when defective. It solves DSBs with minimal 
end processing in an error-prone manner (Chang et al., 2017). Its name is derived from the 
mechanism of action, through which the two breaks end are directly ligated, without using 
the homologous template. This explain the low fidelity of NHEJ products. NHEJ needs the 
activation of KU70/KU80 heterodimer, a ring-like structure which binds DNA at DSB site 
with high affinity and recruits the serine-threonine kinases DNA-PKs, stabilizing them on 
DNA. If the ends of DNA are not compatible, then “overhangs” of DNA need to be removed 
creating a microhomology necessary to guide the process, then re-synthesized by nucleases 
and DNA polymerases such as Artemis. Artemis can form both 3’ and 5’ endonuclease when 
complexed with DNA-PK (Ma et al., 2002). Once the ends are compatible, they can be 
ligated by ligase IV and XRCC4 co-factor (Assis et al., 2013) (figure 1.15). 
A sub-pathway of NHEJ is the alternative-end joining (Alt-EJ), which is activated when 
NHEJ and HR are inhibited or absent, a sort of spare DNA repair pathway, suggesting the 
importance of solving the deleterious DSB for the cell. It can be activated throughout all the 
cell cycle phases and is independent from the KU complex. Alt-EJ uses microhomologies 
distant from DSB, frequently creating deletions or other mutagenic lesions. The key players 
of Alt-EJ are PARP1, XRCC1 and DNA ligase III, and it is promoted by DNA polymerase 
θ (POLQ) (Kent et al., 2015). PARP1 recognizes and binds the DSB competing with KU 
proteins, then XRCC1 and LigIII form a complex to ligate the broken strand (Audebert et 





Figure 1.15 Overview of DNA repair pathways involved in the repair of 
DNA double strand breaks (DSBs) 
NHEJ and Alt-EJ are available during all the cell cycle phases, are quick but error-prone 
mechanisms, while HR acts during replication phase and is a high-fidelity repair system 




1.2.2.6 Fanconi anemia 
Fanconi anemia is a rare inherited syndrome, characterized by congenital defects, 
progressive bone marrow failure and elevated risk of haematological and squamous cell 
carcinomas (Soulier, 2011). The 19 genes of FA encoded for proteins involved in the same 
pathway, which determine ICL repair during the G2/S phase of the cell cycle, orchestrating 
the recognition of the ICL, incision, bypass of the lesion and repair (Kottemann and 
Smogorzewska, 2013) (figure 1.16). When the replication fork meets the ICL, the 
replication stalls and ATR mediate the phosphorylation of FANCM, the first FA protein that 
binds the ICLs, together with two histone fold proteins (MHF1, MHF2). FANCM is a 
scaffold protein for the FA core complex, composed of 14 components including FANCA, 
B, C, E, F, G and L. The core complex on DNA forms nuclear foci visible during G2/S phase 
and functions as a large ubiquitin ligase for two other FA proteins, FANCD2 and FANCI 
(Ceccaldi et al., 2016). Phosphorylation and monoubiquitylation modify the FANCD2-I 
complex and are reverted by the USP28 protein at the end of the process. Post-translational 
modifications are necessary for the correct interaction of FANCD2-I with foci and other 
DNA repair proteins, including BRCA1, BRCA2, RAD51, XPF-ERCC1 and PCNA to 
execute ICL repair (Ceccaldi et al., 2016). The XPF-ERCC1 nuclease complex, as described 
above, has a central role in NER and is necessary to unhook the ICL lesions (Hodskinson et 
al., 2014). Unhooking the DNA leaves the crosslinked nucleotide link to the complementary 
strand, which is bypassed by TLS polymerases REV1 or (REV3–REV7) (Sarkar et al., 
2006). Ligation restores an intact DNA duplex, which functions as a template for HR-
mediated repair of the DSB, further processed by nucleases such as MRN complex or EXO1, 
reducing DSB to a single-stranded DNA overhang. This single-stranded DNA coated with 
RPA is a substrate for RAD51-mediated strand invasion promoted by BRCA2 and 
subsequently the HR pathway completes the repair (Prakash et al., 2015). So, ICL repair 
needs the cooperation of FA, with NER, TLS and HR pathways (Ceccaldi et al., 2016). 
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Figure 1.16 Schematic overview of Fanconi anemia pathway  
Fanconi anemia pathway is activated during G2/S phase to repair ICLs in 
cooperation with NER, HR and TLS (adapted from (Cai et al., 2020)). 
 
1.2.2.7 Translesion synthesis repair 
If damaged DNA bases are not repaired or in presence of ICLs, replication stalls because the 
DNA strands cannot be separated. Stalled replication forks are most frequently resolved 
using error-free mechanisms such as HR. However, replication may proceed by switching 
out regular DNA polymerases for alternative polymerases, such as DNA polymerase η 
(POLH) which is able to use the damaged strand as a template in an error-prone process 
known as translesion DNA synthesis (TLS), triggered by PCNA protein mono-
ubiquitylation. Such a mechanism contributes to survival, but should be considered a DNA 




1.3 MECHANISM OF ACTION OF PLATINUM AGENTS 
1.3.1 Cisplatin and carboplatin 
Cisplatin (Cis-diamminedichloroplatinum (II)) (DDP), was synthesized for the first time at 
the end of 19th century by the Italian chemist Michele Peyrone (Dilruba and Kalayda, 2016). 
Its anti-proliferative effect was observed by Rosenberg in the late 1960s during his studies 
on the effect of electricity on E. coli growth using a platinum electrode (Rosenberg et al., 
1965). Then, the characterization of cisplatin cytostatic/cytotoxic properties was extended 
through in vivo studies in hematologic and solid tumour xenograft models (Rosenberg et al., 
1969). These experiments led to clinical trials and to cisplatin approval in 1979. Cisplatin is 
the oldest member of a wide family of anti-neoplastic drugs borne in the second half of the 
20th century, which contain in their structure a platinum atom that coordinates different 
complexes and named for this reason platinum-based agents or platins. Carboplatin (cis-
diammine-cyclobutanedicarboxylate-platinum (II)) is a cisplatin analogue developed in the 
early 1980s, belonging to the second generation of platinum compounds.  It was approved 
by FDA in 1989, with the aim of reducing the collateral effects of cisplatin (Ho et al., 2016). 
Cisplatin and carboplatin represent the two most effective platinum-agents used for the 
treatment of patients affected by solid malignancies including gynecologic and testicular 
tumours, thoracic malignancies, sarcomas, head and neck, gastric and bladder cancers (Ho 
et al., 2016). The core of their planar chemical structure includes the presence of a doubly-
charged platinum atom surrounded by four ligands: two cis-diammine carrier ligands and 
two specific leaving groups also in cis position, responsible for the covalent binding between 
platinum ion and DNA bases (figure 1.17) (Makovec, 2019). Structurally, carboplatin differs 
from cisplatin for the presence of a bidentate dicarboxylate ligand instead of two chloride 
ligands (figure 1.17), but in terms of activity, it forms the same reaction products at the 
equivalent dose of cisplatin, although with different kinetics (Dasari and Tchounwou, 2014). 
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Carboplatin displays a lower reactivity, a slower kinetic, but also a lower excretion rate, that 
translated in a retention half-life of 30 hours compared to 1.5/ 3.6 hours for cisplatin and is 
less potent, requiring a higher dose to reach the same effectiveness of cisplatin (Dasari and 
Tchounwou, 2014). The toxicological profile of the two drugs is different: carboplatin 
limiting toxicity being myelosuppression, while nephrotoxicity, neurotoxicity and 
ototoxicity are the most frequent side effects of cisplatin (Dasari and Tchounwou, 2014).  
 
 
Figure 1.17 Chemical structures of cisplatin (left) and carboplatin (right) 
 
1.3.2 Mechanism of action  
Platinum agents are administered intravenously and from the blood stream they have to enter 
the cells to exert their therapeutic/cytotoxic effect, but the mechanisms of platinum intake 
are not fully elucidated (Makovec, 2019). Platinum enter the cells mainly by passive 
diffusion or facilitated diffusion, thanks to some membrane transporters of the solute carrier 
super-family. Cisplatin is a substrate of the cation transporters OCT1 and OCT2, primarily 
expressed in liver and kidney respectively (Makovec, 2019), while the role of copper 
transporters CTR1 and CTR2 is still debated. In fact, recent studies seem to exclude these 
trans-membrane proteins directly transporting cisplatin and carboplatin into the cells, as they 
do with copper (Makovec, 2019). Probably, copper transporters bind platinum and this 
interaction leads to a vesicular internalization by pinocytosis that also prevents drug 
inactivation by glutathione (GSH) and metallothioneins (MTs) (Arnesano et al., 2007). In 














manner. Another two copper transporters ATP7A and ATP7B are localized on Golgi 
membranes and on cytosolic vesicles. They internalize platinum molecules in an ATP-
dependent way into vesicles, facilitating the efflux of the drug throughout the cell and 
keeping it outside the nucleus (Zhou et al., 2020). Platinum efflux is catalyzed by multidrug 
resistance-associated proteins (MRP, ABCC), especially MRP2 and MRP4 for cisplatin, 
functioning as ATP-dependent efflux pumps. The balance between these import and export 
mechanisms is such that only 1% of the administered drug will reach the therapeutic target 
(Makovec, 2019).  
Cisplatin and carboplatin can be considered prodrugs, since they need to be transformed into 
the pharmacologically active drug (Gheorghe-Cetean et al., 2017) through a reaction of 
“aquation” that occurs in the cytoplasm and consists in the substitution of one or both the 
leaving groups with molecules of water, leading to a very reactive, positively charged 
molecule. The “aquation” reaction happens spontaneously, probably due to the lower 
intracellular concentration of chlorides than in the extra-cellular environment for cisplatin; 
for carboplatin, the biotransformation in its active form requires an active cleavage of the 
cyclobutane-decarboxylate groups by an esterase (Ho et al., 2016). However, the active 
species derived from cisplatin and carboplatin are the same (Dasari and Tchounwou, 2014). 
The hydrolyzed platinum-derived products are strongly reactive electrophile molecules, 
which bind with any nucleophilic species like proteins enriched in cysteine and methionine 
aminoacids, (i.e. glutathione and metallothioneins), or nitrogen donor atoms on nucleic acids 
(i.e. RNA and DNA). Hence, platinum agents are able to form covalent bindings with both 
DNA or non-DNA targets.  
All platinum targets are responsible for their cytotoxic effect on normal (toxic effects) and 
tumour cells (antitumour effects) (Gheorghe-Cetean et al., 2017). It was estimated that even 
if DNA platination is the main mechanism through which platinum drugs induce cell death,  
only 5-10% of platinum adducts are found in genomic DNA, while the remaining involve 
non-DNA targets (Gheorghe-Cetean et al., 2017) (figure 1.18). The active forms of cisplatin 
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and carboplatin also trigger reactive oxygen species (ROS) production and induce cellular 
oxidative stress, blocking mitochondrial respiration (Aggarwal, 1993) and calcium uptake 
in mitochondria. Excessive accumulation of ROS, damaged mitochondria and imbalance of 
calcium homeostasis can reduce ATPase activity and induce apoptosis besides DNA damage 
(Dasari and Tchounwou, 2014; Kleih et al., 2019). Furthermore, platinum can bind the zinc-
finger motif present in several protein DNA-binding domains, such as DNA polymerase α, 
one of the major players involved in DNA replication (Makovec, 2019). Another non-DNA 
target of cisplatin and carboplatin with lethal consequences for the cell is tubulin. Tubulin 
requires guanosine-5'-triphosphate (GTP) to assembly into microtubule filaments forming 
part of the cytoskeletal structure, but platinum drugs bind to the N7-atom in guanine of GTP 
preventing the exchange of energy between GTP and tubulin, slowing microtubule formation 
and interfering with mitosis, causing cell-cycle arrest and possibly cell death (Makovec, 
2019). GSH represents the main non-DNA target of platinum drugs, due to the amount of 
thiol groups in GSH with which platins strongly interact. This interaction is fundamental in 
the platinum drugs pharmacodynamic, because the intracellular GSH-level and the rate by 
which the enzyme glutation S-transferase (GST) conjugates GSH to the drug determine the 
amount of drug inactivated through cellular excretion (Mistry and Harrap, 1991; Sawers et 
al., 2014). 
The interactions of platinum agents with cellular proteins and DNA, their activation and 




Figure 1.18 Intracellular trafficking of platinum compounds (cisplatin and 
carboplatin) 
Platinum drugs may enter the cell by passive diffusion, cation transporters (OCT1, 
OCT2) or copper transporter proteins–CTR1, CTR2. Once in the cytoplasm, platinum 
drugs are activated by a hydrolysis reaction, where the leaving groups are substituted 
with one or two water molecules. The active form is an electrophilic species which 
interact with DNA, RNA, organelles (lysosomes, endoplasmatic reticulum) and proteins 
enriched in sulfhydryl or thiol groups, especially glutathione (GSH) and 
metallothioneins (MTs). Platinum bound to MTs or GSH by the enzyme glutathione S-
transferase (GST) is actively extruded from the cell by multidrug resistance-associated 
proteins (MRPs) or another P-glycoprotein ATPases (ATP7A, ATP7B).  
 
Despite the presence of multiple non-DNA targets, genomic DNA is the principal target of 
platinum agents responsible for the pharmacological activity (Chaney et al., 2005; Dasari 
and Tchounwou, 2014). In particular, cisplatin and carboplatin form the same irreversible 
DNA-adducts (different from those generated by oxaliplatin) that from here on will be 
named Pt-DNA adducts (Chaney et al., 2005; Schoch et al., 2020). Cisplatin and carboplatin 
bind the nucleophilic N7 atom on the purine bases, the most reactive and accessible atom in 
the nucleotides, forming mono-adducts, which can evolve, forming a second covalent 










































strand crosslinks when platinum binds two adjacent purine bases within the same DNA 
strand or inter-strand crosslinks (ICLs), if the two bases are on opposite strands (Chaney et 
al., 2005). Among the Pt-DNA adducts, the most diffuse are the intra-strand crosslinks, 
especially 1,2-intrastrand p(GpG) crosslinks (~65%) between two guanines (figure 1.19, A), 
and 1,2- intra-strand p(ApG) crosslinks (~25%) (figure 1.19, B); inter-strand p(GpG) 
crosslinks (~10%) (figure 1.19, C) are the most cytotoxic lesions, as they interfere with 
DNA transcription and lead to apoptosis if not removed; 1,3-intrastrand p(GpXpG) 
crosslinks (~3%) between guanine and cellular proteins (figure 1.19, D) described to 
contribute to platinum effect, even if to a lower extent (Dasari and Tchounwou, 2014; 
Eastman, 1987).  
 
Figure 1.19 The most common intra-strand and inter-strand Pt-DNA 
adducts on DNA and their frequency 
A) 1,2-intrastrand p(GpG) crosslink, the most diffuse (~65%) Pt-DNA adduct. B) 1,2 
intrastrand p(ApG) crosslink. C) interstrand p(GpG) crosslink, the most cytotoxic 
lesion. D) 1,3-intrastrand p(GpXpG) crosslink, between guanine and intracellular 




The pathway leading to cell death by unrepairable platinum-induced DNA damages is 
complex and involves several proteins, cascades of signaling pathways, and is triggered by 
the block of DNA transcription and duplication (Dasari and Tchounwou, 2014; Jung and 
Lippard, 2006). Pt-DNA adducts can result in DNA SSBs or the more severe DNA DSBs, 
which are recognized by DNA damage sensors, in particular two kinases ataxia 
telangiectasia mutated protein (ATM) and the ATM- and RAD3-related protein (ATR), 
which act as mediators between DNA damages and the checkpoint regulators checkpoint 
kinase 1 (CHK1) and 2 (CHK2), each substrates and downstream effectors of ATR and 
ATM, respectively (Damia et al., 2001; Galluzzi et al., 2012). Their activation initially 
causes a transient block of the cell cycle, typically in phase G2/M, the stabilization through 
phosphorylation on Serine 20 of the tumour suppressor protein p53 (Galluzzi et al., 2014), 
and activation of specific DNA repair pathways. Typically, Pt-DNA adducts involved NER, 
BER, MMR, HR and TLS (Galluzzi et al., 2014; Martin et al., 2008; Slyskova et al., 2018; 
Zhou et al., 2020). 
If the damage caused by Pt-DNA adducts is too high and cannot be removed in a short frame, 
the cellular balance between survival and apoptosis moves towards the second option and 
different cascade signaling pathways are activated to induce cell death (Galluzzi et al., 2014). 
Besides p53, the master regulator of intrinsic and extrinsic apoptotic pathways, also other 
secondary pro-apoptotic signaling pathways related to mitogen-activated protein kinase 
(MAPK) pathway, such as extracellular signal-related kinase (ERK), c-Jun N-terminal 
kinase (JNK) and stress activated protein kinase (p38-MAPK) can be activated after 
platinum exposure. Activation of these circuitries and their consequences following cisplatin 
treatment are still debated, however, it seems that ERK activation may contribute to cell 
cycle arrest to favour DNA repair, while JNK and p38-MAPK pathways may contribute to 




1.4 MECHANISM OF ACTION OF PARP INHIBITORS 
1.4.1 PARP inhibitors 
The introduction of PARP inhibitors (PARPi) in clinical practice has represented a recent 
revolution in the management of advanced ovarian carcinoma, since the time of approval of 
platinum agents more than forty years ago, both in terms of efficacy and for the novelty of 
its rationale. As previously described, the “synthetic lethality” approach fits well with the 
genomic profile of HGSOCs, that have defects in HR DNA repair pathway in half of the 
cases (Konstantinopoulos et al., 2015). In fact, PARPi have been shown to be extremely 
active in cells lacking HR and their use in HR deficient tumours represents the direct 
translation of these results. However, it has been shown that PARPi clinical activity may be 
extended also to HR-proficient tumours (Franzese et al., 2019). 
 At present, olaparib, rucaparib and niraparib are approved for the treatment of ovarian 
cancer in different therapeutic settings (chapter 1.4), while veliparib and talazoparib are 
under study in late phase clinical trials, in patients with newly diagnosed ovarian cancer, as 
well as in other advanced cancer, as single agent or in combination with other 
chemotherapies (Pilié et al., 2019). Currently, there are no clinical trials comparing head-to-
head different PARPi, but preclinical studies showed pharmacological differences in terms 
of activity and side effects among single compounds. However, PARPi have shown an 
overall safe-profile, with fatigue, gastrointestinal symptoms and myelosuppression being the 
more common toxicities (Jiang et al., 2019). 
Despite the promise and encouraging results obtained with the introduction of PARPi in 
oncology practice, several aspects need to be clarified to improve their clinical use, as the 
identification of PARPi response, beyond tumour HR status and mechanism underlying 




1.4.2 Mechanism of action 
The poly (ADP-ribose) polymerase (PARPs) family includes 18 nuclear highly 
conserved proteins. PARP1 is the most characterized enzyme within this family and is 
involved in a broad spectrum of cellular mechanisms, in particular DNA repair and 
DNA damage response, but also chromatin remodeling, replication, transcription, and 
cell death signaling. PARP2 has similar functions and is believed to be able to 
compensate for the loss of PARP1 in vivo, but its role in DNA repair is less prominent 
(Kamaletdinova et al., 2019). The PARP1 structure includes four domains: one N-
terminal DNA binding domain including two zinc-finger motifs, a C-terminal catalytic 
domain, a central auto-modification domain, and a caspase-cleaved domain (Liu and 
Tewari, 2016). The enzymatic function of PARP enzymes is named poly ADP-
ribosylation (PARylation) and consists in transferring one or more ADP-ribose groups 
(up to 200) to glutamate, aspartate, serine, arginine or lysine residues on PARP1 itself 
or other acceptor proteins, using NAD+ as cofactor (Gavande et al., 2016). PARylation 
is a post-translational modification where PAR chains typically provide interaction 
scaffolds for other binding proteins. Among targets of PARP1 PARylation there are 
DNA repair proteins, whose recruitment is facilitated at the site of DNA damage, 
accelerating DNA repair. At the end of the process, PAR chains are rapidly erased by 
PAR-degrading enzymes, such as poly (ADP-ribose) glycohydrolase (PARG) 
(Kamaletdinova et al., 2019). 
PARP1 can PARylate core histone H1 proteins causing relaxation of chromatin 
structures leaving DNA more accessible to replication machinery, transcriptional 
factors, and DNA repair proteins (Weaver and Yang, 2013). However, PARP1 is 
mostly studied in relation to its role in the repair of DNA SSBs and alkylating agent-
induced DNA damages, since 90% of its PARylating activity is done in response to 
DNA damage (Kamaletdinova et al., 2019). In particular, PARP1 has a critical role in 
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different DNA repair pathways, such as BER, HR and NHEJ contributing to 
maintenance of genomic stability (Franzese et al., 2019). The enzyme is activated in 
the presence of SSB, which recognizes and links by means of its zinc finger binding 
motifs. The interaction with DNA causes a conformational change and its activation, 
leading to PARylation of proteins effectors of BER (i.e. XRCC1, DNA ligase III and 
DNA polymerase beta), which are recruited close to SSB to form a multi-complex that 
executes SSB repair (Franzese et al., 2019) (figure 1.11). The second target of PARP1 
PARylation is PARP1 itself. The auto-PARylation happens in its central auto-
modification domain, causing structure modification allowing the formation of a 
scaffold necessary for the recruitment of other proteins, and subsequently leading to 
its own release from DNA, restoring the catalytic site in the inactive state (Eustermann 
et al., 2015).  
Globally, PARP1 prevents genomic instability by supporting also the repair of DSB, 
by activating the cell cycle regulator ATM during G1-M cell cycle phases, and 
recruiting the HR factors NBS1 and MRE11 to the damaged site, leading to activation 
of HR (Cook and Tinker, 2019). Simultaneously, PARP1 down-regulates the DSB 
error-prone pathway NHEJ, by inhibiting Ku70 and Ku80 (Patel et al., 2011). It is 
noteworthy that in the presence of high levels of DNA damage, the intracellular pool 
of NAD+ may significantly reduce due to hyper-activity of PARP1. This situation, 
common in high proliferative, genomic unstable cancer cells, may determine an energy 
crisis which, if not reestablished, can induce cell death through the activation of JNK 
and release of pro-apoptotic proteins, such as Bax (Franzese et al., 2019). 
In two seminal papers, it was shown that PARP inhibition caused disruption of DNA 
repair at different levels, mainly blocking SSB repair and inducing collapse of 
replication fork, thus generating DSBs. An overwhelming amount of DSB and 
inability to repair them by HR increased genomic instability and led to cell death. 
(Bryant et al., 2005; Farmer et al., 2005).  
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The PARPi currently used in the clinic, are small molecules able to inhibit the catalytic 
function of PARP1 and PARP2 by competing with NAD+ thanks to the nicotinamide 
moieties present in their structure (Mateo et al., 2019). This was the first mechanism 
of action described, and it was believed that prevention of PARylation was sufficient 
to impact the repair of SSB, leading to the activation of NHEJ in cancer cells with 
defective HR. The increased error-prone activity of NHEJ ultimately caused 
replication stress, chromosomal ruptures and finally apoptosis (Lord and Ashworth, 
2016; Lupo and Trusolino, 2014). Subsequently, a second and more critical 
mechanism of action of PARPi was described in which an allosteric conformational 
change due to PARPi stabilizes PARP1/2 association with DNA at the damaged site, 
preventing enzyme release. This mechanism was defined “trapping” and the block of 
PARP proteins on damaged site prevents the recruitment of DNA repair machinery 
and also determines stall or, alternatively, the irreversible block of replication with 
subsequent collapse of the fork, resulting in DSB formation, and in replication stress 
(Murai et al., 2012). This mechanism was firstly described in preclinical models, where 
PARP1 was trapped on DNA damaged sites forming stable PARP-DNA complexes, 
that were not observed in cells lacking PARP1, suggesting also the importance of 
PARP expression for this mechanism (Murai et al., 2012). The efficacy of each PARPi 
better associated with their PARP-trapping ability than with the catalytic inhibition. 
For instance, talazoparib exhibits the greatest cytotoxicity and higher PARP-trapping 
potency, 100-fold higher than olaparib and rucaparib; niraparib has higher trapping 
activity than olaparib and rucaparib (about 10-fold), while veliparib is the least potent 
(100-fold lower than olaparib and rucaparib) (Murai et al., 2012). Ultimately, the 
combination effect of catalytic inhibition, which prevents auto-PARylation of PARP 
and trapping determine a substantial accumulation of PARP on DNA, close to the 
damage sites. PARP-DNA complexes are stable and prevent by steric hindrance the 
binding of DNA repair effectors and cause stalled replication fork that during the S 
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phase of the cell cycle lead to DSBs. This situation in healthy/HR proficient cells can 
be bypassed by activating HR to repair the DSBs, while in HR deficient cells NHEJ 
will take over. Being an error-prone pathway, there will be less efficient and less 
accurate DBS repair leading to DNA damage accumulation and cell death (Franzese 
et al., 2019) (figure 1.20).  
Although, this is the dominant mechanism explaining the activity of PARPi in HRD 
tumours, alternative mechanisms have been proposed to explain the efficacy of PARPi 
in HR-proficient tumours, which rely on the consequences of PARP inhibition in other 
biological processes, such as energy metabolism and chromatin modification 
(Gavande et al., 2016).  
 
Figure 1.20 PARP activity and role of PARP inhibition in DNA repair and 
synthetic lethality  
Left panel: PARP1 (red) binding to an induced single-strand break (SSB) results in 
activation of auto and trans poly ADP-ribosylation, forming PAR chains with scaffold 
function on PARP1 itself and on target proteins. This function aims at recruiting DNA 
repair effectors (i.e. XRCC1, DNA polβ, DNA ligase III) (yellow and green) and 
promotes DNA damage resolution. In the presence of PARP inhibitors (right panel), 
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PARP1is trapped on DNA damaged site, PARylation activity is blocked and replication 
fork stalled and then collapses generating double-strand breaks (DSB). In 
healthy/Homologous Recombination proficient (HR+) cells, HR is activated, DSB are 
repaired and cell cycle proceeds. While, in HR deficient cells (HR-), the error-prone 
DSB repair pathway non-homologous end-joining (NHEJ) is the only pathway 
available, but its activity alone induces DNA fragmentation, genomic instability and 
finally apoptosis (image created using BioRender ((“https://biorender.com/,” ). 
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1.5 DETERMINANTS OF RESPONSE TO PLATINUM AGENTS AND 
PARP INHIBITORS THERAPY IN EOC 
 
Ovarian cancer responsiveness to first-line standard therapy and eventually, to subsequent 
lines in case of tumour relapse, is still an unpredictable and urgent clinical question. Several 
possible predictive biomarkers and assays have been studied for precision medicine, but, at 
present, strong and accurate clinical tests to predict therapy response are still missing. As 
previously mentioned, “platinum-free interval” (PFI) is the reference marker of response 
currently used to choose the best therapeutic regimen in relapsed HGSOC (Milanesio et al., 
2020). In addition, BRCA mutational status, histology, adverse symptoms to previous 
treatments and outcome after surgery are the other criteria considered in clinic to address 
patients to platinum and/ or PARPi-based therapy (Wilson et al., 2017). However, preclinical 
and clinical research are actively searching more accurate determinants of response. 
 
Considering the importance of DNA repair in the mechanism of action of platinum agents 
and PARPi and the fact that more than 50% of HGSOC have defects in HR, I will summarize 
which are the data available on possible DNA repair-associated biomarkers of response to 
both platinum agents and PARPi in dedicated chapters. In addition, a brief summary of other 
mechanisms and pathways not related to DNA repair, but described to be important for the 




1.5.1 Determinants of response to platinum compounds 
Starting from the discovery of platinum compounds, different cellular or cancer conditions 
have been described able to modulate platinum cytotoxic effects. Mechanisms summarized 
in figure 1.21 have been studied in relation with resistance or sensitivity to platinum, in 
preclinical models and in the clinic to find possible predictors of response. However, at the 
present, there are not yet specific molecular biomarkers validated in the clinic.  
 
Figure 1.21 Schematic summary of the most studied pathways and tumour 
conditions able to influence the anti-tumour effect of platinum compounds in 
ovarian carcinoma 
 
1.5.1.1 DNA repair as determinant for platinum-response 
The cytotoxic effect of platinum chemotherapy mainly depends on the activity of several 
DNA repair pathways activated by the cell to cope with the different kinds of DNA damages 
generated by the drugs. It can be stated that monoadducts are repaired by BER, intra-strand 



















through a coordinate interplay of different pathways: HR, FA, NER and NHEJ (Haynes et 
al., 2015). While preclinical evidence suggests that cells lacking NER, HR/FA and NHEJ 
pathways are extremely sensitive to platinum agents (Galluzzi et al., 2014), the inverse 
correlation is not always clear and sometimes discrepancies have been reported in 
experiments aimed to verify if up-regulation of different proteins/ DNA repair systems are 
associated with drug resistance (Galluzzi et al., 2014). 
As described above, ICLs and DNA DSBs induced by platinum compounds, are mostly 
repaired by the HR and FA pathways during G2/S phases of the cell cycle (Deans and West, 
2011; Michl et al., 2016). In addition, at least 50% of HGSOC has been shown to be deficient 
of HR, probably accounting for its extreme sensitivity to platinum drugs. The HR deficiency 
in HGSOC relies mainly on mutations/altered expression of genes involved in the above-
mentioned pathways. Indeed, loss of function germline mutations (~14% of HGSOC) or 
somatic mutations in BRCA1/2 genes (~3% of HGSOC) or in FANCD2 (~1% HGSOC), are 
the most frequently mutated genes involved in HR and FA pathways, respectively (Cancer 
Genome Atlas Research Network, 2011). These patients are extremely sensitive to therapy 
(Garsed et al., 2018; Rocha et al., 2018), because impaired HR/FA function affects the ability 
of cancer cells to cope with platinum-induced ICL (Hoppe et al., 2018). BRCA-mutated 
patients also have a better prognosis than BRCA-wild type/HR proficient carriers, in part due 
to the enhanced sensitivity to chemotherapy (Hoppenot et al., 2018). 
Beside BRCA-mutations, HGSOC may harbour genetic or epigenetic alterations in HR-
related non-BRCA genes, which are involved directly in HR pathways (i.e. core RAD51 
genes), or regulate HR (i.e. CDK12) or are involved in other DNA repair pathways that 
collaborate with HR in the solution of platinum-induced damages (i.e. FA family genes) 
(Konstantinopoulos et al., 2015). Mutations in HR-related non-BRCA genes determine the 
so-called BRCAness phenotype, a synonymous of HRD and a concept defined in 2004 to 
describe this subgroup of sporadic cancers with HRD and a phenotype similar to BRCA-
mutated tumours (Turner et al., 2004). 
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Among them, interestingly, CDK12 is a transcription dependent kinase involved in the 
regulation of transcription of several DNA repair genes, such as ATM, ATR, Chk1, FANCI, 
and RAD51C (Ekumi et al., 2015), and CDK12 amplifications or mutations affecting its 
catalytic domain account for 4% of HGSOC cases (Cancer Genome Atlas Research 
Network, 2011). Preclinical evidence showed that knock-down of CDK12 sensitizes cells to 
both platinum drugs and PARPi, due to the downregulation of HR and FA genes, making 
CDK12 a possible target for therapy in cancer and an interesting possible marker of response 
to therapy (Chilà et al., 2016; Naidoo et al., 2018). The HRD phenotype is shown in HGSOC 
with PTEN suppressor homozygous loss (7% of HGSOC), which interferes with RAD51 
transcription, or with EMSY amplification (6% of HGSOC), whose role has yet to be defined 
(Konstantinopoulos et al., 2015). 
Despite the emerging role of several genes and proteins as potential predictive biomarkers 
in EOC, so far, the presence of germline or sporadic BRCA1/2 mutations is considered the 
best clinical determinant of response to platinum agents, even if the existence of variants of 
uncertain significance (VUS) and the onset of secondary somatic mutations able to restore 
the HR proficient status need to be taken into consideration to avoid false classification of 
HRD tumours (Hoppe et al., 2018). In fact, the most diffuse mechanism inducing platinum 
and PARPi resistance in BRCA1/2 mutated carriers, consists in re-activation of HR function, 
caused by secondary reversion mutations or intragenic deletions. Such mutations are able to 
restore the protein reading frame, recovering the functional protein and consequently, the 
HR proficient phenotype (Galluzzi et al., 2014; Weigelt et al., 2017). These secondary 
mutations were observed in relapsing HGSOC, that have been previously treated with 
platinum agents, confirming their role in acquired drug resistance (Colombo et al., 2014). 
Recently, these mutations have been detected in tumour circulating free DNA (cfDNA) in 
patients with BRCA1/2 germline mutations with breast or ovarian cancers, refractory and 
resistant to platinum or pre-treated with platinum and/or PARPi (Lin et al., 2019; Weigelt et 
al., 2017). In addition, mutations have been also reported in other HR genes, such as 
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RAD51C, RAD51D and PALB2 (Lin et al., 2019). Analysis of BRCA-mutations in cfDNA 
by next-generation sequencing (NGS) is an extremely interesting and explored method, since 
liquid biopsies could be a useful clinical companion technique. The ability to identify in 
“real-time”, one or multiple reversion mutations simultaneously long before the clinical 
manifestation of resistance to platinum or PARPi, and with minor discomfort for the patient, 
could help oncologists to re-direct therapeutic regimens (Milanesio et al., 2020). 
Reacquisition of HR activity can also rely on epigenetic changes, such as demethylation of 
BRCA1/2 or FANCF promoters, often hypermethylated in tumours, with regaining of protein 
expression (D’Andrea, 2003; Patch et al., 2015). Such genetic and epigenetic modifications 
may be the results of genomic instability and chromosomal rearrangements, which usually 
characterizes HR-deficient tumours (Colombo et al., 2014). 
As said, in ovarian cancer patients, germline-BRCA-mutations as well as germline or somatic 
mutations in HR-related genes (included somatic mutations in BRCA1/2) predicted response 
to DDP (p=0.0002) (Pennington et al., 2014). In addition, a better prognosis has been 
reported in germline-BRCA/HR-mutated patients with increased OS compared to BRCA/HR-
wild type patients (HzR 0.6, CI 95% 0.4–0.8, p>0.0006). In particular, germline-BRCA-
mutated patients had a median OS of 66 months, HR-mutated carriers 59 months, and HR-
wild type 41 months, without significant difference between BRCA-mutated and HR-
mutated patients (p=0.09) (Pennington et al., 2014). Using a targeted capture and massively 
parallel genomic sequencing method Pennington et al pinpoint the role of “omics” 
techniques in identifying genomic alterations. In fact, the identification of BRCAness/DDP 
sensitive tumours remains one of the major challenges in cancer management (Lord and 
Ashworth, 2016), and tests able to accurately predict this condition would have also a double 
positive effect, since these patients may eventually benefit by use of PARPi therapy 
(Ceccaldi et al., 2015). 
Deep sequencing methods allowed identification of cancers with altered DNA repair 
pathways large scale disarray in chromosomal structures (Hasty and Montagna, 2014). 
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Specifically, it is now possible to evaluate through a combination of genomic profiling 
techniques (i.e. complementary genomic hybridization (CGH), single nucleotide 
polymorphisms (SNP) genotyping and next generation sequencing) such “genomic scars” 
originating from loss of HR function. Genomic scars are a sort of footprints left in the 
genome after exposure to DNA damage in a repair deficient background, and are generally 
characterized by loss of heterozygosity (LOH) and copy number changes (Hoppe et al., 
2018; Watkins et al., 2014). The comparison between genomic scars in BRCA-mutated and 
BRCA-wild type tumours has shown common profiles associated with HR defects, 
suggesting the presence of a BRCAness phenotype  (Stover et al., 2016). Not only defects in 
HR can determine genomic signatures. For instance, also microsatellite instability can be 
detected in the presence of mismatch repair defects (Akbari et al., 2017; Fusco et al., 2018). 
Specific assays have been developed as companion diagnostic tools to identify HRD and 
platinum sensitive tumours (Watkins et al., 2014). Methods that will be described were 
developed to identify peculiar genomic signatures associated with a DNA repair defective 
to be possibly used as biomarker of HRD. CGH array detects copy number variations (CNV), 
which are gains or losses of genomic material, affecting gene expression (Hehir-Kwa et al., 
2015); it has been applied to identify BRCAness breast cancers and a CGH signature was 
also associated with better responsiveness to platinum therapy (Vollebergh et al., 2014). 
Using SNP array data, two commercial genomic scar assays have been tested in clinical trials 
to identify tumours with HRD. The “myChoice HRD” assay by Myriad evaluates the 
presence of LOH, telomeric allelic imbalance (TAI) and large-scale transitions (LST) overall 
the genome, and based on these signatures an “HRD score” can be calculated, which 
classifies as HRD-positive tumours with score ≥42, and HRD-negative those with a score 
<42 (Pellegrino et al., 2019; Stronach et al., 2018). The “FoundationFocus CDx (BRCA 
LOH)” test by Foundation Medicine, Inc. is based on the presence of BRCA1/2 mutations 
and percentage of the genome affected by LOH, and based on these factors a LOH-score has 
been defined, considering HRD-positive ≥16 and negative <16 (Coleman et al., 2017; 
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Pellegrino et al., 2019). Considered singularly, LOH is frequently found in HGSOC and 
Wang and colleagues estimated LOH and CNV in ovarian cancer patients finding that high-
LOH group patients also include BRCA-mutated patients and was associated with increased 
platinum-sensitivity and PFS, both considering or excluding BRCA-mutated patients from 
this group (Wang et al., 2012). The TAI score quantifies allelic loss or CNV extended from 
the damaged site to the telomere, without crossing the centromere (De Picciotto et al., 2016) 
and a high TAI score was shown to predict platinum-response in ovarian and breast cancer, 
in vitro and in patients, and was associated with BRCA1/2 mutations (Birkbak et al., 2012). 
The LST identifies large chromosomal breaks between adjacent regions (at least 10Mb), and 
a high LST score was found to predict BRCA1/2 inactivation in basal-like breast cancer 
(Popova et al., 2012). Marquard et al. studied the pan-cancer distribution of single 
LOH/TAI/LST-associated signatures and quantified for each a relative score in 5371 
tumours, derived from 15 different tumour types (Marquard et al., 2015). They found that 
the single scores positively correlated with one other, and the distribution of the three 
signatures in the same tumour type had a similar trend, suggesting that LOH, TAI and LST 
depend on tumour biology. Moreover, tumours that received DDP shared higher median 
scores relative to LOH, TAI and LST, suggesting the platinum treatment determines 
reproducible genomic alterations that can be detected with these methods (Marquard et al., 
2015). These data suggested that considering LOH, TAI and LST signatures together could 
be a method to assess a predictive assay, laying the foundation for “myChoice HRD” assay 
development, whose predictive potential for platinum therapy was validated in a 
retrospective analysis on data deriving from three single-arm clinical trials in neoadjuvant 
setting of triple negative breast cancer. The analysis showed that an HRD-positive score 
(≥42) associated with increased possibility to achieve a complete response to therapy or 
minimal residual disease after neoadjuvant therapy, regardless of BRCA-mutational status 
(Telli et al., 2016). In ovarian cancer it was validated as companion diagnostic test in the 
niraparib clinical trial (chapter 1.5.4) (Mirza et al., 2016b). 
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Besides the identification of point mutations in HR genes and CGH and SNP-based arrays 
evaluating genomic scars, mutational signatures can be detected and analysed through NGS 
as distinctive mutational patterns of the single tumours, determined by specific mutagenic 
exposures and processes of repair along the life course of the cell (Hoppe et al., 2018).  
The BROCA test is a targeted capture and massively parallel sequencing assay, that 
identifies mutations in key HR genes and predicts increased primary treatment platinum 
sensitivity and longer overall survival in EOC (Morse et al., 2019; Pennington et al., 2014).  
BRCA-mutated tumours are typically characterized by enhanced mutational burden, which 
can be considered by combining somatic mutation count with CNV. The analysis of these 
genomic alterations led to identify peculiar mutational signatures (Hoppe et al., 2018). 
Signature 3 is a mutational signature described by Alexandrov et al. and was associated with 
the HRD phenotype, in particular with BRCA-mutations (Alexandrov et al., 2013). This 
signature has been recognized in different tumour types including pancreatic, breast and 
other cancers, and used as predictive biomarker for DDP response (Alexandrov et al., 2013), 
and more recently, for rucaparib in triple negative breast cancer (Chopra et al., 2020).  
The HRDetect mutational-signature-based algorithm is a weighted model of mutational 
signatures, including a score of microhomology-mediated deletions, base substitutions and 
rearrangement signatures and HRD score, based on genomic scars. The HRDetect test has 
demonstrated good performance in predicting BRCAness phenotype in breast, ovarian and 
pancreatic cancer, identifying BRCA-deficient tumour in FFPE samples with a narrow edge 
of error (Davies et al., 2017). Interestingly, this assay also considers epigenetic alterations 
in BRCA1 promoter, and it has been able to identify a BRCAness phenotype in one-third of 
the tumours analysed BRCA wt and without known HR-gene mutations  (Davies et al., 2017), 
suggesting its potential use as companion diagnostic in clinical trials. Very recently, the 
HRDetect assay has been tested in a triple negative breast cancer trial aimed to investigate 
the activity of PARP inhibitors. The HRDetect test successfully identified HRD tumours 
(Chopra et al., 2020).  
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However, the predictive value of genomic scar and mutational signature-based tests needs 
to be improved, since they do not reflect the dynamic of tumour evolution. In fact, they lose 
part of their predictive potential in the advanced cancer setting, where metastatic or relapsing 
tumours after treatment may acquire secondary mutations, that restore HR functionality 
leading to drug resistance, without modifying the original genomic scars and mutational 
signatures of HRD (Pellegrino et al., 2019). This is of particular importance in ovarian 
cancer, where secondary mutations restoring BRCA-function occur in approximately half of 
HGSOC with acquired resistance to platinum (Norquist et al., 2018). A possible solution to 
overcome these limitations is the development of assays to evaluate the functional 
proficiency/deficiency of HR repair (chapter 6). 
2% of HGSOC show mutations affecting FA genes, such as PALB2, FANCA, FANCI, 
FANCL, and these tumours are considered HR-deficient, sharing the same hyper-sensitivity 
to platinum-based chemotherapy and PARPi (Konstantinopoulos et al., 2015). The FA 
pathway is activated during S phase to repair ICLs cooperating with HR; however, it has 
been shown that several FA proteins act in NER and TLS, and alt-EJ, regardless of the cell 
cycle phase (Ceccaldi et al., 2016). 
One mechanism of resistance to ICL-inducing agents is the accelerated removal of DNA 
bulky adducts, as observed in ovarian cancer after prolonged exposure to cisplatin, and this  
has been associated also with high level of FANCF (Dabholkar et al., 1994, 1992; Taniguchi 
et al., 2003). The FANCF promoter is often subjected to hyper-methylation in EOC causing 
a reduced protein expression. It was reported that platinum-treatment caused a hyper-
methylation of FANCF promoter and is associated with resistance to DDP and to mytomicin 
C, another ICL-inducer drug (Patch et al., 2015; Taniguchi et al., 2003). Besides ICL-repair, 
the other major function of FA is protection of the replication fork, also in BRCA1/2-
deficient tumours and suppression of the error-prone NHEJ during the replication phase 
(Ceccaldi et al., 2016; Kais et al., 2016), suggesting its importance not only as determinant 
of platinum-chemotherapy, but also to other DNA damaging agents.  
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The NHEJ pathway is the alternative pathway of HR in DSB repair. Contrary to HR, NHEJ 
is active along all phases of the cell cycle and is an error-prone mechanism (Chang et al., 
2017). Recent evidence suggests that it may influence platinum-therapy. DNA-PKs involved 
in classical NHEJ are commonly found upregulated in HGSOC, and high expression is 
associated with advanced stage, poor survival and platinum resistance (Abdel-Fatah et al., 
2014), while alterations in NHEJ have been associated with resistance to rucaparib in ex 
vivo models, and this opens interesting questions, since approximately 50% of EOC present 
defects in NHEJ, independently from HR-activity (McCormick et al., 2017). 
Together with HR, the NER pathway has a key role in the removal of DDP induced DNA 
damage. The NER pathway is responsible for the resolution of platinum-induced inter-strand 
crosslinks and for recognition of ICLs, cooperating with HR, FA and TLS for their removal 
(Spivak, 2015). Patients affected by Xeroderma Pigmentosum, an autosomal recessive 
disease characterized by the loss of NER suffer hyper-photosensitivity and have a high risk 
of developing skin cancer in early age (Black, 2016), suggesting a key role of NER in UV-
induced damage. Cells defective in NER were 100-fold more sensitive to cisplatin than the 
parental line (Damia et al., 1996), and conversely, higher levels of NER were associated with 
platinum-resistance in ovarian cancer cells (Dabholkar et al., 1994, 1992). Recently, data 
from TCGA reported that approximately 8% of EOC harbour homozygous deletions, non-
synonymous or splice mutations in NER genes (Cancer Genome Atlas Research Network, 
2011), and Ceccaldi et al. identified a subgroup of HGSOC characterized by NER 
alterations, which showed enhanced survival (similar to patients harbouring BRCA-
mutations) compared to tumours without NER defects, suggesting that NER deficiency 
could induce platinum-sensitivity and better outcomes (Ceccaldi et al., 2015). Excision 
repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum 
complementation group A and F (XPA, XPF) are the NER proteins most studied in relation 
to platinum response, both in preclinical and in clinical studies (Spivak, 2015). ERCC1 and 
XPF form a nuclease complex with a central role in NER activity, but also in recombination, 
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DSB and ICL repair (Kirschner and Melton, 2010). The role of ERCC1 in platinum 
resistance has been largely studied in different tumour types, but still not completely 
elucidated and controversial results have been reported in ovarian cancer (Bahamon et al., 
2016; Cimino et al., 2013). In non-small cell lung, two studies showed that high ERCC1 
mRNA and protein levels correlated with poor patient outcome (Olaussen et al., 2006; Simon 
et al., 2005), and even in ovarian cancer patients similar results were observed, where high 
ERCC1 protein levels correlated with decreased survival and platinum resistance (Steffensen 
et al., 2009). Recently, evaluating 331 EOC cases, a low level of ERCC1 protein was 
identified as a predictor of platinum response and correlated also with increased PFS 
(Mesquita et al., 2019). However, other studies reported opposite findings, where no 
correlation or even a negative correlation between ERCC1 and platinum-response was 
observed (Ganzinelli et al., 2011; Rubatt et al., 2012; Scurry et al., 2018; Zhao et al., 2018). 
At present, clinical data have not yet validated ERCC1 as a biomarker for platinum-response, 
and possible explanations for the lack of concordant results pinpoint the heterogeneity of 
clinical studies (different design, heterogeneous clinical-pathological features of the 
patients), as well as the presence of different ERCC1 isoforms, of which only one is able to  
complex with XPF (Friboulet et al., 2013b). In addition, a big problem is the lack of a 
validated antibody specific for the active isoform, as reported by Friboulet et al. that could 
not corroborate the predictive potential of ERCC1 in a previously tested cohort of lung 
cancer patients, likely due to the different quality among 8F1 anti-ERCC1 primary antibody 
batches used (Friboulet et al., 2013a).  
ERCC1 polymorphisms were also evaluated as possible biomarkers for response, but up to 
now without success (Caiola et al., 2014, 2013; Tang et al., 2017; Yan et al., 2012). XPF 
expression has been evaluated in relation to platinum response and clinical-pathological 
features in cancer patients, but clear results and clinical validation are still lacking. Partial 
positive results were observed in ovarian tumours, where combined low ERCC1 and XPF 
expression levels, evaluated by IHC, discriminate platinum sensitive patients with a 
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favourable PFS (Mesquita et al., 2019). Other NER genes, such as XPA, XPD, have been 
studied, but none of them correlated with DDP response in ovarian cancer  (Amable, 2016; 
Caiola et al., 2014; Ganzinelli et al., 2011). NER is currently an interestingly mechanism 
with large potential to be exploited as a predictive biomarker, but further studies are required. 
TLS is a pathway involved in bypassing the bulky adducts, including GpG intra-strand 
crosslinks generated by cisplatin (Roy and Schärer, 2016), leading DNA polymerases to 
continue the DNA synthesis in spite of unrepaired DNA, and to progress through the cell 
cycle without arrest (Bassett et al., 2002). DNA polymerases involved in TLS (i.e. DNA 
polymerase β (POLB), polymerase η (POLH), REV3 and REV7 (Shachar et al., 2009)), were 
found upregulated (both as expression and activity) in several platinum-resistant cell lines 
and tumours (Albertella et al., 2005; Bassett et al., 2003; Gomes et al., 2019; Zhao et al., 
2012). POLB activity is most error-prone among all DNA polymerases involved in TLS, 
since it incorporates erroneous nucleotides with high frequency in the presence of cisplatin-
adducts (Bassett et al., 2003). POLB overexpression correlated with DDP resistance; 
however, the use of POLB antagonists resulted in controversial results, as in some 
experiments increased cisplatin efficacy was observed, but not in others (Stewart, 2007; 
Wojtaszek et al., 2019). Defects in POLH and REV3 correlated with increased cisplatin 
sensitivity, while overexpression was associated with resistance (Albertella et al., 2005; 
Knobel et al., 2011).  
The MMR recognizes mismatched and unmatched DNA base pairs, and insertion-deletion 
loops, including the ones caused by both cisplatin and carboplatin treatment and activates 
apoptosis (Martin et al., 2008). MMR genes have been found down-regulated through 
genetic or epigenetic mechanisms in association with DDP-acquired resistance (Lin and 
Howell, 1999; Samimi et al., 2000). Functional inactivation of MMR has been associated 
with the inability to induce apoptosis after DDP treatment, causing drug resistance (Martin 
et al., 2008). Less than 10% of HGSOC present hMLH1 promoter hypermethylated (Leskela 
et al., 2020) and this condition has been associated with platinum resistance (Strathdee et al., 
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1999; Watanabe et al., 2007). Treatment of platinum-resistant, hMLH1 hypermethylated 
ovarian cancer cells with 5-azacytidine reverted the resistant phenotype (Cameron et al., 
1999). The most frequently mutated or silenced MMR genes are MutL Homolog 1 (hMLH1), 
whose promoter appears hypermethylated in ovarian cancer, endometrial, gastric and 
colorectal carcinoma (Bignami et al., 2003; Peltomäki, 2003), MutS homolog 2 (hMSH2) 
and MutS homolog 6 (hMSH6) (Galluzzi et al., 2014; Stewart, 2007). Defects in hMLH1, 
hMSH3 and hMSH6 have been shown to correlate with DDP resistance by activating TLS 
(Vaisman et al., 1998).  
BER is responsible for both removing small single base lesion and for repair of SSB via a 
sub-pathway involving PARP1. BER involvement in ICL repair has been recently postulated  
(Wilson and Seidman, 2010) suggesting that targeting BER enhances sensitivity to cisplatin 
and other ICL-inducer agents (Wang et al., 2009). POLB is the most studied component of 
BER, and its expression has been evaluated as a prognostic marker (Alvisi et al., 2020; 
Horton et al., 2015), or in response to DDP therapy in lung and ovarian cancer models 
reporting contrasting findings (Caiola et al., 2015; Guffanti et al., 2020).  
1.5.1.2 Determinants of response to platinum-based therapy beyond DNA repair pathways 
Responsiveness to platinum relies also on uptake and/or extrusion of the drug, drug 
detoxification, and cell death induction, all factors able to influence the response to the drug. 
In addition, there is mounting evidence on the role of tumour microenvironment, or 
phenotypic transformations, including epithelial to mesenchymal transition (EMT) and the 
onset of undifferentiated-stemness tumour phenotype, in determining sensitivity/resistance 
to platinum-based therapy (Chen and Chang, 2019; Colombo et al., 2014; Galluzzi et al., 
2012; Singh and Settleman, 2010).  
A reduction of cisplatin effective concentration from 20 to 70% was observed in several 
DDP resistant cancer cell lines (Kelland, 1993). This reduction was explained by a fall in 
drug uptake and/or an augmented efflux of the drug outside nucleus and/or cytoplasm (Zhou 
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et al., 2020). DDP exploits the active membrane copper transporter CTR1 to enter the cell 
and CTR1 expression can be down-regulated by elevated intracellular copper concentration 
or cisplatin treatment. Interestingly, CTR1 low levels were associated with DDP resistance 
in vitro (Ishida et al., 2010). As observed in sensitive and in resistant cell lines of small cell 
lung carcinoma, DDP resistant cells display lower CTR1 expression than the sensitive ones 
and reduced DDP and carboplatin cytoplasmic concentrations (Song et al., 2004). 
Combination therapy with carboplatin and the copper lowering agent trientine has been tried 
in five patients with resistant HGSOC, who showed a partial reversion of resistance in 4 out 
of 5 of them (partial remission or stable disease) (Fu et al., 2012). However, other conflicting 
results were reported on the role of CTR1 in platinum resistance and the clinical potential of 
modulating CTR1 is under study (Zhou et al., 2020).  
ATP7A and ATP7B, responsible for keeping cisplatin outside the nucleus confined into 
cytosolic vesicles, have been investigated in platinum resistance with contrasting results in 
different tumour types (Martinez-Balibrea et al., 2009; Stewart, 2007). The most investigated 
proteins responsible for platinum efflux and drug-resistance are those belonging to the 
multidrug resistance family (MRP, ABCC), ATP-binding cassette membrane transporters, 
whose targets are several physiological molecules and drugs (Keppler, 2011). The ABCB1 
gene encodes for the MRP1 or MDR1 protein. Recently, 114 ovarian cancer samples 
deriving from 92 HGSOC patients were analyzed through whole genome sequencing to 
characterize genomic profile associated with primary or acquired platinum resistance (Patch 
et al., 2015). In this study, one of the four mechanisms identified linked to acquired 
resistance, involved structural variants (SVs) of the ABCB1 gene, which determined a fusion 
gene, resulting in upregulation of ABCB1. All patients with this fusion had been previously 
treated with DDP and/or other substrates of the P-glycoprotein MDR1 (Patch et al., 2015). 
Further studies are required to definitively establish the role different transporters in 
platinum efflux, as well as validated methods to assess their expression and/or function; this 
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is an active field of research for the possibility to pharmacologically modulate the 
transporters activity, providing another treatment option to delay/overcome resistance. 
Platinum agents, once entered the cell, undergo possible detoxification by glutathione-S-
transferase to GSH, and by metallothioneins (MTs). Increased GSH and glutathione-S-
transferase (GST) levels has been observed in different platinum resistant tumours (Byun et 
al., 2005; Kelland, 1993; Siddik, 2003). Silencing of GST with shRNA demonstrated to re-
sensitize platinum resistant cells (Möltgen et al., 2020). Therapeutic strategies preventing 
the formation of GS-platinum complexes using GSH competitive inhibitors (Cadoni et al., 
2017) or interfering with GSH synthesis have been evaluated, but were not tumour-specific 
and caused severe toxicity in normal tissues (Estrela et al., 2006). In a similar way, also MTs 
have been investigated, since cytosolic binding of platinum to MT interferes with platinum 
uptake into the nucleus. shRNA against MT could reverse resistance (Lee et al., 2015) and 
some miRNAs have been shown to be involved in the regulation of MT transcription 
(Pekarik et al., 2013). 
Platinum agents can activate apoptosis by both extrinsic and intrinsic pathways, the first 
starting from binding of tumour necrosis factors to cell membrane receptors and subsequent 
activation of caspases, while the intrinsic pathway is activated by switching the balance from 
anti-apoptotic (BCL family proteins) to pro-apoptotic proteins (Bax, Bak), leading to 
enhanced mitochondrial outer membrane permeabilization, release of cytochrome C and 
activation of the caspase signalling (Zhou et al., 2020). Platinum resistant cancer cells have 
problems in activating apoptosis, due to alterations involving key-apoptotic regulators, such 
as p53. HGSOC is one of the tumours presenting the highest prevalence of TP53 mutations, 
suggesting it is a critical tumour suppressor for this disease (Binju et al., 2019; Cancer 
Genome Atlas Research Network, 2011). Typically, anticancer agents act by inducing 
apoptosis, and in case of not functioning or absent p53, the cell is not able to trigger apoptosis 
and cell cycle proceeds, determining continuous proliferation and drug resistance (Vazquez 
et al., 2008). However, nearly 99% of HGSOC are mutated in TP53, but this cancer type is 
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also one of the most responsive tumour types to platinum, pinpointing that apoptosis is a 
complex mechanism modulated by many cellular pathways (Binju et al., 2019). Several 
studies focused on the role of different mutations affecting TP53 function (mostly sited in 
the DNA binding site), in relation with platinum response or survival, but conflicting 
findings do not allow a definitive conclusion (Bischof et al., 2019; Mandilaras et al., 2019).  
Cisplatin resistance may be also affected by extra-tumour conditions such as tumour 
microenvironment (TME). The TME is a complex system of non-malignant cells, which 
actively interact with cancer cells regulating tumour development, metastatic process and 
drug response (Chen and Chang, 2019). The TME includes cancer associated fibroblasts 
(CAFs), vascular cells, extracellular matrix components and immune cells, able to release 
proliferative factors, pro-inflammatory cytokines, chemokines and other molecules, which 
favour cancer survival in hypoxic conditions, escape from the immune system and 
dedifferentiation of epithelial cancer cells towards a mesenchymal phenotype, less 
responsive to therapy (Fiori et al., 2019; Hinshaw and Shevde, 2019; Vaupel and Multhoff, 
2018).  
The TME can physically obstruct platinum drug delivery and diffusion, in the presence of 
poor tumour vascularisation and/or a dense extracellular matrix (Chen and Chang, 2019). 
On the other hand, cellular components of TME, such as tumour associated macrophages 
(TAMs) polarized in a M2 status, favour tumour proliferation and platinum-resistance by 
secreting pro-inflammatory, pro-angiogenic and stimulating cytokines (Coward et al., 2011). 
CAFs secrete growth factors like EGF and IGF-1, which contribute to tumour development, 
and IL-8 that has been reported to induce cisplatin-resistance in gastric cancer (Zhai et al., 
2019), and are able to induce dense stroma surrounding the tumour and limit drug diffusion 
(Erez et al., 2010). 
With the advent of “omics” technologies, it became evident that each tumour, even of the 
same histotype, is different from the others and also areas of the same tumour may change 
over time in terms of proliferation, differentiation and invasion rate (Brabletz et al., 2018). 
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Specifically, HGSOC is characterized by genomic instability and heterogeneity. Different 
studies focused on the impact of genomic heterogeneity on prognosis and chemo-resistance 
(Tothill et al., 2008). The presence of subpopulations of cancer cells with different sensitivity 
to therapy and subjected to a “Darwinian” selective pressure by chemotherapy itself have 
been described. Chemotherapy hits sensitive cells, leaving alive those resistant ones leading 
to resistant recurrence through clonal expansion (Marusyk et al., 2020).  
The complex relationship among EMT, cancer stem cells (CSCs) and platinum resistance 
(Fabregat et al., 2016; Tanabe et al., 2020) has been an active field of research. EMT is a 
physiological cellular program in which epithelial cells switch towards a mesenchymal 
phenotype, due to activation/downregulation of specific transcription factors (Snail, Slug, 
Zeb1, Zeb2), miRNAs (miRNA-200 family members, let-7) and signalling pathways, as 
WNT pathways and TGFβ (Brozovic, 2017). Alterations in these pathways often occur in 
carcinomas, in which cells acquire mesenchymal features becoming less differentiated, more 
aggressive, with an invasive, metastatic and apoptotic resistant phenotype (Brozovic, 2017).  
EMT is associated with resistance to different drugs, including cisplatin and carboplatin, 
even if the underlying mechanisms are still to be elucidated (Brozovic, 2017). Several studies 
have been performed evaluating differences in expression of EMT markers (low levels of E-
cadherin, high levels of vimentin, fibronectin and EMT-transcriptional factors) in cancer 
cells upon treatment, or confronting parental cell lines with their counterpart made resistant 
to DDP (Brozovic, 2017). Upregulation of Snail and Slug discriminated primary sensitive 
EOC versus DDP resistant ones (Haslehurst et al., 2012), and these results were corroborated 
in a non-small cell lung cancer model of acquired resistance to DDP (Wang et al., 2014). 
Snail also associated with induction of stemness phenotype in HGSOC (Hojo et al., 2018). 
In fact, cells during EMT show features similar to those of CSCs and display the activation 
of the same pathways, including MAPK/ERK, TGFβ-SMAD, PI3K-AKT-NFkB and 
WNT/β-catenin (Loret et al., 2019). CSCs are able to self-renewal and to divide originating 
other differentiated cancer cells. They are thought to be in a dormancy state, refractory to 
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chemotherapy, and during certain conditions are able to exit from this state and to proliferate 
(Tanabe et al., 2020). The potential link between EMT and CSCs as a determinant for 
platinum-acquired resistance emerged from different studies. Ricci et al. evaluated the 
expression of several genes associated to both EMT and CSCs in platinum-acquired resistant 
models of ovarian cancer patient-derived xenografts (PDXs), where it was observed the 
higher expression of TCF3, CAMK2N1, EGFR, and IGFBP4 (EMT associated genes) and  
SMO, DLL1, STAT3, and ITGA6 (CSC associated genes) in DDP low-responsive PDXs than 
in the sensitive ones, and  MMP9, CD44, DLL4, FOXP1, MERTK, and PTPRC genes were 
significantly more expressed in re-growing PDXs tumours after DDP treatment (Ricci et al., 
2017), supporting the hypothesis that EMT process and CSC could be enhanced after the 
first cycle of DDP treatment.  
A knowledge of tumour biology is of pivotal importance to better understand all the factors  
that could affect the prognosis and the efficacy of therapy. Even if it is possible to elaborate  
therapeutic approaches to prevent or reduce the negative effects of the above-mentioned 
mechanisms related to drug resistance, it is still challenging to recognize these aspects and 
to individualise them possibly before the onset of resistant recurrent tumours.  
1.5.2 Determinants of response to PARPi 
PARPi share with platinum compounds different mechanisms that influence their anti-
tumour efficacy, such as HR defects, because both platinum and PARPi cytotoxic activity is 
mainly modulated by DNA repair activity. Moreover, drug resistance has been observed also 
for PARPi and the number of resistant cases is increasing in parallel with the expansion of 
their use in clinic, not only to treat ovarian and breast cancers, but also other cancers. For 
these reasons, the study of PARPi determinants of response, as for platinum, is an active 
field of research and the major findings will be described. Firstly, the role of DNA repair 
will be described as a determinant of response, then a series of miscellaneous mechanisms 
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not related to repair. In table 1.4, mechanisms investigated as possible determinants of 
response to PARPi are summarized, putting in evidence those common with platinum agents. 
1.5.2.1 DNA repair as determinant of response to PARPi 
Sensitivity of ovarian and breast cancer towards PARPi treatment has been observed in 
tumours with germline BRCA1/2 mutations, whose inherent defects in HR pathway are 
amplified by PARP enzymes inhibition, leading to an overload of DSB, genomic instability 
and apoptosis (Bryant et al., 2005; Farmer et al., 2005). This is one of the first and more 
successful examples of synthetic lethality translated into clinical practice and which 
identified germline BRCA1/2 mutations as the best clinical biomarker for response to PARPi 
therapy (Kaufman et al., 2015). The use of PARPi was further extended to sporadic tumours 
with somatic mutations in BRCA genes. Several studies demonstrated comparable response 
between germline and somatic BRCA1/2 mutations. An exploratory analysis in Study 19 
reported olaparib treatment was equally effective in HGSOC patients carrying somatic 
mutation in BRCA genes or germline mutations (PFS hazard-ratio 0.17 [95% CI 0.04-1.12] 
and 0.17 [95% CI 0.03-0.34] versus control, respectively) (Dougherty et al., 2017). Similar 
results were reported for rucaparib in an integrated efficacy data analysis of two different 
trials (SOLO10 and ARIEL2), where the objective response rates (ORR) were similar in 
somatic (55.6% [95% CI 30.8-78.5]) and germline BRCA-mutated patients (53.4% [95% CI 
42.5-64.1]) (Oza et al., 2017).  
Because PARPi sensibility mostly relies on HR defects, as well as for platinum agents, DDP 
sensitivity itself is currently a surrogate marker for HRD and clinical biomarker of response 
to olaparib and rucaparib in the presence of BRCA1/2 mutations (Franzese et al., 2019; Rafii 
et al., 2017), or in the case of niraparib maintenance therapy, regardless of BRCA1/2 
mutations (Konstantinopoulos et al., 2020). The predictive value of platinum sensitivity was 
demonstrated in several studies in combination with BRCA1/2 mutations, where HGSOC 
BRCA-mutated patients achieving complete or partial response to platinum first line therapy 
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had a better clinical response to olaparib than platinum-resistant and refractory BRCA-
mutated tumours (Fong et al., 2010; Gelmon et al., 2011). Similar results have been reported 
analysing data from ARIEL2 trial, in which HGSOC platinum-resistant and refractory 
patients, with germline or somatic mutations in BRCA1/2 treated with rucaparib, showed 
ORRs of 25% and 0%, respectively, compared to 43% and 70% in platinum-
sensitive/responsive tumours (Dal Molin et al., 2018).  
The predictive value of platinum sensitivity was also investigated in BRCA wild type (wt) 
tumours, where ovarian cancer patients sensitive to platinum retained a certain sensitivity to 
PARPi measured as objective response rate: ORR 33% in BRCA wt vs. 60% in BRCA 
mutated, platinum-sensitive, but significantly higher than in BRCA wt and platinum-resistant 
patients (ORR 4%) (Gelmon et al., 2011). However, the response to platinum agents does 
not always overlap with that to PARPi, as demonstrated by the evidence tumours sensitive 
to platinum drugs can be resistant to PARPi, and that some platinum-resistant patients were 
sensitive to PARPi (Gelmon et al., 2011). One explanation could be the presence of 
mutations in NER genes leading to inactivation of the pathway, that is responsible for the 
platinum sensitivity, but does not impact on PARPi efficacy, as recently reported in a 
subgroup of HGSOC platinum-sensitive, but resistant to PARPi (Ceccaldi et al., 2015). 
In order to extend as much as possible, the number of beneficiaries of PARPi therapy, 
beyond platinum-sensitive and BRCA-mutated cases, sporadic tumours without apparent HR 
mutations were further investigated with the aim to identify PARPi responsive tumours. 
Despite the overall efficacy of PARPi treatment in well-established HRD tumours, not all 
sporadic cancers belonging to this group appeared to be as sensitive to PARPi as hereditary 
tumours (Mirza et al., 2016b). It was observed that approximately 30% of HGSOC patients 
that did not show HRD phenotype neither BRCA1/2 mutations, were sensitive to PARPi 
(Konstantinopoulos et al., 2015). This apparently contrasting evidence can be explained by 
the fact that HR is a complex and multi-step process, whose factors and regulators are still 
to be completely elucidated.  
91 
 
The wider use of whole genome sequencing (WGS), whole exome sequencing (WES) and 
accurate copy number alteration assessments were exploited to develop genomic assays to 
detect common genomic and mutational signatures in HRD tumours. As previously 
described, two genomic scar assays were introduced in clinical trials for PARPi therapy in 
ovarian cancer to assess their role as predictive biomarkers for PARPi sensitivity. The 
Foundation Medicine’s LOH-based assay was the companion test to evaluate HRD in both 
ARIEL2 and ARIEL3 trials. In ARIEL2 trial, rucaparib was administered as monotherapy 
to relapsed, DDP-sensitive patients, and it was observed that PFS was significantly longer 
in patients BRCA-mutated (median PFS 12.8 months, HzR 0.27, 95% CI 0.16-0.44, 
p<0.0001) or BRCA-wt/high LOH score (≥16) (median PFS 5.7 months, HzR 0.62, 95% CI 
0.42-0.90, p=0.011), compared with patients BRCA-wt/low LOH score (<16) (median PFS  
5.2 months) (Swisher et al., 2017), suggesting that high LOH-score could identify patients 
DDP-sensitive without BRCA-mutations and sensitive to rucaparib. In ARIEL3 trial, the 
efficacy of rucaparib was assessed as maintenance monotherapy in platinum-sensitive 
recurrent ovarian cancers which achieved a complete or partial response to second or later 
line of platinum chemotherapy but that cannot tolerate further treatment lines with platinum. 
While positive LOH-score, associated with HRD condition, even predictive of treatment 
benefit, did not fully explain the increased PFS resulted in patients BRCA-wt and LOH-
negative, where median PFS was 10.8 months in treated patients versus 5.4 months in 
untreated (HzR 0.36, 95% CI 0.30-0.45, p<0.0001) (Coleman et al., 2017). Similar results 
were observed using “myChoice HRD” assay in the ENGOT-OV16/NOVA clinical trial for 
niraparib in maintenance therapy for platinum-sensitive advanced ovarian cancer patients, 
where patients with high HRD score as well as BRCA-mutated patients had higher benefit 
from niraparib treatment than placebo treated patients. However, the genomic assay was 
sensitive enough to detect a subgroup of HRD-negative/BRCA-wt patients who partially 
respond to therapy, even if with a lower extent than BRCA-mutated/HRD high population 
(median PFS 9.3 months vs. 3.9 months in placebo group, hazard ratio 0.45; 95% CI, 0.34 
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to 0.61, p<0.001) (Mirza et al., 2016b). Based on these results, niraparib was approved as 
maintenance therapy for platinum-sensitive relapsing ovarian cancer, regardless of BRCA 
mutations or HRD status. Data from these clinical trials highlight some drawbacks of the 
available assays, such as the unlikelihood to capture dynamic changes in the tumour. 
Unfortunately, resistance also affects tumours treated with PARPi and cases of de novo or 
acquired resistance have been reported both in preclinical and in clinical practice. At present, 
several potential mechanisms and proteins have been identified in preclinical models, even 
if most of them still requires clinical validation (Noordermeer and van Attikum, 2019). 
Notably, the presence of platinum-resistance often predicts resistance to PARPi therapy, 
suggesting that many mechanisms underlying these events may be the same (Fong et al., 
2010; Konstantinopoulos et al., 2015) (table 1.4).  
Restoration of functional BRCA1/2 and RAD51C/D through secondary mutations represents 
a well described mechanism associated with PARPi-resistance in the clinic, in tumours with 
germline or somatic mutations in the above-mentioned genes (Domchek, 2017). As 
previously described for platinum, secondary somatic mutations (i.e. deletions, frameshift, 
nonsense mutations) can restore the open reading frame of the gene, forming a new, non-
wild type, functional isoform, or can restore heterozygosity (Barber et al., 2013; 
Kondrashova et al., 2017; Norquist et al., 2011). Often tumours expressing BRCA1 
secondary mutations are characterized by alt-EJ signature, suggesting that secondary 
mutations may be the result of the error-prone repair of DSB operated by alt-EJ in HRD 
tumours and that POLQ could be a driver of PARPi-resistance (Ceccaldi et al., 2015). 
Secondary mutations were found in both solid and liquid biopsies, where BRCA1/2 reversion 
mutations were present in recurrent HGSOC patients resistant to platinum or PARPi 
(Christie et al., 2017). Reverting mutations turned in frame BRCA2 and PALB2 sequences 
in patients with progressive prostate cancer, pretreated with olaparib (Goodall et al., 2017). 
As previously mentioned, also RAD51C and RAD51D are subjected to secondary reversion 
mutations, which have been described in association with acquired resistance to rucaparib in 
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a cohort of HGSOC patients from the ARIEL2 trial (Kondrashova et al., 2017; Liu et al., 
2017).  
As for platinum-resistance, HR restoration may be mediated also by epigenetic changes. This 
mechanism was observed in breast cancer PDXs with hypermethylation at diagnosis (Ter 
Brugge et al., 2016) and in ovarian cancer patients, where tumours with BRCA1 promoter 
heterozygous methylation were less responsive to rucaparib than those with homozygous 
methylation (Kondrashova et al., 2018). In triple-negative breast cancer adding to mutational 
profile the information regarding homozygous BRCA1-methylation status ameliorated their 
predictive potential to identify patients who might benefit from olaparib/eribulin 
combination (Kawachi et al., 2020). Of note, BRCA1 promoter methylation can be 
overturned by genomic rearrangements that place BRCA1 expression under the control of a 
different promoter, as was found in PARPi-resistant PDX tumours (Ter Brugge et al., 2016). 
Alternative splicing variants of BRCA1 with residual function can still influence the response 
to HRD target therapies (Bouwman et al., 2013). For instance, mice bearing BRCA1Δ11/Δ11; 
p53-/- mammary tumour expressing the BRCA1Δ11/Δ11 variant in which part of the exon 11 is 
lost, are DDP-resistant and partially resistant to olaparib, while tumours with a frameshift 
mutation in exon11 are not resistant (Wang et al., 2016). Breast cancer models with 
BRCA1C61G mutation located in the highly-conserved N-terminal RING domain necessary to 
bind BARD1, rapidly developed in vivo resistance to DDP and olaparib, since BRCA1 
stabilization was enhanced (Drost et al., 2011). Interestingly, it was observed in in vitro 
experiments that under PARPi treatment, BRCA1-mutated protein levels increased and this 
can be explained by the fact that under treatment pressure some clones expressing BRCA1-
mutated in the BRCT domain can be selected (Johnson et al., 2013). BRCT mutated proteins 
are able to recruit heat shock proteins 90 (HSP90), which stabilize BRCA1 preventing 
proteasomal degradation, increasing cytoplasmic accumulation and preventing BRCA1 
interacting with PALB2, RAD51 and BRCA2, determining DDP and PARPi resistance 
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(Anantha et al., 2017; Johnson et al., 2013). Then, it was also demonstrated that this 
mechanism of resistance could be reverted with HSP90 inhibitors (Johnson et al., 2013).  
Another way to restore HR function in BRCA1-deficient cells relies on the concomitant loss 
of NHEJ. The choice between HR or NHEJ pathway to repair DSB, depends on the 
availability of end resection, necessary to HR; on the contrary end protection is necessary to 
NHEJ (Ceccaldi et al., 2016). 53BP1 is a protein of NHEJ that blocks CtIP-mediated DNA 
end resection through different downstream effectors and mechanisms, and promotes NHEJ-
mediated DSB repair (Konstantinopoulos et al., 2015; Noordermeer and van Attikum, 2019). 
Based on this knowledge, three studies using in vitro and in vivo models demonstrated that 
HR defects in a BRCA1-deficiency background could be partially reverted inhibiting 
TP35BP1 which encodes for 53BP1 protein, thus blocking NHEJ, and reducing PARPi 
hyper-sensibility of these tumours (Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 
2009). Notably, only double knockout BRCA1 and TP53BP1 cells restores HR, while this 
effect was not observed in BRCA2-deficient cells, suggesting that restoration of end resection 
via loss of 53BP1 is independent of BRCA1 (Bouwman et al., 2010; Bunting et al., 2010). 
Other experiments supported this hypothesis. In breast cancer mouse models, it was 
observed that BRCA1-deficient tumours and resistant to olaparib had low expression levels 
of TP53BP1 (Jaspers et al., 2013). More recently, it was shown that human ovarian cancer 
specimens, deriving from a phase I trial of the PARP inhibitor ABT-767, BRCA1-deficient 
not responsive to treatment were negative for 53BP1 (stained with validated IHC assay) 
(Hurley et al., 2019). RIF1 and REV7, which are part of the Shieldin (SHLD) complex 
together with SHLD1/2/3 (Noordermeer et al., 2018; Setiaputra and Durocher, 2019), were 
identified as 53BP1 downstream effectors (Chapman et al., 2013; Zimmermann et al., 2013) 
and that again their loss induced PARPi resistance, through increasing resection and 
restoring HR activity (Feng et al., 2013; Mukherjee et al., 2019; Xu et al., 2015). Depletion 
of REV7 was found in vitro to restore HR through CtIP-mediated end resection and cause 
PARPi resistance. Again, it was seen in BRCA1 but not BRCA2-deficient cells, highlighting 
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the different activity of BRCA protein (Xu et al., 2015). SHLD complex which is recruited 
at DSB in a 53BP1- and RIF1-dependent manner, was also identified during genome-wide 
CRISPR/Cas9 screens aimed to identify new PARPi-resistance determinants (Dev et al., 
2018; Gupta et al., 2018). From these screens a second interesting factor, whose loss leads 
to PARPi resistance in BRCA1-deficient cells was identified, DYNLL1 (Noordermeer et al., 
2018). End resection starts with the recruitment of MRN complex and proceeds with 
nucleases (EXO1 and DNA2); DYNLL1 acts blocking MRE11, a component of the MRN 
complex, from access to DNA thus preventing end resection (He et al., 2018). As for the 
other factors, loss of DYNLL1 allow the recruitment at DSB of proteins involved in end 
resection, thus restoring RAD51 foci formation and HR in BRCA1-deficient setting. 
DYNLL1 loss/low levels was observed in a clinical cohort of primary BRCA1 deficient 
HGSOC specimens and associated with fewer chromosomal abnormalities (He et al., 2018); 
in vitro DYNLL1 loss in BRCA1 deficient cell leads to PARPi resistance (Becker et al., 2018). 
NHEJ represents the counteracting pathway of HR, that, if suppressed, can cause PARPi 
resistance (McCormick et al., 2017). Alterations in other DNA repair pathways may affect 
drug response to PARPi, such as TLS repair. CHD4 is a chromatin remodelling factor 
involved in several cellular pathways (Zhang et al., 2019), whose loss in BRCA2-deficient 
ovarian cancer cell line correlated with restored cell cycle progression and enhanced DNA-
damage tolerance, in line with activation of TLS repair. Its loss has been associated with 
cisplatin and olaparib resistance and reduced survival in BRCA2-deficient ovarian cancer 
patients (Guillemette et al., 2015). These data are important since previously it was observed 
that in HR proficient tumours, CHD4 loss enhanced platinum and PARPi sensitivity (Pan et 
al., 2012), suggesting that TLS induction determines resistance independently of HR.  
Beside the rational use of PARPi in BRCA1/2-mutated or HRD tumours (Lord and 
Ashworth, 2017), not all BRCA-deficient tumours are sensitive to PARPi (Gelmon et al., 
2011), as well as PARPi demonstrated efficacy beyond HRD-status (Mirza et al., 2016b; 
O’Connor, 2015). In fact, several studies demonstrated the efficacy of PARPi in other 
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tumour types beyond HRD ovarian and breast cancer, such as small cell lung cancer (SCLC) 
(Murai et al., 2016) and Ewing sarcomas (Tang et al., 2015), which appear to be HR 
proficient suggesting that additional factors may contribute to increase PARPI sensitivity. 
PARP1 protein expression levels was investigated as a possible biomarker of PARPi 
response. In ovarian cancer preclinical models PARP1 protein expression and enzymatic 
activity were measured using a radiotracer, and it was observed that protein expression and 
PARP1 activity positively correlated with the response of olaparib and talazoparib alone or 
in combination with radiotherapy, both in BRCA1-mutated and wild type tumours 
(Makvandi et al., 2016; Sander Effron et al., 2017). Gan et al. observed in a cohort of 174 
sporadic HGSOC a significantly negative correlation between PARP1 expression and patient 
survival, regardless of BRCA1 levels (Gan et al., 2013). Hjortkjær and colleagues did not 
find any correlation between either PARP1 IHC-score and clinical outcome in 170 biopsies 
of primary ovarian cancer, taking also into account BRCA1 levels (high or low) (Hjortkjær 
et al., 2017). These contrasting results suggest that further studies are needed. Mutation in 
PARP1 has been shown to associate with resistance to PARPi. Pettitt et al. by different 
mutational screenings, identified PARP1 loss-of-function as a potent mechanism able to 
prevent trapping and induce acquired resistance to PARPi in normal and in human cancer 
cell lines (Pettitt et al., 2013). More recently the same authors identified close to full-length 
mutant forms of PARP1 that cause in vitro and in vivo PARPi resistance (Pettitt et al., 2018, 
2013). Specifically, mutations affecting the zinc-finger domain of PARP1 were able to 
prevent trapping and cause resistance to talazoparib in vitro. For instance, PARP1 (R591C) 
mutation was found in a HGSOC patient with primary resistance to olaparib (Pettitt et al., 
2018). Loss-of-function mutations that hit PARG protein could reduce PARPi trapping 
activity, and thus reduce their efficacy (Gogola et al., 2018). 
Another critical consequence of PARPi therapy relies on dysregulation of replicative fork 
(RF) due to PARP-trapping, that, in HRD cells, enhances replicative stress, fork collapse, 
and eventually induces cell death (Franzese et al., 2019). BRCA1/2 and PARP1, in addition 
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to their role in DNA repair, protect the RF under replicative stress conditions (Schlacher et 
al., 2012). In BRCA-deficient cells, RAD51 filaments are not stabilized and cannot block the 
nucleolytic activity of MRE11 nuclease that degrades the new ssDNA, thus forming a shorter  
new strand which determines the RF collapse and thus sensitivity to PARPi (Liptay et al., 
2020; Schlacher et al., 2011). The unravelling of the mechanisms at the basis of RF 
protection lead to identification of BRCA downstream effectors having an independent role 
in protecting the RF, such as SMARCAL1/ZRANB3/HTLF (chromatin remodelling 
factors), PTIP, and EZH2. All these proteins are necessary to recruit MRE11; EZH2 recruits 
MUS81 at stalled RF, and mediate PARPi sensitivity in BRCA-deficient cells (Ray 
Chaudhuri et al., 2016; Rondinelli et al., 2017) (figure 1.22). SMARCAL1/ZRANB3/HTLF 
are necessary for MRE11 nucleolytic activity, and their loss in BRCA-deficient cells cause 
PARPi resistance (Taglialatela et al., 2017). Loss of PTIP protects the nascent ssDNA from 
degradation by MRE11, especially in BRCA-deficient cells, where also RAD51 protection 
was lost (Ray Chaudhuri et al., 2016). EZH2 usually recruits MUS81 by methylation of 
lys27 on histone 3 (H3K27me3) at stalled fork. In addition, EZH2 loss maintains stalled RF 
preventing its disruption and causing PARPi resistance, but contrary to PTIP, it has been 
observed only in BRCA2-deficient cells or in mouse models, where low EZH2 and MUS81 




Figure 1.22 Schematic overview of the mechanisms leading to restoration of 
replication fork protection (adapted from (Noordermeer and van Attikum, 2019)).  
 
There are also proteins, not directly involved in protecting the RF, but able to influence its 
dynamic and potentially to influence PARPi response. E2F7 is a transcription factor 
activated in the presence of DSB to arrest the cell cycle in G1/S phase and able to negatively 
regulate the expression of several HR genes, among them, RAD51 and BRCA1 (Mitxelena 
et al., 2018). E2F7 depletion in vitro led to increased RAD51 foci formation and activation 
of RAD51-mediated HR repair and RF stabilization, due to prevention of MRE11 activity. 
All this was associated with the onset of PARPi resistance in a BRCA2-deficient setting 
(Clements et al., 2018).  
In 2012, SLFN11 was firstly discovered as a determinant of response to topoisomerases I 
and II inhibitors and platinum compounds (Zoppoli et al., 2012),  then it has been extended 
also to PARPi (Murai et al., 2016) becoming the subject of several studies. The relation 
between SLFN11 expression and response to PARPi was observed in a panel of 60 NCI lung 
cancer cell lines treated with talazoparib (a potent PARPi) and olaparib, where gene 
99 
 
expression analysis of the treated cells found a significant association between drug response 
and SLFN11 expression levels, irrespective of BRCA-status, and these results have been 
further corroborated in isogenic xenografts for SLFN11 (Murai et al., 2016). SLFN11 is a 
nuclear protein upregulated during replication stress, when it binds and permanently blocks 
the replication fork by opening the chromatin through its ATPase activity, promoting a 
prolonged arrest in S-phase (Noordermeer and van Attikum, 2019). Upon treatment with 
DNA-damaging agents, which induce replication stress, SLFN11 is activated and the 
prolonged S-phase arrest mediated by SLFN11 blocks replication and enhances apoptosis 
and determines hyper-sensibility to the treatment (Murai et al., 2016). Conversely, loss of 
SLFN11 decrease the efficacy of these treatments because cells sustain replication even in 
the presence of DNA damage, enter G2 phase as observed, and thus lead to resistance 
regardless of HR status (Murai et al., 2018, 2016). Trying to elucidate whether SLFN11-
mediated arrest of the cell cycle in S-phase depends from ATR-checkpoint regulation, Murai  
et al. combined talazoparib with an ATR-inhibitor, observing resistant cells recover their 
sensitivity to PARPi and suggesting the use of ATR inhibitors as a possible strategy to 
overcome resistance in SLFN11-deficient tumours (Murai et al., 2016). Since SLFN11 
upregulation or depletion are often observed in a wide range of tumours (Cancer Genome 
Atlas Research Network, 2011; Murai et al., 2019) and SLFN11 expression could be 
considered a very promising biomarker for PARPi regardless of HRD status, these findings 
suggest also the potential use of PARPi in different tumours (Shee et al., 2019). For instance, 
the fusion protein EWS-FLI1, a marker of Ewing sarcoma, is a transcription factor 
constitutively activated, which upregulates SLFN11 transcription and this could explain the 
sensitivity of this tumour to PARPi (Tang et al., 2015).  
Thus, loss of PTIP, RADX, EZH2 and SLFN11 induce resistance to PARPi, without 
increasing HR activity in BRCA-deficient cells, suggesting that mechanisms which protect 
the RF and ensure cell cycle progression or sustain replication stress should be taken into 
consideration as possible determinants of PARPi clinical activity. 
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1.5.2.2 Determinants of response to PARPi beyond DNA repair 
Induction and up-regulation of MET/HGFR signaling pathways contribute to PARPi 
resistance. MET/HGFR is a tyrosine kinase receptor found amplified or upregulated in 
almost 10% of EOC (Cancer Genome Atlas Research Network, 2011). Upregulation of MET 
directly phosphorylates PARP1, increasing its activity and affecting its binding site which 
reduces the interaction with PARPi causing resistance (Du et al., 2016). Preclinical studies 
have evaluated MET inhibitors in combination with PARPi in BRCA-mutated breast and 
HGSOC cancer models, where they showed a synergistic effect and determine cell growth 
inhibition, especially in tumours overexpressing MET, and interestingly, in tumours resistant 
to PARPi (Dong et al., 2019; Du et al., 2016; Han et al., 2019). Combination of MET 
inhibitors and PARPi could be a strategy to overcome PARPi resistance in MET 
overexpressing tumours as observed in preclinical models (Han et al., 2019). Clinical trials 
with MET inhibitors in solid tumours are underway, but none at the moment is testing the 
combination with PARPi (info updated at September 2020).  
PARPi drug availability and intracellular concentrations are regulated by p-glycoprotein 
transporters such as ABCB1 in murine models. ABCB1 upregulation was associated with 
decreased PARPi concentration within the cells (Rottenberg et al., 2008), as well as in an 
ovarian cancer cell line resistant to PARPi, the treatment with verapamil, inhibitor of MDR1, 
reverted the resistant phenotype to sensitive (Vaidyanathan et al., 2016). These results led to 
research of new PARPi molecules with less affinity to MDR1, and new therapeutic strategies 
aimed to combine PARPi and transporter inhibitors (McMullen et al., 2020).  
Most of these findings derived from preclinical studies which have provided evidence for 
multiple mechanisms possibly related to PARPi resistance in BRCA-deficient tumours. 
However, only secondary mutations in HR genes have been validated as mechanism of 
resistance in the clinic to date, and loss of 53BP1 is under study in human tumours. The 
effective impact and frequency of each of these mechanisms are not established and 
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definitive studies are required to assess the relative impact of secondary mutations, loss of 
53BP1, and upregulation of ABCB1 efflux transporters in BRCA-deficient tumours. It would 
be also interesting to assess if different BRCA1/2 mutations may change the impact of these 
mechanisms on therapy response and considering the wide range of potential of different 
PARPi, how their trapping potency or other pharmacologic characteristics could be 




Table 1.4 Mechanisms and molecular alterations associated with PARPi resistance and 
eventually, cross-resistance with cisplatin  
   
Mechanisms of PARPi 
Resistance
Detailed alterations Impact on DDP resistance
Restoration of functional HR
1) Reactivation of functional proteins:
- BRCA & RAD51 reversion mutations
- BRCA1 promoter de-methylation
- BRCA  hypomorphic mutated forms or splicing 
variants with residual activity
- BRCA forms protected from degradation
2) Restoration of end-resection:
- Loss of 53BP1 
- Loss of REV7 
- Loss of DYLLN 
1) Cross resistance
2) DDP  not affected
Alterations in PARP1 or 
PARG which decrease 
PARP-trapping
- Loss of function mutations affecting PARP1 or 
PARG
- PARP1/2 low expression levels 
- Hypomorphic mutated forms with residual 
activity
DDP  not affected
Dysregulation of RF 
stability/
- Loss of SMARCAL1/ZRANB3/HTLF
- Loss of PTIP
- Loss of EZH2
- Loss of RADX
- Loss of E2F7
Cross resistance
Sustained replication 
regardless of DNA damage
Loss of SLFN11 Cross resistance
Activation of TLS repair - Loss of CHD4 Cross resistance
Activation of MET/HGFR 
and PI3K/AKT pathways
1) Amplification/up-regulation of MET/HGFR 
pathway
2) Up-regulation of pro-survival PI3K/AKT pathway
1) DDP  not affected
2) Cross resistance
Increased efflux - Overexpression of ABCB1 gene Cross resistance
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1.6 DNA REPAIR FUNCTIONAL ASSAYS 
Personalized medicine requires new methods to better stratify patients in order to receive the 
best therapy, which means for ovarian cancer patients, to select those patients who will 
benefit from platinum- and PARPi-based treatment. In this context great efforts have been 
made to find biomarkers and to set up tests able to determine the functional activity of some 
DNA repair pathways, especially those involved in DSB repair, to predict therapy response 
and/or the acquisition of drug-resistance. 
Isogenic models and in vitro or ex vivo cell or tissue cultures have been largely used in 
preclinical experiments (Alkema et al., 2016; Clark et al., 2012; Liu et al., 2018; Walton et 
al., 2017); the first are suitable to study the role of a single gene as putative biomarker of 
response, while with the latter is possible to study the cellular response to a given drug. 
These experiments are useful to identify key drivers in DNA repair and possibly identify 
putative biomarkers of response. However, they suffer from poor translatability to clinical 
practice, since patient biopsies are not always available. 
Due to the relevance of HR in determining DDP and PARPi response to therapy, several 
methods aimed to evaluate the expression of key HR genes and HR capacity to repair DSBs. 
In particular, formation of nuclear RAD51 foci is a downstream event in HR and occurs 
when the sister chromatid is available leading to recombination process (Hoppe et al., 2018). 
RAD51 foci formation is absent in BRCA-mutated cells and is generally considered a 
surrogate marker for HR (Bhattacharyya et al., 2000), detectable by common 
immunofluorescence (IF) and immunohistochemical (IHC) techniques. RAD51 foci levels 
have been quantified in ovarian cancer ex vivo models after ionizing radiation, which cause 
DSB repair by HR, and low induced levels correlated with PARPi response (Mukhopadhyay 
et al., 2010; Shah et al., 2014). The interest toward this test has been amplified by recent 
findings that demonstrated its capacity to predict PARPi resistance in BRCA1/2-mutated 
tumours, where revertant mutations had restored HR-proficiency (Waks et al., 2020). In 
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addition, it has also shown to predict PARPi sensitivity in BRCA-wild type tumours, 
identifying BRCAness tumours BRCA1/2 wild type (Castroviejo-Bermejo et al., 2018a).Very 
recently, Cruz et al. set up IF quantification of RAD51 foci in proliferative/geminin positive 
cells in untreated breast cancer FFPE samples, and determined a RAD51 score, which 
discriminated PARPi sensitive (low score) from resistant (high score) tumours (Cruz et al., 
2018). Geminin is a marker of G2/S cell cycle phase, when HR is active, so, the evaluation 
of RAD51 foci in proliferating cells should enforce the test, as suggested also in other studies 
(Naipal et al., 2014). Given that HRD tumours are usually responsive both to PARPi and 
DDP agents, RAD51 assay should be predictive also for DDP therapy. A functional test to 
assign an HR-score based on RAD51 foci levels was established in ovarian cancer ex vivo 
cultures, only evaluating proliferating-G2/S phase cells, after DSB induction with radiation. 
Based on this score, tumours were divided into HR-deficient (HRD) or HR-proficient (HRP) 
and the assay significantly predicted DDP response (Tumiati et al., 2018b). This functional 
assay was also validated in triple negative breast cancer (Tumiati et al., 2018a). The assay 
also scored specimens derived from different sites of the same ovarian cancer patients (i.e. 
omentum, ovary, abdominal metastases), with different levels of HR proficiency being 
observed in samples from the different sites (Tumiati et al., 2018b), corroborating the idea 
that drug-resistance may derive from the selection of subclones and enforcing the role of 
intra-tumour heterogeneity as a possible cause of DDP-resistance.  
A strong indicator of DSB not closely related with HR activity, is the protein H2AX, a 
component of the histone in nucleosome, which is phosphorylated by ATM and ATR kinases 
after DSB induction, necessary to start the recruitment and localization of other DNA repair 
proteins (Kuo et al., 2018). The new phosphorylated protein γH2AX is visible as nuclear 
foci sited close to DSB where repair activity is ongoing, but γH2AX foci are present not only 
during DNA repair, but also during apoptosis caused by DNA fragmentation, especially at 
the later time points after DNA damage induction, and distinguishing apoptosis from DNA  
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repair may be misleading (Rogakou et al., 2000). For this reason, γH2AX foci are considered 
biomarkers of DSB and globally of DDR, associated with cellular stress condition and 
genomic instability (Palla et al., 2017). Stefanou et al. described a method to test DDR 
induction through γH2AX foci quantification in peripheral blood monocyte cells from 
BRCA-mutated EOC patients and healthy donors observing a higher basal level of γH2AX 
foci in EOC patients, index of genomic instability, and γH2AX expression levels correlating 
with response to DDP-based therapy (Stefanou et al., 2015), but validation in a larger cohort 
of patients is needed.  
Another strategy to improve specificity of foci-based tests to enforce their potential as 
predictor of therapy response, consists in evaluating different markers for DSB at the same 
time, for instance γH2AX, RAD51 and Nbs1, a component of MRN complex, 
phosphorylated by ATM in response to DSB and involved in recognition of the DSB 
(Wilsker et al., 2019). Time course and spatial quantification of the three proteins by 
quantitative multiplex IF assay, named IFA, aimed to assess the activation of DDR in 
colorectal cancer FFPE samples after exposure to different DNA damaging agents, cisplatin 
included. Preliminary results in PDXs tumours and human specimens were encouraging and 
an increased IFA-score suggested activation of DDR (Wilsker et al., 2019). 
A functional test widely used in preclinical studies to directly evaluate the functionality of 
HR or NHEJ to solve DSB is a green fluorescent protein (GFP)-based plasmid assay, where 
two plasmids are co-transfected within the cells to be tested for HR or NHEJ proficiency. 
The first plasmid encodes for the restriction enzyme I-SceI, while the second reporter 
plasmid includes the restriction site for I-SceI and the substrate for the specific DNA repair 
pathway to be analyzed. Once co-transfected, I-SceI cleaves the reporter plasmid at the level 
of GFP coding plasmid, whose homologous sequence has been selected to be specifically 
detected and repaired by one of the main DSB end-joining pathways. If the cell is DNA 
repair proficient, the GFP gene will be repaired and the protein transcribed and the green 
fluorescent signal will be detected by fluorescence-activated cell sorting (FACS) analysis. 
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The percentage of positive/proficient cells will be quantified and normalized over a 
population transfected with plasmid containing the wild-type GFP gene. This assay, or 
similar based on the same principle, have been largely used in in vitro cells, peripheral blood 
lymphocyte cells and in ex vivo cultures to establish the effective DSB repair proficiency 
and to detect genotoxic carcinogens (Deniz et al., 2013; Ireno et al., 2014; Keimling et al., 
2012). The potential of the GFP-based functional assay to correlate the efficacy of DSB 
repair to DNA-damaging agents response has been explored in breast cancer cells, where 
encouraging findings have been shown (Deniz et al., 2017).  
Another assay has been recently described to correlate NHEJ activity with sensitivity to 
rucaparib in a panel of primary and commercial ovarian cancer cell lines (McCormick et al., 
2017). It requires the cellular extracts to which linear plasmids are added. If the cells are 
NHEJ proficient, the plasmids will be end-joined and will acquire a multimer conformation 
(McCormick et al., 2017). The results showed a significant correlation between NHEJ 
deficiency (NHEJD) and resistance to rucaparib (p=0.0022), also in HRD tumours 
(NHEJD/HRD vs NHEJ/HRD cells, p=0.0045) (McCormick et al., 2017).  
Defects in replication fork protection have been reported to correlate with sensitivity to 
carboplatin in 33 HGSOC short-term patient derived organoids (Hill et al., 2018). In these 
organoids, which well recapitulate the original human tumour characteristics, the DNA fiber 
assay was used to evaluate the replication fork stability. Stable RF was found in the majority 
of carboplatin resistant organoids (91%), while defects in stalled RF were observed in 61% 
of organoids and this condition correlated with sensitivity to carboplatin sensitive ones (Hill 
et al., 2018), suggesting that RF stability established by DNA fiber assay could be used to 
predict carboplatin response in HGSOC. 
The NER pathway as previously mentioned, is a versatile mechanism and several data 
suggest it has a significant impact on DDP-based therapy, and emerging results sustained 
also its role in influencing PARPi treatment (Ceccaldi et al., 2015). ERCC1 and XPF form 
a heterodimer nucleasic complex, which can be considered a read-out of the NER activity 
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(Faridounnia et al., 2018). The proximity ligation assay (PLA) has been set up and applied 
to detect the ERCC1/XPF functional complex both in IHC on FFPE samples, and in IF 
(Friboulet et al., 2013a; Guffanti et al., 2020). The use of PLA by-passes the lack of validated 
primary antibodies to specifically detect the functional ERCC1-isoform 202, the only one 
out of four able to complex with XPF (Friboulet et al., 2013b). Preclinical evidence 
suggested that the ERCC1/XPF complex can be detected by PLA (Friboulet et al., 2013a), 
but the predictive potential of ERCC1 or ERCC1/XPF as a biomarker for DDP response 




1.7 PATIENT-DERIVED XENOGRAFT MODELS 
Patient-derived xenografts (PDXs) are the most relevant EOC human models currently used 
in the field of preclinical EOC research (Ricci et al., 2014). EOC PDXs may be generated 
by heterotopic (i.e. subcutaneous) or orthotopic (i.e. intra-peritoneum or intra-bursal) 
transplantation of human cancer cell lines, or directly from fragments of patients’ biopsies 
or cells from ascitic fluid into immunodeficient mice (Hidalgo et al., 2014). The rationale 
beside the establishment of PDXs aimed to create models recapitulating the complexity of 
EOC (Aparicio et al., 2015). In fact, PDXs retain the main histological and molecular 
characteristics of donor tumour as confirmed in several studies, even after some in vivo 
passages when the tumour is propagated, confirming their genomic stability (Liu et al., 2019; 
Ricci et al., 2014). PDXs have been obtained from all the EOC subtypes, especially from 
HGSOC, which is the most prevalent and clinic relevant histotype. Large collections of 
extensively characterized PDXs have been established reflecting the heterogeneity of EOC 
(Heo et al., 2017; Ricci et al., 2014). Another advantage offered by PDXs, especially 
orthotopic models, is the possibility to study the process of tumour progression, metastasis 
formation and dissemination, as well as the role of tumour microenvironment and 
vascularization on EOC therapy (Bizzaro et al., 2018; Ricci et al., 2014). The second most 
relevant application of PDXs relies in drug-response studies and in the preclinical 
development of novel therapies (Hidalgo et al., 2014; Karakashev and Zhang, 2021). 
Validation studies showed a good correlation between PDXs response to chemotherapy and 
what observed in the original donor patient (Topp et al., 2014), and the ability to recapitulate 
the clinical spectrum of sensitivity to established therapies (Ricci et al., 2014). The 
correlation suggests the PDXs may have a predictive value and thus a role in the field of 
personalized medicine and in the search of biomarkers (Hidalgo et al., 2014), as well as in 
the studies on chemoresistance (Guffanti et al., 2018; Nagaraj et al., 2015). Notably, it is 
also possible to induce in vivo acquired chemoresistance by prolonged exposure to the drug, 
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similar to what observed in the clinic (Ricci et al., 2017). These acquired-resistant models 
have been utilized to explore the molecular mechanisms at the basis of acquired 
chemoresistance and to test novel pharmacological strategies to overcome this important 
clinical issue. However, as all models, also PDXs suffer from some limitations. Differently 
from in vitro and ex vivo models, PDXs are not suitable for high-through put screening tests, 
due to different reasons: low engraftment rate; relative slow tumour growth rate; high costs 
associated with long term experiments and the necessity of specialized trained personal 
(Karakashev and Zhang, 2021). Moreover, PDXs cannot be genetically modified and the use 
of immunocompromised mice precludes the studies of novel immunotherapies, that may be 
investigated using alterative, but challenging, humanized immune system mice (Choi et al., 









Epithelial ovarian cancer (EOC) is a lethal malignancy and, even if the majority of patients 
are initially extremely sensitive to platinum-taxol based chemotherapy, most of the 
responding tumours will recur within five years after diagnosis with a platinum-resistant 
phenotype. Recently, the therapeutic approach of EOC has been revolutionised by the 
introduction of PARP inhibitors (PARPi), particularly effective in homologous 
recombination (HR) deficient tumours. However, also for PARPi, cases of intrinsic or 
acquired resistance have been observed. For these reasons, the ability to identify patients 
who will effectively respond to therapy and the possibility to predict the onset of resistance 
to both platinum and PARPi will help to address patients receive the most appropriate 
treatment and to delay the onset of resistance, avoiding unnecessary and toxic treatments. 
50% of high grade serous ovarian cancers, the most diffuse subtype, harbour defects in the 
HR DNA repair pathway, involved in the repair of DNA double strand breaks and intra-
strand crosslinks, making these tumours very sensitive to both platinum agents and PARPi. 
HR deficiency is an important determinant of platinum/PARPi sensitivity and the most 
studied one; however, considering that these drugs cause different kind of lesions, involving 
many different DNA repair pathways, such as FA, BER, NER, MMR and TLS, the study of 
other possible DNA repair key determinants is warranted. Due to the complexity and the 
inter-connection among the various DNA repair mechanisms, the role of each pathway and 
how their presence or absence determines the final cell response to therapy is still an open 
question. In addition, there are no validated functional tests correlating the tumour DNA 
repair status and response to therapy. 
Starting from this background, we hypothesized that among DNA repair effectors could be 
possible to identify predictive biomarkers and finding functional tests able to measure the 
DNA repair activity of the tumour. The present PhD thesis aims to better elucidate the role 
of different DNA repair pathways in determining the response to cisplatin and olaparib (a 
PARPi) in a preclinical setting to find possible predictive biomarkers. This work has been 
carried out using ovarian cancer patient-derived xenograft (PDX) models established during 
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the last decade in the Department of Oncology at the Mario Negri’s Institute, where I 
undertook the PhD course. 
In particular, the present thesis is organized into the following parts: 
- in the first part, an overview of the xenobank is presented. We demonstrated that our PDXs 
are robust models, recapitulating the original tumours from which they derived. They 
resemble well the heterogeneity of EOC, and the most frequent HR genetic alterations. 
Moreover, the PDXs show a spectrum of response to DDP and olaparib similar to what is 
observed in the clinic, making them a good model for our studies; 
- the EOC-PDXs have been characterized at different molecular levels and these features 
have been correlated with tumour response to therapy. In particular, I analysed the 
expression levels of 35 genes involved in the main DNA repair pathways, described to be 
involved in cisplatin and olaparib mechanism of action, the promoter methylation status of 
selected DNA repair genes and the HR mutational profile of the PDXs. Then, these data have 
been correlated with response to DDP and olaparib; 
- in the third part, I focused on the research of possible determinants of HR activity. The 
HRDetect assay was applied to ten PDXs to evaluate their HR status, and the expression of 
RAD51 nuclear foci was quantified using and comparing two different 
immunohistochemical approaches in FFPE untreated xenograft tumours and correlated with 
the response to DDP and olaparib; 
- in the fourth section, ERCC1, ERCC1/XPF complex and POLB were studied at different 
levels (mRNA and protein expression), as surrogate markers for NER and BER activity in 
response to DDP therapy.  
Taken together the studies presented in my PhD thesis had the overall aim to improve 
understanding of the role of DNA repair in ovarian cancer as a determinant of response to 
platinum and PARPi-based therapy and to find possible DNA repair functional tests able to 












3.1 IN VIVO STUDIES 
3.1.1 Patient specimen collection and clinical data 
Fresh clinical specimens (primary ovarian tumours, omental metastasis or ascitic fluid) were 
obtained from patients undergoing cytoreductive surgery for ovarian tumour by laparotomy 
or paracentesis at the San Gerardo Hospital (Monza, Italy) and at the European Institute of 
Oncology (IEO) (Milan, Italy). Clinical data were obtained from medical records. Primary 
surgery was performed to establish the diagnosis, staging and debulking. Surgical staging 
was based on the FIGO (International Federation of Gynaecology and Obstetrics) 
classification. The study protocol for tissue collection and clinical information was approved 
by the Institutional Review Board and patients provided written informed consent 
authorizing the collection and use of the tissue for biomedical research purposes. 
 
3.1.2 Compliance with guidelines and laws regulating animal research 
Procedures involving animals and their care were conducted in conformity with institutional 
guidelines at the Institute of Pharmacological Research Mario Negri IRCCS (Milan, Italy), 
which adheres to the principles set out in the following laws, regulations, and policies 
governing the care and use of laboratory animals: Italian Governing Law (D. lg 26/2014; 
Authorization n°.19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri 
Institutional Regulations and Policies providing internal authorization for persons 
conducting animal experiments (Quality Management System Certificate-UNI EN ISO 
9001:2015–Reg, N°6121); the NIH Guide for the Care and Use of Laboratory Animals (2011 
edition) and EU directive and guidelines (EEC Council Directive 2010/63/UE). All in vivo 
experiments complied with protocols approved by the Ethical Committee of the Institute of 
Pharmacological Research Mario Negri IRCCS and the Italian Ministry of Health (approval 
numbers 510-2016 and 296/2018-PR). 
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In addition, intensive in vivo training is required by Institute of Pharmacological Research 
Mario Negri IRCCS guidelines to ensure respect and compliance with the above-mentioned 
laws.  
 
3.1.3 Animals and establishment of patient-derived xenografts 
All the experiments involving animals were carried out using six- to eight-week old female 
NCr-nu/nu mice obtained from Envigo Laboratories (Italy). Mice were maintained under 
specific pathogen-free conditions, housed in isolated vented cages, and handled using aseptic 
procedures.  
For the isolation of patient-derived xenografts, tumour specimens were engrafted in nude 
mice within 24 hours from the surgical intervention. Specifically, fragments from tumour 
masses (primary tumour or metastasis) were engrafted subcutaneously (s.c.), whereas ascitic 
fluid were injected intraperitoneally (i.p.) as cancer cell suspension.  
To obtain s.c. models, mice were anesthetized using an automatic delivery system that 
provides a continuous flow of 3% isoflurane (Florane, Abbott Laboratories) in 1% oxygen. 
A fragment of fresh human tumour specimen, dissected free of necrotic tissue, was injected 
subcutaneously in the flank of animals by incision with sterile scissors and the use of a trocar. 
The animals were followed for appearance of the tumour once a week. Once tumour 
formation was observed, mice were monitored at least twice a week, and tumour weight 
(TW) and body weight (BW) were measured. TW was monitored with a Vernier calliper and 
the TW (1mg= 1mm3) was calculated as follows: [length (mm) x width (mm)2]/2. When the 
TW reached 20% of mouse total BW (approximately, 1500 mg), mice were euthanized by 
CO2 exposure. Skin was disinfected with ethanol and an incision was performed to access 
the tumour mass, which was collected using sterile surgical instruments. Then, tumours were 





To obtain i.p. models, ascitic fluid from paracentesis was centrifuged, washed repeatedly, 
resuspended in phosphate buffered saline (PBS) solution, and injected intraperitoneally in 
mice at a dose of 10 x106 to 20x106 cells in 200 uL of saline solution (0.9% NaCl). Criteria 
for growing tumours were abdominal distension and palpable tumour masses in the 
peritoneal cavity. Mice were monitored at least twice a week, and the animal BW were 
measured. Mice were euthanized when an increment of 10-15% of their BW was observed 
and the day of the autopsy was considered as survival time. Ascitic fluid and subsequent 
peritoneal washings (3 ml sterile saline solution) were harvested using a 5 ml syringe, 
collected in a 15 ml tube, and centrifuge at 1200 rpm for 10 min at 4°C. Pellet was washed 
1 to 3 times with Red Blood Cell Lysis Buffer (Merk) to remove the erythrocytes following 
the manufacturer instructions. 1 ml of pellet was considered to contain 100x106 cancer cells.   
 
3.1.4 PDX samples storage 
At the time of euthanizing, xenograft tumour specimens were in part immediately frozen in 
dry ice and stored at -80°C for molecular studies. For histopathological and 
immunohistochemical studies, part of the sample was fixed in formalin solution (10% 
phosphate-buffered formalin (BioOptica) for 24 hrs to avoid excessive crosslink formation 
and loss of antigens, and maintained in a solution of 70% of ethanol until to be paraffin-
embedded (FFPE).  
FFPE tumour samples from 60 EOC-PDXs were included in a tissue microarray (TMA), 
using a standard technique (Pilla et al., 2012). The pathologist selected two core biopsies 
from distinct areas of FFPE PDX samples and these were randomly included to generate a 
TMA. All the samples are included in duplicate. Besides PDXs tumour samples, the TMA 
also includes specimens of murine healthy ovaries, murine ovarian carcinomas and ovarian 
cancer xenografts from human ovarian cancer cell lines, as internal controls.  
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3.1.5 Antitumour pharmacological activities 
Cisplatin (Sigma-Aldrich) diluted in saline solution was given intravenously (i.v.) at the dose 
of 5 mg/kg, every seven days for three times. Olaparib (Targetmol) was dissolved in 10% 
v/v dimethyl sulfoxide (DMSO) in 10% w/v HP-beta-ciclodestrine and diluted in sterile 
water, given per os at the dose of 100 mg/kg, daily for 28 days.  
The tumour growth of EOC-PDXs was monitored, and when the s.c. PDXs reached 
approximately 120 mg of TW, mice were randomized to receive the treatment or in the 
control group to receive the vehicle of the drug. i.p. PDXs were randomized to treatment at 
an advanced stage (i.e. 25% of expected median survival time). Each group comprised 8-10 
mice.  
For s.c. PDXs, treatment efficacy was expressed as best tumour growth inhibition (T/C), 
calculated as follows:  
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For i.p. PDXs, treatment efficacy was expressed as the best increase in lifespan (ILS), 
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Drug activity was defined as follows:  
 
s.c. PDXs  i.p. PDXs  
Very sensitive T/C% ≤10% ILS% ≥100% 
Sensitive 10%< T/C% <50% 40%< ILS% <100% 
Resistant T/C% ≥50% ILS% ≤40% 
 
The best T/C% parameter used to assess the response to antitumour treatments in s.c. PDXs 
was compared with the modified Response Evaluation Criteria in Solid Tumours 
(mRECIST) method, similar to that applied in the clinical setting (Castroviejo-Bermejo et 
al., 2018a; Cruz et al., 2018). To assess the best response for olaparib and cisplatin treated 
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PDXs, we considered the minimum value of % tumour volume change (min ΔVt %) 
sustained for at least 10 days. Antitumour response was classified into four groups:  
 
Complete response (CR) min ΔVt % ≤ -95% 
Partial response (PD) -95% < min ΔVt % < -30% 
Stable disease (SD) -30 < min ΔVt % < +20% 
Progressive disease (PD) ΔVt % ≥ 20% 
 
3.2 HISTOPATHOLOGICAL ANALYSIS 
Dr Patrizia Perego, Director of the Department of Surgical Pathology, Cytology and Medical 
Genetics, at the San Gerardo Hospital (Monza, Italy), performed all the 
immunohistochemical analyses. FFPE tissue slides (1μm) were dewaxed in xylene and 
rehydrated through decreasing ethanol concentrations, then washed in Tris Buffer Saline 
(TBS) pH 7.6 twice. Antigen retrieval was performed using Antigen Retrieval Buffer pH 6 
for 30 min at 98°C. Endogenous peroxidases were inhibited by incubating the samples in 
3% H2O2 for 5 min followed by washing in TBS. The slides were incubated for 30 min with 
primary anti-human antibody. In particular, anti- cytokeratin pool (65-67, 64, 59, 58, 56.5, 
56, 54, 52, 50, 48, 40 KDa) and anti-CA125 (DAKO). Then samples were incubated for 20 
min with a biotinylated link antibody and alkaline phosphatase-labelled streptavidin 
(Labeled Streptavidin Biotin (LSAB) + System-HRP, DAKO) and finally washed in TBS. 
The chromogen diaminobenzidine (provided by LSAB+ System-HRP, DAKO) was then 
applied for 5 min with Mayer’s haematoxylin diluted 1:4 in distilled water, dehydrated, 




3.3 MOLECULAR ANALYSES 
3.3.1 DNA extraction and purification 
Genomic DNA was extracted from snap frozen xenograft tumours using the Maxwell® 16 
System (Promega). The Maxwell® 16 DNA Purification Kit (Promega) was used to isolate 
genomic DNA in combination with the Maxwell® 16 Instrument. Maxwell® 16 Instruments 
are magnetic particle handlers that efficiently pre-process liquid and solid samples, transport 
the paramagnetic microbeads through purification reagents in the prefilled cartridges and 
mixes during processing.  
Cells or tissue biopsy were directly added to the first well of the cartridge containing the 
lysis buffer. Then, the cartridge was loaded into the instrument, which was set up with the 
proper extraction protocol. DNA purification employed a guanidine thiocyanate-based 
procedure to disrupt cells and denature proteins and magnetic microbeads to separate DNA 
from other cellular components. After the automatic procedure, DNA is eluted in 300 μl of 
sterile H2O and 2 µl was used to determine the concentration with a NANODROP nd-1000 
spectrophotometer (Thermo Fisher Scientific). The absorbance of DNA or RNA samples 
was measured at 260 nm, 280 nm and 230 nm. The concentration was automatically 
established by the instrument using the Lambert-Beer formula, relating the absorbance 
measured by the instrument with the concentration of the absorbing molecule. Nucleic acid 
purity was controlled based on the 260/280 and 260/230 ratios (nucleic acids vs proteins and 
nucleic acids vs contaminants, respectively). Accepted ratios range from 1.7 to 2.1. 
3.3.2 STR analysis 
Short tandem repeats (STR) analysis was performed by Dr Mirko Marabese, Head of the 
Molecular Genetic Unit at the Institute of Pharmacological Research Mario Negri IRCCS, 
using a multiplex STR-specific PCR, based on the Powerplex® 16 HS system kit (Promega). 
This PCR was used to simultaneously amplify 16 STR loci across the human genome in each 
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sample: D3S1358, TH01, D21S11, D18S51, Penta-E, D5S818, D13S317, D7S820, 
D16S539, CSF1PO, PENTA_D, Vwa, D8S1179, TPOX, FGA, and the Amelogenin 
(AMEL) locus for sex determination. The PCR reaction was done following the 
manufacturer instructions provided with the Powerplex® 16 HS system kit (Promega) and 1 
ng of purified DNA was required for the PCR. The multiplex-PCR was performed in a 
Veriti96-well Thermal Cycler (Applied Biosystem). 
STR profiles were generated with GeneMarker HID (SoftGenetics).  
3.3.3 Mutational status analysis 
For the present thesis, I performed the mutational status analyses of TP53 (exons 5 to 9), 
BRAF (exons 11 and 15), KRAS (exon 2) and PI3Kα (exons 10 and 21) using the Sanger 
method on the EOC-PDXs of the xenobank. Whole genome sequencing was conducted on 
10 selected PDXs (detailed in chapter 4.2.3) in collaboration with Dr Nik-Zainal at the 
Wellcome Trust Sanger Institute (Hinxton, UK), who performed the WGS focusing on HR 
DNA repair pathway genes (Chopra et al., 2020; Davies et al., 2017). The NGS and RNA-
seq analysis and subsequent validation with Sanger methods to detect aberrations and 
mutations in HR genes were described by Dr Francesca Bizzaro, PhD student in the Therapy 
of Tumor Metastases Laboratory at the Mario Negri’s Institute (Bizzaro, Francesca, 2018). 
3.3.3.1 Sanger method 
PCR reaction 
Genomic DNA was obtained from EOC-PDXs and amplified by PCR with primers designed 




Primers sequences were the following: 
Gene Exons Primer forward (5’-3’) Primer reverse (5’-3’) 
TP53 5-6 TTGCTTTATCTGTTCACTTGTGC GCCACTGACAACCACCCTTA 
 7 TGCTTGCCACAGGTCTCC GGTCAGAGGCAAGCAGAGG 
 8-9 CAAGGGTGGTTGGGAGTAGA CCCCAATTGCAGGTAAAACA 
KRAS 2 CTTAAGCGTCGATGGAGGAG AGAATGGTAATGCACCAGTAA 
BRAF 11 AAGGGGATCTCTTCCTGTATCC GAAACTTTTGGAGGAGTCCTGA 
 15 AACACATTTCAAGCCCCAAA CTGATTTTTGTGAATACTGGGAACT 
PI3Kα 10 TGAAAATGTATTTGCTTTTTCTGT ACATGCTGAGATCAGCCAAA 
 21 GCTTTGTCTACGAAAGCCTCT ATGCTGTTCATGGATTGTGC     
 
The mix for gene amplification (Promega) was prepared as follow: 
PCR reaction mix components (Promega) 
Volume per single 
reaction 
BUFFER 5x FLEXI (without MgCl2) 10 µl 
MgCl2 (25 mM) 5 µl 
dNTP (10 mM) 1 µl 
Primer Forward /Reverse (10µM) 2 µl + 2 µl  
TaqHotStart enzyme 0.25 µl 
DNA  5ng/ µl 10 µl 
H2O 10 µl 
Final volume 50 µl 
 
PCR amplification conditions were reported below:   
Cycles Duration Temperature 
1 2 min 94°C 
35 
15 sec 94°C 
30 sec 60°C 
45 sec 72°C 





PCR product purification 
PCR products were verified by detecting single band-amplicons with a 1.5% agarose gel. 
Amplified DNA was purified using the Illustra™ GFX PCR DNA and Gel Band Purification 
kit (GE Healthcare) following the kit instructions. 500 ul of capture buffer were added to 
each sample and transferred to a GFX column and centrifuged. After two washing steps, the 
elution buffer (20 ul) was added to each column and again centrifuged to recover purified 
DNA.  
Sequencing of amplified DNA 
Mycrosynth Seq Lab service (Germany) performed the sequencing. Results were shown as 
chromatograms and FinchTV software (Geospiza) was used to analyse them. 
3.3.4 Promoter methylation status analysis 
Promoter methylation status in the PDXs was assessed using two methods: pyrosequencing 
technique for BRCA1, MLH1, ERCC1, XPA genes, and MS-PCR for BRCA1, FANCF and 
XPG genes. In both cases, specific small promoter regions (<500 pb) including several CpG 
sites were analysed after conversion with sodium bisulfite.  
3.3.4.1 Sodium bisulfite conversion 
Sodium bisulfite treatment is used to convert cytosine in uracil, while 5-methylcytosines 
remain intact. Then, 1 μg of genomic DNA was converted with Epitect Plus DNA Bisulfite 
Kit (Qiagen) according to the manufacturer instructions. To verify successful sodium 
bisulfite conversion of the samples, a region of the Calponin promoter was amplified by MS-




Gene Primer forward (5’-3’) Primer reverse (5’-3’) 
Calponin GGAAGGTAGTTGAGGTTGTG CCCAAACTCAAAACTCTAACCT 
 
The PCR mix and conditions are described in (Sriraksa et al., 2010) and are reported below:  
 
PCR reaction mix components 
(Promega) 
Volume per single reaction 
BUFFER 5x FLEXI (without 
MgCl2) 
5 µl 
MgCl2 (25 mM) 3 µl 
dNTP (10 mM) 5 µl 
Primer Forward /Reverse 
(10µM) 
1 µl + 1 µl 
TaqHotStart enzyme 0.12 µl 
DNA converted 20 ng/uL  1 µl 
H2O 8.9 µl 
Final Volume 25 µl 
 
 
Cycles Duration Temperature 
1 5 min 95°C 
35 
30 sec 95°C 
30 sec 63°C 
1 min 72°C 
1 5 min 72°C 
 
3.3.4.2 Pyrosequencing technology 
After bisulfite conversion, PCR is required to amplify the converted DNA samples. 
For BRCA1, MLH1, ERCC1 and XPA pre-designed primers (Pyromark CpG Assays 






Figure 3.1 Chromosomal location of the PyromarkCpG assays (Qiagen) used to 
analyse the methylation status of BRCA1, ERCC1, MLH1 and XPA through 
Pyromark PCR and Pyrosequencing (Qiagen) 
Genomic coordinates are shown along with PyromarkCpG assays (in black) and promoters 
(dark grey).  
 
Table 3.1 List of the PyromarkCpG Assays (Qiagen) used for Pyrosequencing 
 
20 ng of DNA converted were amplified by PCR using the Pyromark PCR kit (Qiagen) and 

































Cycles Duration Temperature 
1 15 min 95°C 
45 
30 sec 95°C 
30 sec 56°C 
30 sec 72°C 
1 10 min 72°C 
 
PCR products were checked by agarose gel analysis before Pyrosequencing. 
The PyroMark ID96 platform, an in vitro nucleic acid sequence-based detection test based 
on pyrosequencing technology, and PyroMark ID96 software were used to sequence and 
analyse pyrograms of the promoter regions of the selected genes giving the % of CpG sites 
found methylated.  
3.3.4.3 MS-PCR 
For BRCA1, FANCF and XPG, the analysis of promoter methylation status was performed 
with methylation specific-PCR and primers designed ad hoc to distinguish the methylated 



































The region in BRCA1 promoter was different from those previously analysed and it ranges 
from 41277722 bp to 41277808 bp.  
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20 ng of bisulfite converted DNA were amplified with MS-PCR. Mixture (Promega) and 
conditions were those reported for Calponin, except for the temperature of annealing relative 
to each couple of primers: for BRCA1 62°C, for FANCF 58°C and for XPG 52°C. 
 
MS-PCR products were then separated on 2% agarose gels and visualized with SYBR Green 
I Nucleic Acid Gel Stain (Thermo Fisher Scientific) and images were acquired with Odyssey 
Fc (Licor) system.  
3.3.5 Gene expression analysis 
3.3.5.1 RNA extraction and retrotranscription 
Total RNA was extracted from snap frozen tumour tissues or tumour cells with Maxwell® 
RSC simplyRNA Tissue Kit (Promega). Similarly, for DNA extraction, the kit provided all 
the reagents and prefilled cartridges required for RNA extraction from as few as 106 cells. 
The extraction was then carried out automatically by the Maxwell® RSC Instrument 
(Promega). 
The first step required is manual, and it is necessary before loading the sample into the 
cartridge. It required the incubation of cells with a mixture containing 20μl of thioglycerol 
in 200μl of Homogenization Solution per sample. Snap frozen tissue homogenization was 
facilitated with an automatic homogenizer (UltraTurrax-Ika). Then, 200μl of a guanidine 
thiocyanate containing solution (Lysis Buffer), which maintains the integrity of RNA while 
dissolving cell components, were added to the homogenate solution. The final solution was 
vortexed for 20 sec and the overall volume of 400μl was loaded into the first well of the 
cartridge (figure 3.2).  
The Maxwell® RSC Instrument was set up for the protocol of RNA extraction from cells and 
it employs magnetic microbeads to separate RNA from the other cellular components, 
sequential ethanol-based washing steps and DNAse enzyme to digest the DNA. At the end 
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of the process, RNA was found eluted in 50μl of RNAse free water and then quantified using 
Nanodrop spectrophotometer. RNA samples were storage at -80°C until use.  
Figure 3.2 Maxwell® RSC cartridge system (Promega) employed for automated 
RNA extraction from tissues or cells 
Samples homogenized with Lysis Buffer were loaded into the first well of the cartridge. A 
plunger needs to be added into the last well and 5μl of DNAse containing solution into the 
fourth well. The Maxwell instrument automatically extracted RNA from the sample, washed 
it and eluted it in the tube in front of each cartridge. 
 
High Capacity cDNA Archive kit (Life Technologies) was used to perform retrotranscription 
reaction. A range from 200ng to 1µg of total RNA was retrotranscribed to single-stranded 
cDNA using random hexamers.  
The reaction protocol was: 25°C for 10 min followed by 2h at 37°C.  
cDNA reaction products were kept at -20°C until the RT-PCR step. 
3.3.5.2 Real time-PCR reaction 
The absolute quantification of the mRNA copies of 35 DNA repair genes was determined 
using real time-PCR with SYBR green® technology. 
Optimal primer pairs were chosen, spanning splice junctions, using Primer3 software as 
above mentioned. Synthesis of oligonucleotides used as primers was performed by Metabion 
(Germany). Primer specificity was verified by detecting single-band amplicons of the PCR 
products in agarose gel. They were also tested for the human specificity using murine cDNA.  
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All the DNA samples extracted from PDXs were also tested with PCR in order to assess the 
% of murine DNA contamination using primers specifically designed to distinguish between 
murine and human ACTB. We accepted for the experiments xenografts tumours having more 
than 70% of human DNA. 
 
Experiments were run in triplicate, and absolute quantification of the number of mRNA 
molecules was determined by RT-PCR thermocycler (ABI-7900, Applied Biosystems), 
loading 384-well plates with an EpMotion 5075 robot (Eppendorf).  
Expression data were normalized employing the geometric mean of two housekeeping 




A detailed list of the primers used in the RT-PCR experiments is reported: 
Gene function Gene Primer forward (5’-3’) Primer reverse (5’-3’) 
Housekeeping ACTB TCACCCACACTGTGCCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG 
Housekeeping CYP GACCCAACACAAATGGTTCC TTTCACTTTGCCAAACACCA 
Homologous 
recombination (HR) 
BRCA1 GAACGGGCTTGGAAGAAAAT GTTTCACTCTCACACCCAGA 
BRCA2 TGTCACAACCGTGTGGAAGT TGATGGACGCCAAATACTCA 
RAD51 CAGATGCAGCTTGAAGCAAA TTCTTCACATCGTTGGCATT 
PALB2 CTTGGCAGTGGGAAAAACTT TTCCCAAAGCTACACACACG 
RAD51C GCCTTGCTTGTTCCTGCATT TGGCTGGGTGACTTGTACAA 
DNA DSB response 
53BP1 TGGTTCCATCAGTCAGGTCA ACAGCAGGAGCAGATTCCAC 
ARTEMIS ACAGGAGACTTCAGATTGGCG CACTCCTCCCGACTTGGAATT 
PTIP AGGAAAGCCATGTTCACAGC CACCTGCCAAATAAGCCATT 
Base excision repair 
(BER) 
PARP1 AAGAAATGCAGCGAGAGCAT CCAGTGTGGGACTTTTCCAT 
POLB TGCCTGGAGTAGGAACAAAAA GGAAATTGATGGATGAACTCG 
OGG1 CTCCACTCCTGCCCTGTG CCAGTGTGCAGGACTTTGC 
Nucleotide excision 
repair (NER) 
XPA ATGCGAAGAATGTGGGAAAG CTTGTTTTGCCTCTGTTTTGG 
XPD GTGGCCATCAGCTCCAAAT CAGCAGGAGGTTCCCATAGT 
XPF TTGTGAGGAAACTGTATCTGTGG AGCAAGCATGGTAGGTGTCA 
XPG TCTGGAAGCTGCTGGAGTG GACAAAAGGAATGGCAGGAG 
ERCC1 tot CCAACAGCATCATTGTGAGC TCTTGGCCCAGCACATAGTC 
ERCC1iso2 GACCACCGTGAAGTCAGTCA GGGCATAAGGCCAGATCTTC 
Fanconi anemia 
(FA) 
FANCA GAGACCAGTCACCCTGTGCT CAGAAGGAAAGACGGGAGAA 
FANCC GGCAAAAGCTTGTTGGAATC CCAGGAGTTAAGTTTTGATTGTCC 
FANCF GCTAGTCCACTGGCTTCTGG GGTGGCGGCTAGTCACTAAA 
FANCD2 CCTCGACTCATTGTCAGTCAAC GATGATGTCATGCTGCAGGT 
Mismatch repair 
(MMR) 
MLH1 AAGCCATGTGGCTCATGTTA AGGGGCTTTCAGTTTTCCAT 
Non-homologous 
end joining (NHEJ) 
KU70 GCTTCTGCCTAGCGATACCA CCCATGAGCATCAAACCTGG 
KU80 TGAGAAGACAGACACCCTTGA CCGGGGATGTAAAGCTCTGT 
DNA-PK GCACTTTCAGCCCTGGAATC CTGCTCCATAAAGTACTGCAGT 
Microhomology end 
joining (MMEJ) 
POLQ GCTGGAACTTTTGCTGACCA TCATGCCAACGATTTGCACA 
Translesion repair 
(TLS) 
POLH CTGGCACAAGTTCGTGAGTC CGTTCAATCACAGCAAAACG 
Regulator of DNA 
repair gene 
transcription 
CDK12 TTGTCACAGATAAACAAGATGCAC TGCACCAAACCAGATTCTAGC 
DNA damage 
response 
SLFN11 TGGGTAGGCATGATGACAGA AAGGGGAGGCCCACTAGATA 
Chromatin organizer 
ARID1A GTGTTGCTCAGTCTCGCTCA ATTGGTTCATGGAAGGATGC 
CARM1 ATCCGGATCCTGATGGCCA AGCAACGTCAAACCAGAAAGC 
CHD4 ACCCAAGAAAGTAGCTCCCC ACTGGCATCATCGAAGTCAGA 
Cell cycle regulators 
REV7 AGTGGTGGTGGTGATTTTGG AGCTGCTCCACATGAGACAA 
CCNE1 AATGCGAGCAATTCTTCTGG CGCCATATACCGGTCAAAGA 
Deubiquitination USP28 AGTGCTGCCAACAAGGAAGT TTGAATTTTGGGAGACTCCAG 





The RT-PCR reaction mix was prepared as follow: 
PCR reaction mix components  Volume per single reaction 
2X Go Taq qPCR Master Mix (Promega)  5 µl 
Primers F / R 10 μM 0.2 µl + 0.2 µl 
H2O 0.6 µl 
cDNA 2,5 ng/µl 4 µl 
Final Volume 10 µl 
 
The reaction conditions were: 
Cycles Duration Temperature 
1 2 min 50°C 
1 10 min 94°C 
40 
15 sec 94°C 
1 min 60°C 
1 15 sec 95°C 
1 15 sec 60°C 
 
The last two steps were added when a dissociation curve protocol was needed. 
Raw data were generated with SDS Relative Quantification Software (Applied Biosystems).  
Standard curves for each gene were included for the absolute quantification of mRNA 
copies. To generate the calibration curve of a specific gene, a RT-PCR was run with a cDNA 
sample (i.e. an ovarian cancer cell line, which expresses the gene of interest) at the condition 
described above. After RT-PCR, the amplification product was run in agarose gel and the 
sample band was then extracted and purified with Gel Band Purification kit (GE Healthcare) 
as previously detailed. Next, the PCR amplicon diluted in RNAase free water, was quantified 
with the Nanodrop instrument.  
The calculation of the number of mRNA molecules for each PCR product was performed 
with the following formula:  
N° of mRNA copies= 
. 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Next, the starting “mother dilution” corresponding to 108 mRNA copies was prepared in 
RNAse free water, and the subsequent dilution points were prepared by serial dilution from 
the first “mother”, from 107 to 1 copy of mRNA (107, 106, 105, 104, 103, 102, 101, 100).  
The calibration points were added into the definitive 384-well plate, 4 μL of each point, in 
triplicate, instead of sample.   
The standard curve obtained in this way at the end of the RT-PCR run allowed me to 
extrapolate the exact quantity of mRNA starting from the number of Ct for each sample. 
A robust standard curve must have a slope of -3.3 (±0.3) and Y-intercept ranging from 1 to 
0.98. 
3.3.6 HRDetect assay 
The HRDetect assay was applied to ten of our PDXs in collaboration with Dr Nik-Zainal, 
who set up this assay and the relative algorithm, aimed to elaborate a score indicative of the 
HRD status of a tumour sample. The detailed method is described in (Chopra et al., 2020; 
Davies et al., 2017). 
Briefly, genomic DNA was extracted from the snap frozen PDX tumours. We checked the 
amount of human ACTB vs murine ACTB contamination (only samples with >70% of human 
DNA were accepted) and 1000 ng of DNA in 30 ul of TE buffer was sent to the Wellcome 
Trust Sanger Institute to perform the whole genome sequence (WGS), in parallel with an 
aliquot of the germline DNA of the patient from which the PDX was derived from, extracted 
from blood sample, stored in the PANDORA Biobank at the Mario Negri Institute.  
500-bp insert genomic libraries were constructed according to Illumina library protocols and 
150 bp paired-end sequencing performed on an Illumina HiSeq X Ten using HCS (v3.5.0) 
for HiSeq X systems, to an average sequence depth of 38.5× for both tumour and normal. 
The resulting reads were aligned to the reference patient genome.  
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Mutation calling was performed as described in (Nik-Zainal et al., 2016), evaluating somatic 
substitutions, indels, structural variants, allele-specific copy number variations and loss of 
heterozygosity (LOH) across the BRCA1, BRCA2 and PALB2 genes.  
Mutational signature contributions for substitution signatures 3 and 8, rearrangement 
signatures 3 and 5, deletions at microhomology and HRD LOH index were calculated for 
each sample as input into the weighted model, HRDetect.  
The HRDetect algorithm is based on a lasso logistic regression model, which was used to 
identify the genomic features that could distinguish the two categories of samples: the HRD 
and HR proficient tumours, and to assign a probabilistic score to each sample. The HRDetect 
algorithm was run as described in (Davies et al., 2017). 
The HRDetect score could be >0.7, suggesting an HRD tumour, and, vice versa, <0.7 
indicative of HR proficiency. 
3.3.7 Nuclear foci immunofluorescence-based assays 
To detect and quantify RAD51 foci, we applied two immunofluorescence (IF)-based 
methods. The first was performed in collaboration with Dr Deborah Wilsker of the Frederick 
National Laboratory for Cancer Research (MD, USA), where RAD51 foci where detected 
on the TMA including 60 PDXs of our xenobank. The second method we applied was 
recently set up by the Experimental Therapeutics Group, at the Vall D’Hebron Institute 
(Barcelona, Spain) headed by Dr Violeta Serra (Castroviejo-Bermejo et al., 2018a; Cruz et 
al., 2018). This latter assay was employed on FFPE tissue samples of PDXs. 
3.3.7.1 IF detection of RAD51 foci on TMA 
 5 μm TMA slice was deparaffinised, and prepared for the staining following the method 
described in (Wilsker et al., 2019).  
IF co-staining was performed to detect RAD51 foci using a custom-conjugated Rad51-DNP 
primary antibody detected with the use of Alexa Fluor 488, conjugated anti-Dinitrophenyl- 
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KLH Rabbit IgG Antibody fraction, (DNP-488; Thermo Fisher Scientific) (FITC channel) 
and B-catenin, using a mouse primary antibody detected with the use of Alexa Fluor 546 
(TRITC channel). B-catenin was used as marker of cancer cells and RAD51 foci was 
quantified in this population of cells. 
Automatic images acquisition was performed with a Nikon 90i confocal microscope (20x) 
and over 2500 images were acquired. 
A Quality Control process was followed according to (Marrero et al., 2016), excluding poor 
quality tissue (low number of cancer cells or no tumour tissue); aspecific FITC signal, due 
to RBCs, autofluorescence, or damaged tissue; high background due to microscope Gain; 
only β-catenin positive tissues were analysed. 
Samples with a minimum of 2900 countable nuclei were considered significant and high 
confidence.   
The quantitative analysis was performed by Definiens Tissue Studio® software (Definiens 
AG, Germany) for analysis of marker expression and nuclear segmentation and enumeration.  
RAD51 assay reported the % of cells per sample expressing ≥5 RAD51 foci per nucleus, in 
compliance with the Quality Control process. 
3.3.7.2 IF detection of RAD51 foci on FFPE samples (PARPiPred test) 
3 μm FFPE tissue sections were deparaffinised with xylene and hydrated with decreasing 
concentrations of ethanol solutions.  
Antigen retrieval was performed boiling the tissue sections in a microwave for 4 min at 
110°C in DAKO Antigen Retrieval Buffer pH 9.0.  
Samples were cooled down in MilliQ water and ice, then permeabilized in PBST solution 
(PBS + Tween 20%) for 5 min and incubated with the blocking buffer solution (PBST + 1% 
bovine serum albumin fraction V (BSA)) for 1 hr.  
The following primary antibodies were used for IF experiments:  
- rabbit anti-RAD51 ab133534 (Abcam), diluted 1:1000 
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- mouse anti-geminin NCL-L (NovoCastra), diluted 1:100 
- mouse anti-γH2AX monoclonal antibody clone JBW301 (Millipore), diluted 1:200 
- mouse anti- BRCA1 c-terminus (D9) sc6954 (SantaCruz), diluted 1:50 
- rabbit anti-geminin 10802-1-AP (ProteinTech Group), diluted 1:400. 
Primary antibodies were diluted in blocking buffer solution, properly diluted, and incubated 
at room temperature for 1 hr. For the co-staining it was used the anti-body anti the foci- 
protein of interest and the antibody anti-geminin, according with the proper species. 
After washing buffer with PBST, secondary antibodies were diluted in blocking buffer 
1:500, using Alexa Fluor 488 (FITC) (usually for geminin) and Alexa Fluor 568 (m-Cherry) 
(usually for nuclear foci) (Life Technologies), and incubated at room temperature for 30 
min, in dark chamber.  
Again, two washing steps with PBST were repeated and tissue sections were put into distilled 
water for 5 min, before dehydration was performed with increasing concentration of ethanol.  
Nuclei were stained with 4',6-DiAmidino-2-PhenylIndole (DAPI) (30 ng/ml in PBS, Sigma-
Aldrich) 10 min in dark chamber, following two washes in PBS and one in distilled water. 
Slides were mounted with Vectashield solution (VectorLab). 
Slices were stored at -20°C, protected from light, until analysis. 
Slices were observed using the ECLIPSE Ti2-E (Nikon) fluorescence microscope, with the 
objective 60x/1.27 WI Plan APO IR, ∞ 0.15/0.19 WD 0.18-0.16 Nikon. 
RAD51 foci was quantified by scoring the % of geminin-positive tumour cells with ≥5 foci 
per nucleus (RAD51+/GEM+). Scoring was performed blind. At least hundred GEM+ cells 
in three different areas of the tissue section were analysed.  
The same scoring was performed for BRCA1 foci (BRCA1+/GEM+ cells) and γH2AX 
(γH2AX+/GEM+). 
We considered RAD51 positive tumours those samples, which included ≥10% 
RAD51+/GEM+ cells; BRCA1 positive tumours those with ≥35% BRCA1+/GEM+ cells 
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(calculated on the median of BRCA1+/GEM+ cells expressed in our EOC-PDXs); γH2AX 
positive tumours those with ≥25% γH2AX+/GEM+ cells. 
3.3.8 Immunohistochemical analysis 
ERCC1 and POLB immunohistochemical (IHC) analyses were performed in 5 μm TMA 
sections.  
Sections were deparaffinised in xylene and hydrated with decreasing concentrations of 
ethanol solutions. 
Antigen unmasking was done boiling the TMA section at 95°C for 30 min in MS-Unmasker 
tris (EDTA) pH 7.8 solution (Diapath, Italy), then endogenous peroxidases were quenched 
and the section was incubated with blocking solution (PBST+ 1% BSA) to block the 
aspecific sites.  
For POLB, IHC used a rabbit anti-POLB primary antibody ab26343 (Abcam), diluted in 
blocking solution and incubated following datasheet instructions. Then it was incubated with 
a biotinylated secondary antibody (VC-BA-1000-MM15, Vector Laboratories, Burlingame, 
CA, USA). Sections were labelled by the avidin–biotin–peroxidase (ABC) procedure with a 
commercial immune-peroxidase kit (VC-PK-6100-KI01, Vector Laboratories). The 
immune-reaction was visualized with 3,3′-diaminobenzidine (DAB), (VC-SK-4100-KI01, 
Vector Laboratories) substrate. 
For ERCC1, IHC used a rabbit anti-ERCC1 primary antibody Sc-10785 (Santa Cruz 
Biotechnology), diluted and incubated following datasheet instructions. Then, tumour 
sections were incubated with a secondary antibody poly-HRP (RE7200-K, Novo Castra). 
The immune reaction was visualized adding peroxidase 3,3′-diaminobenzidine (DAB) and 
its substrate (NovoCastra). Sections were then counterstained with Mayer’s haematoxylin 
and cover slipped. 
A semiquantitative score was assigned to each tumour by Prof Eugenio Scanziani, the 
pathologist who performed the analyses at the University of Milan. 
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For both ERCC1 and POLB the signal staining intensity was measured as follows: 
 







A second score was assigned to each tumour based on the % of positive cells. 
- For POLB the score-scale was: 
% of POLB positive cells Positivity score 
0% 0 
0.1% - 25% 1 
26% - 50% 2 
51% - 75% 3 
76% - 100% 4 
 
- For ERCC1 the score-scale was: 
% of ERCC1 positive cells Positivity score 
0% 0 
1% - 9% 0.1 
10% - 49% 0.5 
> 50% 1 
 
The final IHC score was calculated by multiplying the intensity score with the positivity 
score. If the two cores of the same tumour in the TMA were both evaluable, the final score 
was calculating on the average of the two single scores.  
3.3.9 Proximity Ligation Assay   
Proximity ligation assay (PLA), or Duolink® PLA technology, allows detection of 
endogenous protein-protein interactions in situ with high sensitivity and specificity. Briefly, 
cells or tissue were stained with two IHC or IF primary antibodies to target the two proteins 
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of interest (i.e. ERCC1 and XPF). The two primary antibodies must derive from different 
species (i.e. mouse and rabbit). Next, the Duolink® PLA PROBES kit (Merk) provided two 
secondary antibodies known as PLA probes (PLUS and MINUS) that bind to the constant 
regions of the primary antibodies and contains a unique DNA strand. If the proteins of 
interest interact and are close to each other (< 40 nm), the DNA probes hybridize making a 
circular DNA molecule. This DNA can be amplified and visualized by fluorescent 
complementary oligonucleotide probes (Duolink® Fluorescent Detection Reagent kit 
(Merk)) or by HRP-labelled probes and the substrate components (Duolink® Detection 
Reagents for Brightfield, Merk) required for HRP enzymatic reaction, that need to be 
incubated with the cells. The schematic diagram of Duolink® PLA (Merk) is shown in 
figure 3.3. 
 
Figure 3.3 Duolink® PLA workflow 
1) Two primary antibodies generated in different species bind the two proteins of interest on two 
epitopes of a single protein. 2) Secondary antibodies with MINUS and PLUS probes, which are 
species-specific, are added. 3) Two circle-forming DNA oligonucleotides and the ligase enzyme are 
added. 4) Polymerase enzyme amplifies the circular DNA. Fluorescent labelled, complementary 
oligonucleotides probes or HRP-labelled probes with its substrate are added and bind the amplified 
DNA, making visible the protein complex. 
 
Protein-protein interactions were visualized as dots, and the number and intensity of the dots 
can be quantified by fluorescence or brightfield microscopy. 
3.3.9.1 PLA on TMA (brightfield technology) 
5 μm FFPE-TMA sections were put onto poly-lysine-coated glass slides. Sections were 
dewaxed and hydrated as usual, then, the first step requires antigen retrieval, leaving the 
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slides in the in MS-Unmasker Tris (EDTA) pH 7.8 solution (Diapath, Italy) and boiling at 
95°C for 30 min. Once cooled down, the peroxidise quenching is required, incubating the 
tissues with H2O2 solution for 5 min. Then, blocking of aspecific sites was performed by 
adding the Blocking solution ready-to-use in the Duolink® PLA Probes kit (Merk) and 
leaving to incubate at 37°C in a wet chamber for 30min. Primary antibodies were used to 
detect ERCC1 (anti-rabbit, Sc-10785, Santa Cruz Biotechnology) and XPF (anti-mouse, 
MA56-12060, Thermo Fisher Scientific) diluted 1:100 and 1:200, respectively, in the same 
mixture with Antibody Diluent Solution of the same kit. Incubation was done at 4°C over- 
night, and a tissue slide was used as blank and it was left to incubate without primary 
antibodies. Next, PLA Probes MINUS and PLUS were added to the samples and left to 
incubate at 37°C for 1 hr and 30 min in a wet chamber, following manufacturer instructions, 
and allowing the formation of oligonucleotides. Then, the oligonucleotides were 
subsequently hybridized, ligated, amplified using the reagents and manufacturer instructions 
of the Duolink® Detection Reagents for Brightfield kit (Merk).  
Slides were then counterstained with Vector® Nuclear Fast Red (VectaStain), dehydrated 
and mounted with Vectashield solution (VectorLab).  
Images were acquired with the VS120-Virtual Slide microscope (Olympus) at 40X 
magnification and analysed with ImageJ software (ImageJ). In particular, the number of dots 
corresponding to the ERCC1/XPF complex were normalized by the number of nuclei visible 
in pink, evaluating at least three different areas of the tissue and counting at least 150 cancer 
cells for each tumour core. The final result was expressed as number of ERCC1/XPF foci 
per nucleus for each core. When two cores of the same PDXs were available the mean was 
calculated. 
3.3.9.2 Cell culture conditions and in vitro treatment 
Cell culture procedures were carried out aseptically in a class II laminar flow hood. Cells 
were maintained in a Heraeus CO 2 Auto-Zero incubator at 37°C in a humidified atmosphere 
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of 5% (v/v) CO2 in air and routinely sub-cultured twice weekly. Cell lines were routinely 
tested for mycoplasma contamination by PCR and authenticated with the PowerPlex® 16 HS 
System (Promega) every 6 months by comparing the STR profiles to those deposited in the 
American Type Culture Collection (ATCC) and/or in the German Collection of 
Microorganisms and Cell Cultures (DSMZ) databases. 
The human cancer cell line used in this project was the ovarian cancer cell line A2780, 
previously obtained from ATCC. The A2780 cell line was maintained in RPMI1640 with 
the addition of 10% foetal bovine serum (FBS) and 2 mM L-Glutamine (Lonza).  
For the experiment, 40.000 cells/ml were seeded in 24-well plates. After 24 hrs, cells were 
treated with DDP (Sigma-Aldrich) at the IC50 dose of 10 μM (previously established in our 
laboratory) and 20 μM for 2 hrs. Then, DDP was removed and fresh medium was added into 
the wells. 24 hrs and 48hrs after the end of the treatment, cells were fixed with pure cold 
methanol at -20°C for 30 min, washed with PBS and storage in PBS at 4°C until PLA was 
performed.  
3.3.9.3 PLA on A2780 DDP-treated cells (IF technology) 
The PLA procedure was similar to that previously described for the brightfield conditions. 
The difference relies on the use of the Duolink® Fluorescent Detection Reagents Green 
(Merk) instead of the Duolink® Detection Reagents for Brightfield kit (Merk). The same 
primary antibodies were used for ERCC1 and XPF, at the same condition.  
A2780 cells were incubated with DAPI solution (30 ng/ml in PBS, Sigma-Aldrich) for 10 
min in a dark chamber, washed with PBS and then mounted. 
The PLA signal was detected using the VS120-Virtual Slide microscope (Olympus) with 
FITC and DAPI channels at 40X magnification and imaging analysis was performed as 
previously described.  
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3.4 STATISTICAL METHODS 
Statistical analyses were performed in collaboration with Dr Maria Francesca Alvisi and Dr 
Maddalena Fratelli, biostatisticians at the Mario Negri Institute, where this PhD thesis has 
been done. The agreement between T/C and mRECIST values used to establish the response 
of PDXs to chemotherapy, was assessed by Cohen's kappa index, as well as to verify the 
concordance between DDP and olaparib response.  
The linear correlation between gene expression levels was measured by the Pearson test, 
while Spearman correlation coefficients were calculated for the correlation between 
continuous variables.  
Response to therapy was analysed as categorical variable grouped in very sensitive (VS), 
sensitive (S) and resistant (R) based on the T/C and ILS values. For comparison of the three 
groups with different drug responses and the gene expression level, one-way ANOVA 
followed by a Tukey post-hoc test was applied. Microarray gene expression data of TCGA 
ovarian serous cystadenocarcinoma samples and CDK12 co-expression analysis were 
retrieved from the cBioPortal platform (“http://www.cbioportal.org,” n.d.). RNA sequencing 
v.2 expression data for a subset of the same database were retrieved from the TCGA data 
portal (“https://tcga-data. nci.nih.gov,” n.d.).  
The % of RAD51/BRCA1/γH2AX-foci positive cells were considered both as continuous 
variables and categorical variables by dichotomizing using these cut offs:  10% for RAD51, 
35% for BRCA1 and 25% for γH2AX % foci. Non-parametric analyses were done if the 
assumption of normality was not satisfied. The Kruskall-Wallis test was used to analyse the 
association between the continuous % of RAD51/BRCA1-foci positive cells and response 
to DDP and olaparib, while Jonckheere-Terpstra per trend test was applied to analyse the 
statistical significance trend between % of RAD51/BRCA1 foci and response to DDP and 
olaparib. The Kruskall-Wallis test was also used to analyse the association between 
ERCC1/XPF foci, ERCC1 IHC score, POLB IHC score, ERCC1/XPF/POLB mRNA levels 
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and response to DDP. Spearman correlation index was calculated for the correlations 
between continuous variables. The unpaired t-test was used to analyse PLA foci number in 
untreated vs DDP-treated cells and the gene expression in hypermethylated PDXs vs non-
hypermethylated.  
P-values≤0.05 were considered statistically significant. SAS version 9.4 (SAS Institute, 











4.1 THE EOC XENOBANK  
During the last decades in the Department of Oncology at the Institute for Pharmacological 
Research “Mario Negri” IRCCS, where this PhD project has been developed, great efforts 
have been carried out to establish a large platform of transplantable patient-derived EOC 
xenografts (EOC-PDXs). This platform, also named xenobank, is continuously updated and 
enlarged with new tumours deriving from our collaboration with the Gynaecological 
Division of San Gerardo Hospital in Monza (Italy) and the European Institute of Oncology 
(IEO) in Milan (Italy).  
Clinical specimens (primary tumour, metastasis or ascitic fluid) are obtained from ovarian 
cancer patients undergoing surgical cytoreduction of the solid malignancy or paracentesis of 
ascitic fluid. Acceptance of the written informed consent gave the authorization for the 
collection and use of the tissue for research purposes. Clinical specimens are transplanted 
into nude immunodeficient mice subcutaneously or orthotopically/intraperitoneally to 
generate the PDXs (figure 4.1).  
Currently, the xenobank includes more than sixty EOC-PDXs representing all the different 
EOC histotypes: serous, endometrioid, clear cell, mucinous, carcinosarcoma, müllerian 
mixed and undifferentiated carcinomas, at different grade and stage. Among them, 34 have 
been already described in Ricci et al. (Ricci et al., 2014), while the others have been recently 
introduced in the xenobank. These PDXs generally resemble well the original tumour from 
which they derived in terms of biological behaviour, histopathological and molecular 
features and they keep this consistency for several in vivo passages (Ricci et al., 2014). Our 
xenobank is a reliable tool to tackle various clinical unmet issues, such as the research of 
biomarkers and to evaluate functional assays to predict response to chemotherapy, which are 
the final aims of this thesis. 
During my PhD, I contributed to the molecular profiling of the PDXs and their 
pharmacological characterization for the response to platinum/taxol, the standard drugs used 
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in the clinic for the management of EOC. Recently, given the importance of PARPi in 
ovarian carcinoma treatment, olaparib antitumor activity has also been tested. Furthermore, 
starting from PDXs sensitive to therapy, we have recently obtained three models of acquired 
resistance to cisplatin through repeated in vivo treatments, useful to study molecular 
determinants of acquired resistance to platinum therapy (Ricci et al., 2017) (figure 4.1).  
In this first section, I will describe the PDXs selected for the experiments performed along 
my PhD project. In particular, the clinical-pathological features of the original tumours from 
which the PDXs derived, the mutational profile of the PDXs, the promoter methylation status 
of some DNA repair genes of interest, and PDXs response to cisplatin and olaparib will be 
reported. Parts of these data have been previously published (Guffanti et al., 2018; Ricci et 
al., 2014), others have been recently obtained, because the xenobank is a dynamic collection, 





Figure 4.1 Establishment, characterization and application of the Mario Negri’s 
EOC xenobank  
Ovarian cancer specimens deriving from cytoreductive surgery or paracentesis interventions are 
received and transplanted within 24 hrs in athymic Foxn1nu mice, subcutaneously or 
intraperitoneally. Once stabilized, the xenografts are histologically and molecularly characterized. 
The EOC-PDXs are characterized for their response to the standard drugs used in the clinic for 
the management of EOC (i.e. cisplatin, paclitaxel); recently, olaparib has been evaluated. Starting 
from cisplatin responsive PDXs, it was possible to induce resistance to therapy after repeated in 




4.1.1 Clinical-pathological characteristics of the patient tumours from 
which the EOC-PDXs derived 
The specimens used to generate the PDXs usually derive from cytoreductive surgery of 
primary tumours localized at the ovary, omentum, or from paracentesis at diagnosis or at 
relapse. The percentage of tumours successfully engrafted in vivo is around 25%, regardless 
of the histopathological characteristics of the tumour and the site of injection (Ricci et al., 
2014). Currently, our xenobank consists of 68 models. Considering those PDXs whose 
histological subtype is known, the xenobank includes 44 high grade serous/endometrioid 
tumours, 2 low grade serous carcinomas, 3 clear cell carcinomas and 1 mixed clear cell/high 
grade endometrioid tumour, 2 mucinous, 1 mixed müllerian, 1 carcinosarcoma, 1 
undifferentiated and 1 not classified tumour, while for the others the histological information 
is not currently available.  
In table 4.1 are summarized the main clinical-pathological characteristics of the original 
EOC specimens engrafted in nude mice to originate the PDXs we have available. The 
information includes: histotype, grade and stage of tumour at the diagnosis, first line 
treatment received and the origin (primary tumour or relapse) and source (ovary, omental 
metastasis or ascitic fluid) of the specimens used to establish the PDXs.  
Except three patients (MNHOC18, MNHOC164 and MNHOC506) who received 
neoadjuvant therapy, all the PDXs from primary specimens are chemotherapy naïve, while 
those obtained from relapsing tumours have been almost all previously treated with platinum 
agents. The majority of patients received the standard treatment platinum-taxol doublet with 
the addition of bevacizumab in three cases (MNHOC263, MNHOC508, MNHOC513) or 
they received a therapeutic regimen containing cisplatin or carboplatin, except MNHOC182 
and MNHOC258 who were not treated, and MNHOC18 and MNHOC78 who received 





Table 4.1 Clinical-pathological characteristics of the original EOC from which PDXs 
derived 
 
Abbreviations: Ov: ovary; Om: omentum; Asc: ascite; i.p.: intraperitoneum; s.c.: subcutaneous; neoad: 
neoadjuvant chemotherapy; na: info. not available; CR: complete response; PR: partial response; SD: stable 
disease; PD: progressive disease; NED: not evident disease. §First line treatment: CBPT= carboplatin; DDP= 
cisplatin; PTX= paclitaxel; BEVA: bevacizumab; Epi: epirubicin; Dx: doxorubicin;CP= cyclophosphamide; 
TIP: PTX, DDP, isofosphamide; PAC: DDP, adriamicin, CP; PEC: DDP, Epi, CP. 
 
  
Ov Om Asc Om Asc ip sc
MNHOC8 HGSOC G3 IV CBPT PR X X
MNHOC8Y HGSOC G3 IV Epi-Dx PD X X
MNHOC8R HGSOC G4 IV na na X
MNHOC10 HGSOC G3 IIIC DDP PD X X
MNHOC22 HGSOC G3 IIII DDP PD X X
MNHOC76 HGSOC G3 IIIC PAC PD X X
MNHOC84 HGSOC G3 IIIC DDP-PTX na X X
MNHOC106 HGSOC G3 IIIC PAC PR X X
MNHOC107 HGSOC G3 IIIC PAC PR X X
MNHOC111/2C HGSOC G3 IIIC DDP-PTX PD X X
MNHOC125 HGSOC G3 IV CBPT PR X X
MNHOC239 HGSOC G2 IV CBPT-PTX CR X X
MNHOC143 HGSOC G3 IIIC CBPT-PTX NED X X
MNHOC149 HGSOC G3 IIIC CBPT-PTX NED X X
MNHOC244 HGSOC G2 IV CBPT-PTX CR X X
MNHOC250 HGSOC G3 IIIC CBPT-PTX CR X X
MNHOC258 HGSOC G3 IIIC not treated X X
MNHOC263 HGSOC G3 IIIC CBPT-PTX-BEVA CR X X
MNHOC266 HGSOC G2 IIIC CBPT-PTX na X X
MNHOC268 HGSOC G2 IIIC CBPT-PTX PR X X
MNHOC270 HGSOC G3 IIC CBPT-PTX CR X X
MNHOC271 HGSOC G3 IIIC CBPT-PTX na X X
MNHOC276 HGSOC G3 III CBPT-PTX na X X
MNHOC280 HGSOC G3 IIC CBPT-PTX CR X X
MNHOC281 HGSOC G3 IIIC CBPT-PTX PR X X
MNHOC289 HGSOC G3 IIIC CBPT-PTX CR X X
MNHOC316 HGSOC G3 IV CBPT-PTX na X X
MNHOC500 HGSOC G3 IIIC CBPT NED X X
MNHOC506 HGSOC G3 IIIC CBPT-PTX (neoad.) PD X X
MNHOC508 HGSOC G3 IIIC CBPT-PTX-BEVA NED X X
MNHOC511 HGSOC na na CBPT-PTX CR X X
MNHOC518 HGSOC na na na na X
MNHOC124 HGS/HGE OC G2 IIIIC CBPT-PTX SD X X
MNHOC212 HGS/HGE OC G2 IIIIC CBPT-PTX PR X X
MNHOC315 HGS/HGE OC G2 IIIIC CBPT na X X
MNHOC18 HGEOC G3 IV Epi-CP (neoad.) PD X X
MNHOC78 HGEOC G2 IIIIC CP SD X X
MNHOC154 HGEOC G2 IIC CBPT-PTX CR X X
MNHOC218 HGEOC G3 IIIC CBPT-PTX CR X X
MNHOC230 HGEOC G3 IIB CBPT-PTX CR X X
MNHOC261 HGEOC G2 IIIC CBPT-PTX CR X X
MNHOC503 HGEOC G3 na na na X
MNHOC513 HGEOC na na CBPT-PTX-BEVA NED X X
MNHOC520 HGSOC na na na na X
MNHOC241 LGSOC G2 IC CBPT-PTX CR X X
MNHOC109 LGEOC G2 IC CBPT CR X X
MNHOC79 HGEOC/CCC G3 IIIC DDP SD X X
MNHOC94/2C CCC G2 na na PD X X
MNHOC119 CCC G3 IC CBPT CR X X
MNHOC142 CCC G3 IIIC CBPT-PTX na X X
MNHOC164 MC G2 IV CBPT-PTX (neoad.) SD X X
MNHOC182 MC G1 IC not treated X X
MNHOC135 Mixed müllerian G3 IIIB TIP CR X X
MNHOC88 Undifferentiated G3 IIIC DDP na X X
MNHOC151 Carcinosarcoma G3 IIB na na X
MNHOC9 not classified na IIIC CBPT-PEC PR X X
#ID EOC-PDXs
Tumour at diagnosis
Patient first line 
treatment§








4.1.2 The EOC-PDXs well resemble the tumour of origin 
To exclude any possible phenotypic drift of the PDXs from the tumour of origin and after 
repeated in vivo passages, the histology of xenograft tumours has been compared by Dr 
Patrizia Perego of the Surgical Pathology Department of San Gerardo Hospital (Monza, 
Italy) with the tumour of the patient it derived from.  
All the cases analysed retained the morphology and architecture of the tissue of origin, also 
after several in vivo passages, as demonstrated by haematoxylin/eosin (HE) staining. Two 
representative EOC-PDXs are shown in figure 4.2, where the patient’s tissue was compared 
with the first in vivo passage of the PDX and after 7 and 10 passages, respectively. Besides 
the HE staining, the pathologist also evaluated the expression of pan-cytokeratin and CA125, 
markers generally used for the EOC diagnosis. All the EOC-PDXs expressed these markers 
and retained the positivity also after several in vivo passages, even if a slight decreased 







Figure 4.2 Comparative histological and immunohistochemical (IHC) analyses 
of tumours deriving from EOC-PDXs at different in vivo passages and the 
original patient tumour it derived from 
Two EOC-PDXs are shown as representative cases, MNHOC124 (upper panel) is a mixed 
high grade serous/endometrioid tumour (HGS/HGEOC), while MNHOC164 (lower panel) 
is a mucinous carcinoma (MC). Three different staining have been performed for the 
comparison among patient and early and late in vivo passages of the PDXs: 
haematoxylin/eosin (HE) to evaluate the tissue structure and IHC analysis for pan-





We have also analysed the short tandem repeat (STR) sequences of the original patient 
tumours with those of the derived PDXs at different passages, to verify the origin of the 
tissue sample.  
STR analysis is an informative approach widely used to verify tissue sample of origin and it 
is based on the comparison of allelic repeats at specific loci in DNA of different samples. 
STR are microsatellites with repetitive sequences of 3-7 base pairs diffuse along the human 
genome, whose number of repeats varies among individuals. We used this method to check 
that the STR sequences of the patients were preserved in the established PDXs. 16 different 
loci of the genome were analysed in half of the PDXs (at the first and later in vivo passages) 
of the xenobank and all of them maintained the same or significantly similar STR sequences, 
confirming the genetic stability of the PDXs also at later passages. Figure 4.3 shows the 
allele report of the STR analysis in MNHOC124, as a representative PDX of the xenobank, 
where the STR sequences were compared between patient DNA (pt) and PDX at different 







Figure 4.3 Allele report of MNHOC124 STR analysis 
DNA from tumour patient (pt) 124 and from PDX after 3 and 15 passages in vivo (MNHOC124 p3 and MNHOC124 p15) were 
analysed for the STR profile in 16 different STR sites. In the upper table are summarized for each of the three samples the STR 
profile. The lower graphs show the STR peaks which mostly correspond among the samples, showing that the PDX retain the 





D3S1358 TH01 D21S11 D18S51 Penta_E D5S818 D13S317 D7S820 D16S539 CSF1PO  Penta_D AMEL vWA  D8S1179 TPOX FGA
124 pt 15, 18 6,8 29.2 13 12 10,11 11,12 7,8 9,13 10,13 11 X 17,18 8,12 8,11 10,21
MNHOC124 p3 15, 18 6 29.2 13 12 10,11 11,12 7,8, 222.22 9,13 10,13 11 X 17,18 8,12 8,11 10,21





4.1.3 Mutational profile of the EOC-PDXs 
The molecular characterization of EOC-PDXs included the analysis of the mutational status 
of genes involved in the pathogenesis of EOC (i.e. TP53, KRAS, PIK3C, PTEN and BRAF) 
and HR genes (i.e. BRCA1, BRCA2, ATM, ATR, PALB2, FA genes).  
All the high grade serous and endometrioid PDXs analysed harbour non-synonymous TP53 
mutations. All the TP53 mutations found in the PDXs localize in the exons 5-9 encoding for 
the DNA binding domain of the protein and are almost all pathogenic missense substitution 
mutations. Conversely, the clear cell (MNHOC94/2C, MNHOC119), mucinous 
(MNHOC164, MNHOC182) and low grade serous (MNHOC109, MNHOC241) PDXs have 
a wild type TP53 or synonymous mutation (MNHOC109), consistent with data from the 
literature (Ahmed et al., 2010; Cancer Genome Atlas Research Network, 2011).  
Among the other genes frequently mutated and involved in the pathogenesis of EOC, we 
found KRAS heterozygous mutations in exon 2 in MNHOC84 (p.G12A) and in the mucinous 
MNHOC182 (heterozygous mutation, p.G12D), while MNHOC18 shows an amplification 
of KRAS, and a PTEN nonsense mutation was found in the CCC MNHOC94/2C.  
No mutations were found in the other analysed genes (BRAF and PIK3C).  
While the previously described genes were analysed mostly by the Sanger technique, 
mutational data of the HR genes was derived from sequencing experiments (whole genome 
sequencing, next generation sequencing or RNA-seq) performed on selected PDXs in 
collaboration with other laboratories (i.e. Dr Nik-Zainal lab., Wellcome Trust Sanger 
Institute) or companies (i.e. Astra Zeneca). Most of the reported mutations were 
subsequently validated in Sanger and these results are reported in the PhD thesis of Dr 
Francesca Bizzaro (Bizzaro, Francesca, 2018).  
14 EOC-PDXs (13 HGOC, 1 MC) are mutated in BRCA1 and/or BRCA2. BRCA1 frequently 
harbours substitution/missense and truncation/frameshift mutations, all described to be 
pathogenic (“ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/,” n.d.), except that observed in 
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MNHOC276, even if it is likely to be pathogenic. MNHOC513 contains a complete deletion 
of exon 23 of BRCA1, which determines the loss of function of the protein.  
BRCA2 has a heterogeneous spectrum of mutations: MNHOC508 harbours a pathogenic 
frameshift deletion, MNHOC511 an unknown missense mutation; MNHOC18 carries a 
neutral, non-pathogenic missense mutation, while the MNHOC182 harbours a pathogenic 
mutation, without site specific LOH, rare in this histological subtype (Pennington et al., 
2014). However, in these two latter cases, one of the alleles is wild type, so BRCA2 should 
be transcribed and the protein be present, and so it is considered wild type.   
The mutational status of other investigated HR genes is detailed in table 4.2. However, the 





Table 4.2. Mutational profile of the most common mutated genes in EOC 
Abbreviations: wt= wild type; mut= mutated/mutation; LOH= loss of heterozygosity; del= 
deletion; fs= frameshift. 
#ID EOC-PDXs Hystotype TP53 KRAS,  B-RAF, PI3Ka BRCA1, BRCA2 Other HR genes
MNHOC8 HGSOC c.514G>T p.V172F WT
MNHOC8Y HGSOC c.514G>T p.V172F WT
MNHOC8R HGSOC MUT
MNHOC10 HGSOC c.659A>G p.Y220C WT
MNHOC22 HGSOC
g.14755 G:C>T:A splice site 
c.993+1 G>A
BRCA1 (nonsense mutation)
PALB2: heterozygous mut. 
(unknown/missense, non 
pathogenic)
MNHOC76 HGSOC c.723delC p.S241fs*5 WT
MNHOC84 HGSOC
g.14451 G:C>T:A splice site 
c.783-1 G>T
KRAS WT/ c.35G>C p.G12A WT
MNHOC106 HGSOC
g.13999 G:C>T:A  splicing 
site  c.673-1 G>C
BRCA1 truncation 
frameshift (fs del)
MNHOC107 HGSOC c.517G>A p.V173M
BRCA1 truncation 
frameshift (fs del)
MNHOC111/2C HGSOC c.839G>A p.R280K WT
MNHOC125 HGSOC c.517G>A p.V173M BRCA1 (missense mut.)
MNHOC239 HGSOC c.776A>T p.D259V WT
MNHOC143 HGSOC MUT WT




MNHOC244 HGSOC c.537G>A p.C135Y
MNHOC250 HGSOC c.844C>T p.R282W
MNHOC258 HGSOC c.125G>A p.C42Y
MNHOC263 HGSOC c.854delT p.S241fs*22
MNHOC266 HGSOC c.818G>A p.R273H BRCA1: p.R1699Q LOH
ATR c.2228_2262del35 (del 
fs) NOT in ClinVar
MNHOC268 HGSOC c.164_165delGT p.G55fs*21
MNHOC270 HGSOC c.421T>C  p.C141R 
MNHOC271 HGSOC c.556delC p.C141fs*28
MNHOC276 HGSOC  c.396G>T p.K132N
BRCA1 c.2332dupT (fs, 
very likely pathogenic, not in 
ClinVar)
MNHOC280 HGSOC c.609C>T p.A159V
MNHOC281 HGSOC c.1048C>T p.R306C
MNHOC289 HGSOC c.660G>T p.C176F WT
MNHOC316 HGSOC mutc.557G>A p.R175H
MNHOC500 HGSOC MUT





MNHOC506 HGSOC MUT WT
MNHOC508 HGSOC MUT
BRCA2 truncation frameshift 
(fs del)
MNHOC511 HGSOC c.523C>G p.R175G
BRCA1 mut (missense); 
BRCA2 mut (unknown/ 
missense)
MNHOC518 HGSOC
MNHOC124 HGS/HGE OC c.524G>A p.R175H WT
MNHOC212 HGS/HGE OC c.951G>A p.R273H WT
MNHOC315 HGS/HGE OC
 c.569G>A p.146(W/*); 
c.909A>G p.D258N
MNHOC18 HGEOC c.527G>T p.C176F KRAS amplification 
BRCA2 mut (missense, non 
pathogenic)
MNHOC78 HGEOC c.518T>G p.V173G
BRCA1 truncation frameshift 
(fs del)
MNHOC154 HGEOC c.844C>T p.R282W BRCA1.p.C61G LOH
ATM C>G  wt/p.A235G and 
ATR: c.2595C>G p.H865Q
MNHOC218 HGEOC  c.841G>A p.D281N
MNHOC230 HGEOC c.927T>C p.L265P WT
MNHOC261 HGEOC p.258_261 del WT
MNHOC503 HGEOC
MNHOC513 HGEOC MUT






MNHOC109 LGEOC c.639A>G p.wt (R213R) WT
MNHOC79 HGEOC/CCC g.14755 G:C>T:A WT
MNHOC94/2C CCC WT PTEN nonsense mut. WT
MNHOC119 CCC WT WT
MNHOC142 CCC
MNHOC164 MC WT
MNHOC182 MC WT KRAS WT/ c.35G>C p.G12D




MNHOC135 Mixed müllerian c.527G>T  p.C176F WT
MNHOC88 Undifferentiated p.A189fs*58
MNHOC151 Carcinosarcoma
MNHOC9 Not classified p.C275G
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4.1.4 Promoter methylation status 
The promoter methylation status of some DNA repair genes has been investigated in BRCA1, 
FANCF, ERCC1, MLH1, XPA and XPG genes, and described to be hypermethylated in 
ovarian cancer and associated with decreased gene transcription (Cancer Genome Atlas 
Research Network, 2011; D’Andrea, 2003; Sabatino et al., 2010). 
For these analyses, two different methods were used: pyrosequencing with pre-custom 
assays (Qiagen) and methylation specific-PCR (MS-PCR) with primers designed ad hoc.  
For pyrosequencing analysis, three promoter regions in BRCA1 and ERCC1 have been 
analysed including 11 and 15 CpG sites, respectively, and corresponding to the three assays 
provided by manufacturer. For MLH1 and XPA two pre-custom assays for pyrosequencing 
were used for both genes, covering regions including 11 and 6 CpG sites, respectively.  
From pyrosequencing analyses, BRCA1 was the most hypermethylated gene, where 51% of 
the PDXs analysed had all three regions with more than 10% (threshold suggested by 
manufacturer) of the CpG sites hypermethylated, and 86% with almost one region 
hypermethylated. One of the two regions of XPA promoter was hypermethylated in five 
PDXs (MNHOC212, MNHOC239, MNHOC76, MNHOC8Y and MNHOC506). MLH1 
appeared strongly hypermethylated in MNHOC19 (96% and 87% of CpG sites methylated 
in both regions analysed), while MNHOC500 presented 11% of methylation in only one 
region. In table 4.3 are reported the % of CpG islands found methylated, detailed for each 
PDX.  
 In EOC patients BRCA1 promoter hypermethylation associates with low protein levels and 
occurs in 10% of HGSOC (Cancer Genome Atlas Research Network, 2011), so the high 
frequency found in our PDXs let us to hypothesize that the regions analysed were not those 
responsible for the transcription of the gene. To clarify this point, we set up a MS-PCR to 
analyse a different region of BRCA1 promoter, whose hypermethylation has been described  
to correlate with low transcriptional levels of BRCA1 in breast cancer PDXs (Ter Brugge et 
al., 2016). 55 of our EOC-PDXs have been analysed and 4 had a % methylation range from 
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84% to 100% (MNHOC212, MNHOC8Y, MNHOC8, MNHOC518), while MNHOC520 
had 49% of CpG sites methylated. None of the other PDXs were hypermethylated from MS-
PCR results (figure 4.4 and table 4.3). 
MS-PCR has also been used to analyse FANCF and XPG. None of the PDXs analysed 
showed methylation in XPG promoter (figure 4.5 panel A), while FANCF was found 





Table 4.3 Quantification of the % of CpG islands methylated in different promoter 
regions of six DNA repair genes in the EOC-PDXs 
 
In light blue are highlighted those regions considered hypermethylated, having >10% of CpG 
sites methylated. 
  
XPA_01 XPA_02 ERCC1_01 ERCC1_02 ERCC1_03 MLH1_01 MLH1_04 BRCA1_01 BRCA1_02 BRCA1_03 BRCA1_04 FANCF XPG
MNHOC8 1% 0% 2% 15% 2% 3% 39% 73% 84% 0% 0%
MNHOC8Y 3% 13% 3% 3% 7% 5% 0% 96% 81% 83% 100% 0% 0%
MNHOC10 0%
MNHOC22 0%
MNHOC76 2% 20% 2% 3% 4% 2% 5% 58% 23% 83% 0% 0% 0%
MNHOC84 6% 2% 2% 5% 3% 1% 71% 7% 77% 0% 0% 0%
MNHOC106 5% 6% 3% 3% 4% 3% 5% 94% 70% 84% 0% 0% 0%
MNHOC107 2% 5% 2% 2% 3% 2% 8% 89% 8% 91% 0% 0% 0%
MNHOC111/2C 3% 3% 2% 3% 5% 3% 1% 93% 73% 82% 0% 0% 0%
MNHOC125 4% 5% 3% 3% 5% 3% 4% 96% 69% 94% 0% 0% 0%
MNHOC239 5% 13% 1% 2% 4% 5% 5% 5% 8% 13% 0% 0% 0%
MNHOC143 3% 0% 2% 1% 8% 2% 0% 3% 2% 5% 0% 0% 0%
MNHOC149 3% 3% 2% 2% 3% 2% 2% 6% 4% 29% 0% 0% 0%
MNHOC244 6% 3% 3% 3% 6% 4% 1% 94% 70% 95% 0% 0% 0%
MNHOC250 5% 7% 3% 3% 4% 4% 3% 92% 35% 93% 0% 0% 0%
MNHOC258 4% 5% 3% 2% 5% 3% 1% 93% 58% 96% 0% 0% 0%








MNHOC500 4% 4% 3% 2% 5% 3% 11% 86% 55% 79% 0% 0% 0%
MNHOC506 2% 22% 1% 4% 6% 5% 79% 90% 0% 0% 0%
MNHOC508 2% 4% 2% 2% 95% 84% 0% 0% 0%
MNHOC511 3% 3% 2% 2% 3% 2% 1% 5% 3% 13% 0% 0% 0%
MNHOC518 100%
MNHOC124 5% 7% 3% 3% 19% 4% 3% 95% 82% 90% 0% 0% 0%
MNHOC212 4% 12% 3% 3% 6% 5% 2% 95% 71% 92% 100% 0% 0%
MNHOC315 0%
MNHOC18 3% 1% 1% 2% 3% 2% 1% 4% 5% 7% 0% 70% 0%
MNHOC78 4% 3% 2% 2% 4% 3% 2% 3% 3% 6% 0% 0% 0%
MNHOC154 4% 4% 3% 2% 5% 3% 2% 90% 33% 91% 0% 0% 0%
MNHOC218 0% 0%
MNHOC230 5% 4% 3% 2% 4% 3% 3% 94% 41% 90% 0% 0% 0%
MNHOC261 4% 5% 4% 2% 5% 3% 2% 64% 30% 72% 0% 0% 0%
MNHOC503 2% 1% 1% 1% 4% 2% 2% 15% 53% 0% 0% 0%
MNHOC513 0%
MNHOC520 49%
MNHOC241 4% 5% 3% 2% 5% 3% 2% 8% 6% 22% 0% 0% 0%
MNHOC109 4% 0% 3% 2% 8% 96% 87% 6% 5% 31% 0% 0% 0%
MNHOC79 3% 0% 1% 1% 0% 1% 2% 90% 46% 91% 0% 0% 0%
MNHOC94/2C 4% 1% 2% 2% 4% 2% 1% 1% 3% 5% 0% 0% 0%
MNHOC119 3% 3% 2% 1% 4% 3% 0% 93% 6% 82% 0% 10% 0%
MNHOC142 2% 2% 4% 3% 5% 3% 3% 47% 35% 80% 0% 0% 0%
MNHOC164 4% 8% 4% 5% 5% 4% 1% 92% 37% 77% 0% 0% 0%
MNHOC182 2% 3% 1% 1% 5% 4% 3% 41% 12% 77% 0% 0% 0%
MNHOC135 6% 8% 4% 3% 8% 4% 3% 83% 46% 82% 0% 0% 0%
MNHOC88 0%
MNHOC9 3% 3% 4% 3% 4% 3% 2% 14% 10% 50% 0% 0% 0%






Figure 4.4 Methylation status of BRCA1 promoter in the EOC-PDXs  
55 PDXs of our xenobank have been analysed by MS-PCR using primers specifically designed to amplify the methylated (M) or 
unmethylated (U) region of interest. Two EOC cancer cell lines (A2780 and IGROV) were used as internal controls. EpiTect PCR 
Control DNA set (Qiagen) was used as PCR internal control (CTR M: methylated DNA and CTR U: unmethylated DNA). B: blank. In 





Figure 4.5 Methylation status of XPG and FANCF promoters  
EOC-PDXs analysed by MS-PCR with couples of primers designed for the methylated (M) or 
unmethylated (U) region. A) XPG methylation status by MS PCR. The upper gel shows the 
MS-PCR with M primers; the lower panel shows the MS-PCR with U primers. B) FANCF 
methylation status by MS PCR. In this gel samples amplified with primer for M or U region 
have been loaded alternatively. EpiTect PCR Control DNA set (Qiagen) was used as PCR 
internal control (CTR M: methylated DNA and CTR U: unmethylated DNA). B: blank. PDXs 





4.1.5 Pharmacological characterization of the EOC-PDXs 
I will focus here on the antitumor activity of the two drugs, DDP and olaparib, that are the 
focus of my thesis: 48 EOC-PDXs have been characterized for their response to cisplatin 
and 26 for olaparib.  
The efficacy of the treatment has been expressed as the best tumour growth inhibition 
(T/C%) for subcutaneous tumours and increase in lifespan (ILS%) for intraperitoneal 
xenografts. The T/C value represents the magnitude of tumour growth inhibition after 
treatment (the lower the value, the higher the antitumor effect) for s.c. growing tumours and 
ILS represents the increase in life span over untreated/control group (the higher the value, 
the higher the antitumor effect) for i.p. transplanted tumours. Best T/C% and ILS% are not 
the only parameters used to evaluate the tumour response to therapy in vivo. In the clinical 
setting, response to cancer treatment in solid tumours follows the Response Evaluation 
Criteria in Solid Tumours (RECIST) (Eisenhauer et al., 2009; Schwartz et al., 2016; Therasse 
et al., 2000) that classifies response in: complete response (CR), partial response (PR), stable 
disease (SD) and progressive disease (PD), mainly based in the modification in tumour 
diameter after treatment over baseline pre-treatment condition. For s.c. tumours, in which a 
quantification of the change in tumour dimensions can be done, we could apply a modified 
RECIST (mRECIST) criteria, as recently described (Castroviejo-Bermejo et al., 2018a; Cruz 
et al., 2018) and compared the two different metrics. Table 4.4 reports a heat-map 
representation of EOC-PDXs response to therapy calculated with the different parameters. 
A good concordance could be observed between the mRECIST method and T/C value for 
olaparib (Cohen’s k= 0.86), with only one case misclassified; while lower concordance was 
found when considering DDP response to therapy (Cohen’s k= 0.33), probably due to the 
wider range of DDP antitumor effect (figure 4.6). Not being able to apply the RECIST 
method to orthotopically transplanted tumours, we decided to express the data as T/C and 
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ILS, as this allowed, in aggregate, classifying tumour drug response in three types: very 
sensitive (VS), sensitive (S) and resistant (R), as specified in Materials and Methods. 
Remarkably, 73% of the PDXs present in the xenobank are VS/ S to DDP treatment, while 
only one third (31%) of the xenografts are responsive to olaparib treatment. This platinum 
sensitivity pattern reflects the % of response in the clinical setting (Lheureux et al., 2019b).  
Among the biomarkers of olaparib response, DDP response has been advocated (D’Andrea, 
2018). In the 26 PDXs characterized for both drug sensitivity, we observed that all the 
olaparib responsive tumours (n=8) were sensitive to DDP and all the DDP resistant tumours 
did not respond to olaparib (n=8). However, 10 PDXs classified as very sensitive/sensitive 
to DDP were resistant to olaparib (table 4.4 and figure 4.6). These data showed a low 





Table 4.4 Classification of EOC-PDXs based on their response to DDP and olaparib 
therapy 
Based on the maximal percentage of tumour growth inhibition (T/C%) calculated for subcutaneous tumours 
(s.c.) or increase in life span (ILS%) for intraperitoneal PDXs (i.p.), PDXs were classified into three groups: 
VS= very sensitive; S= sensitive; R= resistant to therapy. Following mRECIST metric (only for s.c. PDXs) 
tumours were divided into four groups: CR= complete response; PR= partial response; SD= stable disease; 
PD= progressive disease.  
#ID EOC-PDXs DDP OLA DDP OLA 
Best T/C% or ILS% mRECIST
MNHOC218 VS VS CR PR
MNHOC508 VS VS PR PR
MNHOC511 VS VS PR PR
MNHOC513 VS VS PR PR
MNHOC500 VS VS PR PR
MNHOC124 VS R PR PD
MNHOC316 VS R PR PD
MNHOC271 S S PD PD
MNHOC239 S R SD
MNHOC18 S R PD PD
MNHOC84 S R PD PD
MNHOC143 S R PD PD
MNHOC94/2C R R PD PD
MNHOC94/2TR R R
MNHOC124 DDPR R R PD PD
MNHOC182 R R PD
MNHOC239 DDPR R R PD PD






































Figure 4.6 Best treatment response to DDP and olaparib of EOC-PDXs 
pharmacologically characterized  
A) For tumours grown subcutaneously the best T/C% has been evaluated for DDP and 
for olaparib. As detailed in Materials and Methods, tumours were classified as resistant 
(R) to therapy with T/C% ≥ 50%; sensitive (S) 10%<T/C<50% and very sensitive (VS) 
T/C% ≤10%. The dashed lines indicate the T/C% thresholds that divide the response 
into the three categories. Different coloured bars are associated with DDP (blue/light 
blue) and olaparib (red/yellow) treatment.  
B) Similarly, for orthotopic PDXs the best ILS% has been evaluated for each treatment. 
As detailed in Materials and Methods, tumours were classified as resistant (R) with 
ILS% ≤ 40%; sensitive (S) 40%< ILS%<100% and very sensitive (VS) ILS%≥100%. 
The dashed lines indicate the ILS% thresholds that divide the response into the three 
categories. Different coloured bars are associated with DDP (blue/light blue) and 
























































































































































































4.1.6 Discussion I 
A collection of EOC-PDXs has been established in the Department of Oncology of the Mario 
Negri Institute, where I undertook the PhD course. The xenobank presented in this section, 
includes all the main histological subtypes of EOC: high grade serous and endometrioid, low 
grade serous, mucinous, clear cell, mixed müllerian, carcinosarcoma and undifferentiated 
tumours, reflecting the heterogeneity of EOC and the prevalence of these subtypes, with 
about 80% of high grade tumours present in the xenobank. Ricci et al., demonstrated the 
consistency of these models, which maintain the main characteristics of the patient’s tumour 
from which they derived, both at histological and molecular levels regardless of the site of 
injection (subcutaneous or intraperitoneal) (Ricci et al., 2014). The PDXs are constantly 
monitored to avoid phenotypic drift by histopathological analyses, and we check that the 
STR regions are similar to those of the original tumour, regardless of the number of in vivo 
passages. 
I contributed to PDXs molecular characterization by performing the mutational profiling and 
the analysis of promoter methylation status in some genes of interest. Regarding the 
mutational profile, all the high grade tumours harbour mutations in the DNA binding domain 
of TP53, in line with data reported in the literature (Ahmed et al., 2010; Cancer Genome 
Atlas Research Network, 2011; Cole et al., 2016). For BRCA1 and BRCA2, as well as other 
HR genes, mutational status is still under investigation. Up to date, we have analysed 33 
selected PDXs through genomic sequencing (whole genome sequencing and RNAseq), and 
then validated in Sanger (Bizzaro, Francesca, 2018) (and present thesis). 14 PDXs harboured 
a BRCA1/BRCA2 mutation, even in two of them no LOH or non-pathogenic mutation could 
be observed and were considered to have a functional protein, so, wild type tumours 
(MNHOC182 and MNHOC18).  
The analysis of HR gene mutational profile helped us to identify those PDXs that could have 
a BRCAness phenotype, a condition associated with a good response to DDP and olaparib 
therapy (Lord and Ashworth, 2016; O’Connor, 2015; Turner et al., 2004). Since not  
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only mutations in BRCA1 but also epigenetic alterations may induce the BRCAness 
phenotype, the promoter methylation status of BRCA1 has been analysed, together with other 
DNA repair genes involved in FA, NER and MMR pathways, whose methylation status can 
be found altered in EOC with consequences on gene transcription and response to 
chemotherapy (Chen et al., 2010; Lahtz and Pfeifer, 2011; Olopade and Wei, 2003; Sabatino 
et al., 2010). We used the pyrosequencing method to analyse 3 different regions of BRCA1 
promoter, ERCC1, XPA, and MLH1, while a MS-PCR with primers designed ad hoc and 
already reported in literature (D’Andrea, 2003; Sabatino et al., 2010; Ter Brugge et al., 2016) 
was performed to evaluate a region of BRCA1 promoter, besides FANCF and XPG. We 
observed for BRCA1 promoter regions analysed by pyrosequencing with pre-custom assays, 
a wider hypermethylation status, with 51% of the PDXs having high % of CpG sites 
methylated in all the three areas analysed, leading us to suspect that these regions were not 
those involved in the regulation of gene transcription. In fact, when we used validated 
primers, which amplify another promoter region, 8% of the PDXs were strong methylated 
in line with the frequency of cases reported for EOC (Cancer Genome Atlas Research 
Network, 2011; Konstantinopoulos et al., 2015). Regarding the other genes investigated, 
only sporadic PDXs were methylated, with different % of CpG islands interested, while none 
showed XPG hypermethylation.  
The pharmacological characterization was essential to define our EOC-PDXs and their 
response to the most used chemotherapy drugs involved in ovarian cancer treatment. The 
majority of the PDXs have been characterized for DDP, paclitaxel and trabectedin, a drug 
historically studied in our Department of Oncology. Recently, with the introduction of 
PARPi in EOC management, we began to characterize the sensitivity of PDXs to olaparib. 
In this thesis I will focus on PDXs response to DDP and olaparib.  
A correct and reproducible classification of these PDXs based on their response to therapy, 
is essential for studies looking at biomarkers of response. There are different ways to  
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evaluate the best therapy response of tumours and we compared our standard method with 
mRECIST parameters, adapted to evaluate the drug response of our PDXs (Castroviejo-
Bermejo et al., 2018a; Cruz et al., 2018). We found a clear association between mRECIST 
criteria and the T/C method regards the evaluation of olaparib antitumor activity (Cohen’s 
k= 0.86), because in both cases we could similarly classified the drug antitumor effect. This 
association was even lower (Cohen’s k = 0.33) when considering DDP antitumor activity, 
probably due to the wider range of antitumour activity observed. On top of this, the main 
limit in applying the mRECIST criteria was the exclusion of all the non-solid/intraperitoneal 
PDXs present in our xenobank, which cannot be evaluated by mRECIST. Thus, considering 
our method, we divided the PDXs into three response groups: very sensitive to treatment (in 
these cases we usually observed tumour regression or complete response), sensitive and 
resistant. The majority of our PDXs (73%) are responsive to DDP therapy, as observed in 
the clinic (Lheureux et al., 2019b) and DDP showed a wide range of response, while for 
olaparib we have 31% of the PDXs very responsive to therapy and the others resistant, 
confirming that PARPi are extremely active only in a subgroup of EOC cases.  
This overview of the xenobank was necessary to introduce the models used to investigate 
the role of DNA repair in determining response and resistance to platinum and PARPi 





4.2 EXPRESSION OF DNA REPAIR GENES AND HR MUTATIONAL 
STATUS OF THE EOC-PDXs IN RESPONSE TO THERAPY 
Impairment of DNA repair is a common oncogenic event in most human cancers, including 
EOC, that has been exploited to enhance the anti-tumour activity of DNA damaging agents 
and more recently, by PARPi, which have been shown to be particularly active in HR 
deficient tumours. However, if DNA repair defects are associated with great sensitivity to 
DDP and PARPi (Bryant et al., 2005; Damia et al., 1996; Farmer et al., 2005; Lehmann, 
2003) it is not completely clear whether increased DNA repair activity can be associated 
with resistance to therapy and there are still no validated biomarkers associated with DNA 
repair efficiency in tumour cells.  
In the EOC-PDXs available in our xenobank, we explored the expression of genes involved 
in different DNA repair pathways and the mutational status of HR genes as possible 
biomarkers of DDP and olaparib treatment response. We quantified through real time-PCR 
the number of mRNA copies of 35 genes involved in different DNA repair pathways and in 
other mechanisms described in preclinical studies to have a role in DDP and/or PARPi 
response (table 4.5). We also evaluated the BRCA1/BRCA2 mutational status in some PDXs 
by using a whole genome sequencing-based test, which allows the application of the 
HRDetect algorithm and the definition of a HR score.  
In addition, we verified if the methylation promoter status of BRCA1, FANCF, XPA, XPG, 
ERCC1 and MLH1 was associated with a reduction of the transcription levels of the genes 
controlled by the promoter. Then, we analysed all these molecular features in relation with 




4.2.1 Gene expression levels 
Initially, a panel of 42 EOC-PDXs was chosen including all the histotypes and in these 
models we analysed the mRNA levels of 20 selected DNA repair genes (table 4.5, A), 
including CDK12, which is not properly involved in the DNA repair mechanism, but it 
regulates the transcription of several DNA repair genes and is found mutated in 3% of 
HGSOC (Cancer Genome Atlas Research Network, 2011).  
Table 4.5 Lists of genes analysed and pathways in which they are involved 
 
 
All the 20 genes analysed by RT-PCR with primers designed ad hoc were heterogeneously 
expressed in the PDXs and cluster analysis did not show specific expression patterns among 
the histotypes (figure 4.7). Considering that ERCC1 expresses four isoforms, but only 
isoform 202 is involved in NER (Friboulet et al., 2013b), we used two couples of primers to 
amplify a region shared by all the isoforms (ERCC1 tot) and another shared only by the two 
isoforms 202 and 204 (ERCC1 iso2), because it was not possible to design primers entirely 
specific for the functional isoform 202 involved in NER. However, data obtained did not 
show differences between ERCC1 iso2 and ERCC1 total expression levels.  
 
  
A B Pathway Genes investigated
Base excision repair (BER) PARP1, OGG1, 
Homologous recombination (HR) 
& DNADSB response 
ARTEMIS, BRCA1, BRCA2, 
RAD51, PTIP, RAD51C, 53BP1,
Non-homologous end joining 
(NHEJ) KU70, KU80, DNA PK
MMEJ POLQ
DNA damage response (DDR) SLFN11
Chromatin organization CHD4, ARID1A, CARM1
Cell cycle regulation REV7, CCNE1
Deubiquitination USP28
Drug transporter MDR1
DNArepair pathway Genes investigated
Base excision repair (BER) PARP1, OGG1, POLβ
Nucleotide excision repair 
(NER)









Mismatch repair (MMR) MLH1
Microhomology end joining 
(MMEJ) POLQ
Translesion repair (TLS) POLH






Figure 4.7 Expression pattern of DNA repair genes in all the EOC-PDXs analysed 
The heat map represents the mRNA expression levels (low levels in green; high levels in red) 
of 20 genes involved in different DNA repair pathways (rows) analysed by RT-PCR in 42 EOC-
PDXs (columns). Each pathway is associated with a coloured square: blue=HR; light blue=FA; 
pink=NER; orange=BER; red=MMR; green=TLS; yellow=MMEJ; grey=CDK12. 
 
Considering that 80% of the PDXs in the xenobank are high grade tumours, which represent 
the most diffuse subtype also among patients, we decided to focus the analyses on this 
homogeneous population. 29 out of 42 PDXs were HGSOC/HGEOC and their gene 
expression pattern was similar to that of all the PDXs. We decided to investigate the presence 
of possible correlations between the single genes, since DNA repair pathways are multistep 
processes and the studies of possible genes association could be important. Dr Maddalena 
Fratelli, who performed the statistical analyses calculated the Pearson correlation index 
between each single gene (table 4.6). It was observed that OGG1, FANCD2, XPF, FANCD2, 
PALB2 and CDK12 expression significantly correlated with at least four other genes, and, 





Table 4.6 Correlations between single gene expressions of DNA repair genes analysed in the high grade EOC-PDXs 
The linear correlation between the expression levels of different genes was measured by the Pearson test. Significant correlation values are in red.  
For CDK12 significant correlation with PALB2, 53BP1 and XPF has been reported also in the TCGA databases (yellow). 
 
  
gene MLH1 OGG1 PARP1 POLB 53BP1 BRCA1 RAD51 PALB2 POLQ POLH FANCA FANCC FANCD2 FANCF XPA XPD XPF XPG ERCC1 CDK12
MLH1 1,00 0,35 0,05 -0,14 -0,12 -0,06 0,01 -0,01 0,22 0,11 0,15 0,11 0,26 0,31 0,03 0,07 0,08 -0,06 -0,04 0,12
OGG1 0,35 1,00 0,41 0,18 0,16 0,00 0,41 0,41 0,52 0,49 0,45 0,65 0,69 0,53 0,24 0,18 0,47 0,24 0,12 0,25
PARP1 0,05 0,41 1,00 0,15 0,32 -0,06 0,25 0,44 0,27 0,44 0,33 0,18 0,25 0,05 0,01 0,02 0,29 0,23 -0,04 0,29
POLB -0,14 0,18 0,15 1,00 0,30 -0,10 0,04 0,23 -0,02 0,02 -0,11 0,24 0,21 0,02 -0,15 0,56 0,13 0,05 0,18 0,43
53BP1 -0,12 0,16 0,32 0,30 1,00 0,50 0,24 0,38 0,14 0,18 0,10 0,08 0,09 0,16 -0,04 0,24 0,24 0,03 0,02 0,62
BRCA1 -0,06 0,00 -0,06 -0,10 0,50 1,00 -0,10 -0,03 0,03 -0,06 0,01 -0,11 -0,24 0,32 0,12 -0,11 -0,07 -0,12 -0,30 0,27
RAD51 0,01 0,41 0,25 0,04 0,24 -0,10 1,00 0,65 0,55 0,22 0,25 0,44 0,72 0,03 0,31 0,01 0,72 0,03 -0,11 0,33
PALB2 -0,01 0,41 0,44 0,23 0,38 -0,03 0,65 1,00 0,41 0,28 0,13 0,16 0,48 -0,08 -0,06 0,09 0,79 0,21 -0,05 0,45
POLQ 0,22 0,52 0,27 -0,02 0,14 0,03 0,55 0,41 1,00 0,13 0,42 0,37 0,71 0,45 0,34 0,38 0,46 0,28 0,24 0,17
POLH 0,11 0,49 0,44 0,02 0,18 -0,06 0,22 0,28 0,13 1,00 0,28 0,13 0,16 0,12 -0,04 -0,22 0,24 -0,07 -0,25 -0,07
FANCA 0,15 0,45 0,33 -0,11 0,10 0,01 0,25 0,13 0,42 0,28 1,00 0,54 0,29 0,37 0,34 -0,17 0,07 -0,05 -0,14 -0,01
FANCC 0,11 0,65 0,18 0,24 0,08 -0,11 0,44 0,16 0,37 0,13 0,54 1,00 0,59 0,44 0,45 0,23 0,29 0,16 0,24 0,24
FANCD2 0,26 0,69 0,25 0,21 0,09 -0,24 0,72 0,48 0,71 0,16 0,29 0,59 1,00 0,26 0,28 0,36 0,65 0,04 0,15 0,26
FANCF 0,31 0,53 0,05 0,02 0,16 0,32 0,03 -0,08 0,45 0,12 0,37 0,44 0,26 1,00 0,21 0,29 -0,04 0,06 0,25 0,19
XPA 0,03 0,24 0,01 -0,15 -0,04 0,12 0,31 -0,06 0,34 -0,04 0,34 0,45 0,28 0,21 1,00 -0,01 0,24 0,26 -0,10 -0,05
XPD 0,07 0,18 0,02 0,56 0,24 -0,11 0,01 0,09 0,38 -0,22 -0,17 0,23 0,36 0,29 -0,01 1,00 0,07 0,33 0,71 0,37
XPF 0,08 0,47 0,29 0,13 0,24 -0,07 0,72 0,79 0,46 0,24 0,07 0,29 0,65 -0,04 0,24 0,07 1,00 0,10 -0,11 0,42
XPG -0,06 0,24 0,23 0,05 0,03 -0,12 0,03 0,21 0,28 -0,07 -0,05 0,16 0,04 0,06 0,26 0,33 0,10 1,00 0,61 0,03
ERCC1 -0,04 0,12 -0,04 0,18 0,02 -0,30 -0,11 -0,05 0,24 -0,25 -0,14 0,24 0,15 0,25 -0,10 0,71 -0,11 0,61 1,00 0,08
CDK12 0,12 0,25 0,29 0,43 0,62 0,27 0,33 0,45 0,17 -0,07 -0,01 0,24 0,26 0,19 -0,05 0,37 0,42 0,03 0,08 1,00
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For CDK12, which correlated with PALB2, 53BP1, XPF and POLB in our xenobank, we 
analysed the gene expression data reported in the TCGA Affymetrix microarray and 
RNAseq databases. We found that CDK12 mRNA levels correlated with PALB2, 53BP1 and 
XPF transcripts in both the databases, while POLB showed a modest significance (p-value 
~ 0.05) only in the RNAseq dataset (table 4.7). These data seem to support the role of 
CDK12 as a transcription regulator protein of some DNA repair genes.  
Table 4.7. Correlation of CDK12 with other DNA repair genes from two TCGA 
databases 
Genes highlighted in grey were found correlated with CDK12 in our experiment. 
 
  
Gene r to CDK12 p-value Gene r to CDK12 p-value
BRCA1 0,298019 7,40E-07 PARP1 0,26 2,28E-10
53BP1 0,286066 2,10E-06 MLH1 0,25 1,14E-09
PARP1 0,262365 1,46E-05 PALB2 0,22 9,36E-08
POLH 0,260016 1,75E-05 XPF 0,2 1,28E-06
XPF 0,240594 7,37E-05 53BP1 0,19 4,31E-06
POLQ 0,218424 3,32E-04 BRCA1 0,19 4,31E-06
PALB2 0,187205 0,002169 POLQ 0,16 0,000113
POLB -0,17445 0,00432 RAD51 0,15 0,000299
ERCC1 -0,16503 0,00699 XPA 0,14 0,000746
FANCC 0,1567 0,010482 FANCD2 0,13 0,001753





Then, we extended the gene expression characterization to all the PDXs whose response to 
DDP and olaparib was known (n=46), evaluating the mRNA expression of 21 DNA repair 
genes and others described in preclinical studies to affect in some extent the response to 
DDP and olaparib in EOC (table 4.5, B). 
As in the previous analysis, all the PDXs expressed the genes studied with considerable 
variability as reported in figure 4.8. 
 
Figure 4.8 Expression pattern of the genes involved in platinum and PARPi 
response studied in all the EOC-PDXs 
The heat map represents the mRNA expression levels (low levels in red; high levels in green) 
of 21 genes involved in different DNA repair pathways (rows) analysed by RT-PCR in 46 





We correlated the expression levels between single genes in all the 46 PDXs. Three strong 
significant positive correlations were found between ARTEMIS and CHD4 (ρ=0.81, 
p<0.0001), ARTEMIS and USP28 (ρ=0.82, p<0.0001), and CHD4 and REV7 (ρ=0.80, 
p<0.0001). As in the previous analysis, we then considered the subgroup of high grade 
PDXs. In this subset, the correlations between ARTEMIS and USP28 (ρ=0.81, p<0.0001) 
and CHD4 and REV7 (ρ=0.82, p<0.0001) have been confirmed, even if, from a preliminary 
analysis, these correlations have not been observed in the TCGA databases. The detailed 
correlation indexes and p-values of the significant correlations are reported in table 4.8. 
Table 4.8 Significant correlations between single gene expression in all the PDXs and 
in the subgroup of high grade PDXs 
The linear correlation between the expression levels of different genes was measured by Spearman 






gene ro p-value n
CHD4 ARTEMIS 0.81 <0.0001
USP28 ARTEMIS 0.82 <0.0001
CHD4  REV7 0.80 <0.0001
USP28 ARTEMIS 0.81 <0.0001







4.2.2 Correlation between gene promoter methylation status and mRNA 
expression 
Pyrosequencing data showed that all the three BRCA1 promoter regions analysed were 
hypermethylated in half of our PDXs (table 4.3); we did not find any correlation between 
BRCA1 promoter methylation status and BRCA1 mRNA copies. On the contrary, the five 
PDXs hypermethylated in the region of BRCA1 promoter analysed by MS-PCR showed a 
significant reduction of the number of mRNA copies compared with the average number of 
mRNA copies in all the other not methylated PDXs (t-test p=0.0015) (table 4.9).  
The MLH1 promoter was scarcely methylated in our PDXs panel, with few exceptions. 
MNHOC109 displayed a % of CpG sites in the two promoter regions evaluated close to 
100% and associated with a 100-fold less expression level of mRNA as compared to non-
methylated PDXs. In MNHOC500 we observed a reduction of MLH1 expression in line with 
the low % of CpG sites methylated (11%) (table 4.9).  
Similar reduction in gene expression has been observed in MNHOC8 and MNHOC124, 
which displayed 15% and 19% of methylation, respectively, in one of the two ERCC1 
promoter regions analysed (table 4.9).  
The two PDXs with FANCF hypermethylation showed a reduction of mRNA copies, even 
with 10% of CpG sites methylated (MNOC119) (table 4.9).  
XPA methylation status seems not to be associated with the gene expression, in fact, the 5 
PDXs, which displayed a similar percentage of methylation, ranging from 12% to 22%, 




Table 4.9 Comparison between methylation status and gene expression in PDXs 
resulted hypermethylated in selected genes 
 
n°= number of PDXs where mRNA copies have been quantified. 
 
4.2.3 HRDetect score 
In collaboration with Dr Nik-Zainal, who set up the HRDetect algorithm (Davies et al., 
2017), WGS was performed in 10 EOC-PDXs of the xenobank. The HRDetect algorithm 
allowed me to assign a HR score to each sample. The HRDetect assay is based on the analysis 
of a pattern of mutational signatures characteristic of HR deficiency (figure 4.9, A) and a 
HR score >0.7 is indicative of HR deficiency (Davies et al., 2017).  
5 out of 10 PDXs had a HR score >0.90, while in the other five PDXs the score was lower 
than 0.2, indicative of HR proficiency. Considering the positive PDXs (HR score >0.7), 
MNHOC154 and MNHOC266 harbour a germline BRCA1 mutation and MNHOC212 shows 
BRCA1 promoter hypermethylation, that could explain the BRCAness phenotype. 
MNHOC230 and MNHOC135 had a positive score but no mutations in BRCA1, BRCA2 and 
other HR genes investigated through WGS, nor BRCA1 promoter hypermethylation were 






Mean mRNA copies 
normalized in the non-
methylated PDXs (R0)
n° R1/R0
MNHOC212 100% 1,68E-04 0,003
MNHOC8 84% 7,05E-04 0,015
MNHOC8Y 100% 2,91E-04 0,006
MNHOC518 100% 1,05E-03 0,022
MNHOC520 49% 4,39E-04 0,009
MNHOC500 11% 3,94E-01 0,276
MNHOC109 96%, 87% 1,25E-03 0,001
MNHOC8Y 13% 7,22E-02 2,679
MNHOC76 20% 1,55E-02 0,574
MNHOC239 13% 1,85E-02 0,687
MNHOC506 22% 1,01E-02 0,374
MNHOC212 12% 1,18E+00 43,941
MNHOC8 15% 8,95E-01 0,353
MNHOC124 19% 7,97E-01 0,314
MNHOC18 70% 3,23E-01 0,119












Figure 4.9 HRDetect assay 
The HR score calculated in 10 EOC-PDXs, included two with acquired resistance to DDP 
(MNHOC124 DDPR, MNHOC239 DDPR). HR-positive PDXs (HR score >0.7) were 
enriched for pathogenic BRCA1 mutations and showed BRCA1 promoter hypermethylation 
compared with HR-negative PDXs. Blue bar: BRCA1/BRCA2 mutations; yellow bar: 
BRCA1 promoter hypermethylation; grey bar: PDXs HR-positive with unknown HR 


























4.2.4 DNA repair gene expression levels and HR mutational status 
associated with response to therapy in EOC-PDX tumours 
The relation between gene expression levels or HR mutational status and antitumour activity 
of DDP and olaparib were studied in order to find possible biomarkers of therapy response.  
Firstly, we studied the correlation between DDP response and the expression levels of the 
20 DNA repair genes in the high grade PDXs divided into the three response categories: VS, 
S and R, according to the parameters described in Materials and Methods.  
The expression of three genes negatively associated with DDP response, meaning that higher 
mRNA levels were expressed in resistant xenografts: XPF (p=0.016), PALB2 (p=0.019) and 
CDK12 (p=0.017) (figure 4.10, panel A, B, C). Then, we tried to confirm these data using 
the independent and public database of the TCGA, where gene expression data and ovarian 
cancer clinical information are available. Only regarding CDK12, we found that patients 
with higher expression levels of CDK12 mRNA had a higher risk of relapse (HzR=1.119, 
95% CI 0.9188-1.564, p=0.179), even if the difference did not reach statistical significance, 
while XPF and PALB2 data were not confirmed. However, the analysis included a bias, since 
the population considered included also those patients with CDK12 inactivating mutations 
(Ekumi et al., 2015). We then re-analysed these data considering them as not expressing 
CDK12 protein and stratifying patients for the residual tumour (RT) after surgery (more or 
less than 2 cm). We found that patients with higher levels of CDK12, even with a RT< 2 cm 
(per se a good prognostic indicator) have a worse prognosis than those with low protein 
levels (HzR=1.295, 95% CI 1.016-1.651, p=0.0367) (figure 4.10, panel D). We could not 
validate the results obtained in our PDXs regarding PALB2 and XPF, because no correlation 
between the expression levels of these two genes associated with patient prognosis in the 





Figure 4.10 DNA repair gene expression levels and DDP response in high grade 
PDXs 
Panels A, B, C: box plots showing the XPF, PALB2, CDK12 mRNA levels, respectively, in 
high grade PDXs classified as DDP resistant (R), sensitive (S) and very sensitive (VS). *: p 
<0.05. Panel D: forest plot of the relation between CDK12 gene expression and ovarian cancer 
patient survival. The estimated risk of recurrence in patients with different CDK12, XPF and 
PALB2 gene expression levels (I- lower risk, -I higher risk, dot: estimated risk). Risk 





We then correlated the expression levels of the second panel of 21 genes with DDP and 
olaparib PDX response.  
A significant correlation was observed between USP28 (p=0.0082), ARTEMIS (p=0.0232), 
ARID1A (p=0.0246) and MDR1 (p=0.0241) and DDP response in all the PDXs (figure 4.11). 
Only USP28 was confirmed in the high-grade models (p=0.047). No correlations between 
olaparib response and gene expression levels in either all the PDXs, or in the high-grade 
subgroup, were found. Only a trend was also found between USP 28 and olaparib response, 
that however, did not reach a statistically significant p-value (p=0.0526). 
 
Figure 4.11 mRNA expression levels of genes significantly associated with DDP 
response in all the EOC-PDXs 
Box plots showing the ARID1A, ARTEMIS, MDR1 and USP28 mean (diamond) and median 
(line) of the mRNA copies expressed by all the PDXs classified for their response to DDP in 
resistant (R), sensitive (S) and very sensitive (VS).  p<0.05. mRNA copies are calculated as 








We considered the HR status (deficient/proficient) of the PDXs, based on the presence of  
BRCA1/BRCA2 mutations and/or HR ≥0.7 to define PDXs as HR deficient. Conversely, 
BRCA1/BRCA2 wt and/or score <0.7 are indicative of HR proficiency. We looked for 
possible associations with DDP and olaparib response and HR status. The analysis between 
HR status and response to therapy showed a significant association with both DDP 
(Jonckheere-Terpstra test: p=0.001, n=34) and olaparib (Jonckheere-Terpstra test: p=0.017, 
n=19). Figure 4.12 shows the drug response to DDP and/or olaparib in both subcutaneously 
(figure 4.12, A) or orthotopically transplanted PDXs (figure 4.12, B), and reports for each 
PDX BRCA1/BRCA2 mutational status, HR score positive or negative and the BRCA1 














































































































































































Figure 4.12 Overview of the best treatment response to DDP and olaparib and 
HR related profile of the EOC-PDXs under study 
Response to DDP (blue bars) and olaparib (red bars) in the subcutaneous and 
intraperitoneal PDX models. BRCA1/BRCA2 mut= mutated; wt= wild type; HR score: 
yellow box = positive/ HRD; green box = negative/ HR proficient; BRCA1 promoter 
methylation status: red box = hypermethylated. 
A) For tumours grown subcutaneously the best T/C% has been evaluated for DDP and 
for olaparib. As detailed in Materials and Methods, tumours were classified as resistant 
(R) to therapy with T/C% ≥ 50%; sensitive (S) 10%<T/C%<50% and very sensitive 
(VS) T/C% ≤10%. The dashed lines indicate the T/C% thresholds that divide the 
response into the three categories. Different coloured bars are associated with different 
DDP (blue/light blue) and olaparib (red/yellow) response to treatment.  
B) For orthotopic PDXs the best ILS% has been evaluated for each treatment. As 
detailed in Materials and Methods, tumours were classified as resistant (R) with ILS% 
≤ 40%; sensitive (S) 40%< ILS%<100% and very sensitive (VS) ILS% ≥100%. The 
dashed lines indicate the ILS% thresholds that divide the response into the three 
categories. Different coloured bars are associated with different DDP (blue/light blue) 


































































Not treated with olaparib
wt wt wt wt M wt wt M M wt
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4.2.5 Discussion II 
DNA repair is an important determinant of the tumour response to DDP and olaparib, and 
we aimed to explore its potential as a predictive biomarker of chemotherapy response. Using 
a panel of EOX-PDXs characterized for their response to DDP and olaparib therapy, we 
selected 35 DNA repair genes and others described to be involved in mechanisms of drug 
sensitivity/resistance, and quantified by RT-PCR the absolute number of mRNA copies in 
the PDXs. 
All the genes were variably expressed in our models, without showing histotype-specific 
clusters of expression. This might be explained by the presence of only two cases of 
mucinous samples, three clear cells, 2 low grade serous/endometrioid and 80% of 
HGSOC/HGEOC, which reflect the incidence observed in the clinic (Duska and Kohn, 
2017). This is the reason why we focused some analyses in this large subgroup. We analysed 
the correlation between the expression levels of single genes and found significant 
correlations among genes of the same pathway (i.e. FA genes), which could be explained by 
the fact that FA DNA repair pathway is a multistep process and their genes should be 
correlated with each other. We also found that CDK12, involved in the regulation of DNA 
repair gene transcription, positively correlated with PALB2, XPF and 53BP1. Besides this 
role, CDK12 is a kinase involved in chromosome organization, stress induced gene 
expression and possibly RNA processing factors (Chilà et al., 2016). It has been found 
mutated in 3% of EOCs (Cancer Genome Atlas Research Network, 2011) and inactivating 
mutations in the catalytic site of the proteins have been associated with impaired HR and 
sensitivity to DNA damaging agents (Chilà et al., 2016; Ekumi et al., 2015). Moreover, we 
found positive correlations also between USP28, a deubiquitinase protein, able to modify 
and stabilize some DSB repair proteins (Knobel et al., 2014), and ARTEMIS, an 
endonuclease of the NHEJ pathway, and between CHD4 and REV7, both involved in the 
mechanism of resistance to PARPi (Gupta et al., 2018; Pan et al., 2012). A preliminary 
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search in the literature and in public datasets did not report these correlations and required 
further investigations.   
We investigated whether the promoter hypermethylation status found in some PDXs in 
selected DNA repair genes (BRCA1, FANCF, XPA, XPG, ERCC1 and MLH1) effectively 
affected the transcription of the genes. BRCA1 methylation has been evaluated in 5 different 
areas of the promoter, but only two have been already described to reduce the transcription 
levels (Ter Brugge et al., 2016). In fact, the other three regions, found strongly 
hypermethylated in half of the PDXs, did not correlate with BRCA1 mRNA levels, while 
considering the other two regions, 5 PDXs were strongly hypermethylated and showed a 
significant reduction of BRCA1 gene expression (p=0.0015) compared with the average of 
mRNA copies expressed in the non-hypermethylated PDXs. Regarding the other genes 
investigated, they were scarcely hypermethylated, confirming similar results in EOC 
(Cancer Genome Atlas Research Network, 2011; Sabatino et al., 2010). MNHOC109, 
hypermethylated in MLH1 promoter, was also the PDX with the lowest MLH1 mRNA 
expression level. The low expression of MLH1 induced by promoter hypermethylation has 
been reported to associate with DDP resistance (Strathdee et al., 1999). However, 
MNHOC109 was sensitive to DDP, and MNHOC500, found scarcely hypermethylated 
(11%) was very sensitive to DDP (table 4.4), suggesting other factors could determine the 
final response to DDP of the tumour. Similar considerations could be applied to FANCF, 
where the two hypermethylated PDXs showed a reduction of FANCF mRNA, but were not 
associated with DDP response. ERCC1 was found hypermethylated in two very sensitive 
PDXs to DDP, and the mRNA was reduced. While XPA methylation status in 5 PDXs did 
not associate with gene expression, maybe, the 2 regions evaluated, as for BRCA1, were not 
those responsible for the regulation of transcription.  
We correlated the gene expression levels with DDP and olaparib response, focusing in 
particular on the subgroup of the high grade serous and endometrioid PDXs. CDK12, 
PALB2, XPF and USP28 mRNA levels significantly correlated with DDP response. In 
184 
 
particular, higher mRNA levels of CDK12, PALB2 and XPF have been expressed in DDP 
resistant PDXs tumours and we could corroborate the potential role of CDK12 as prognostic 
factor in the TCGA dataset, while PALB2 and XPF expression did not correlate with patient 
prognosis in the same database. It has been observed that ovarian cancer patients expressing 
higher levels of CDK12 protein have a worse prognosis, even if they had a residual tumour 
< 2 cm after surgery, which is generally considered a good prognostic marker. Conversely, 
higher mRNA levels of USP28 have been expressed in DDP very sensitive tumours, and this 
significant correlation was reported in all the PDXs and it was maintained also in the high 
grade PDXs. Regarding olaparib, none of the selected genes significantly correlated with 
response to therapy, even if a trend of association was also found between UPS28 and 
olaparib response, suggesting other biomarkers are necessary to predict olaparib response.  
The deficiency in HR has been associated with sensitivity to both DDP and olaparib 
(Konstantinopoulos et al., 2015; Vollebergh et al., 2014). However, as already discussed in 
the introduction, the functional HR status (proficient/deficient) is not easily determined in 
tumours. Inactivating germline and somatic mutations of genes involved in HR (i.e. 
BRCA1/BRCA2, PALB2, FANCD2, RAD51C), low/absent protein level (due to do promoter 
hypermethylation or mutations) could all contribute to a deficiency in HR. In addition, 
different genomic tests, such as Myriad Choice or Foundation Medicine test have been 
described able to capture, even if not entirely, the BRCAness phenotype (Coleman et al., 
2017; Stronach et al., 2018). We analysed 10 of our PDXs with the HRDetect assay, which 
uses an algorithm to analyse different genomic mutational signatures related to the 
BRCAness phenotype, besides the presence of BRCA1/2 mutations, and elaborates a final 
HR score indicative of HR status, suggesting that HRDetect test could enlarge the population 
that could benefit from DNA damaging therapies (Chopra et al., 2020; Davies et al., 2017). 
We observed that 5 PDXs were HR deficient, having a HR score ≥0.7. Among them, two 
were effectively BRCA1 mutated and one had BRCA1 promoter hypermethylation, while in 
the other two the causes of HRD are unknown.  
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We analysed the association between HR deficient status (based on HR score and BRCA1/2 
mutational profile of the PDXs) and DDP and olaparib response, and a significant 
association has been found between HRD and both the drugs. These data corroborate the 





4.3 STUDY OF RAD51 FOCI AS PREDICTIVE BIOMARKER FOR 
RESPONSE TO PLATINUM AND PARPI THERAPY 
Evidence from PARPi preclinical and clinical studies suggest that their activity extends 
beyond BRCA1/BRCA2 germline and/or somatic mutated tumours (Pilié et al., 2019). In 
addition, it has been reported that platinum sensitive or BRCA1/2 mutated tumours don’t 
always benefit from PARPi (Ceccaldi et al., 2015; D’Andrea, 2018), as suggested also by 
our previous data, where some PDXs even extremely sensitive to DDP, or BRCA-mutated, 
were resistant to olaparib, suggesting an intricate scenario. Tests able to predict HR status 
based on genomic signatures and mutational profiling of the tumour are not completely 
successful in predicting response to therapy. Tests able to capture the functionality of 
different DNA repair pathways would help. 
Having available a xenobank of PDXs, whose sensitivity to DDP and olaparib is known, we 
explored if functional surrogates of HR (i.e. RAD51 foci) and NER (i.e. ERCC1/XPF 
complex) pathways could correlate/associate with drug response. 
4.3.1 Quantitative immunofluorescence assay to evaluate RAD51 foci in a 
tissue microarray representative of the xenobank 
We have available in our laboratory a tissue microarray (TMA) from FFPE EOC-PDX 
tumours, which includes 60 PDXs samples, representing all the EOC histotypes and the wide 
spectrum of tumour sensitivity to DDP and olaparib (table 4.10). From each donor, two 
different areas of the tumours were selected by the pathologist and included into the TMA 




Table 4.10 List of the EOC-PDXs included in the TMA 
 
Legend: VS= very sensitive; S= sensitive; R= resistant. 
#ID EOC-PDXs Histotype DDP sensitivity Olaparib sensitivity
MNHOC22 HGSOC VS R
MNHOC125 HGSOC VS
MNHOC212 HGSOC VS
MNHOC266 HGSOC VS R
MNHOC500 HGSOC VS VS
MNHOC506 HGSOC VS R
MNHOC508 HGSOC VS VS
MNHOC511 HGSOC VS VS
MNHOC124 HGS/ HGE OC VS R
MNHOC218 HGEOC VS VS
MNHOC230 HGEOC VS
MNHOC261 HGEOC VS
MNHOC8 HGSOC VS VS
MNHOC84 HGSOC S R
MNHOC106 HGSOC S
MNHOC107 HGSOC S
MNHOC143 HGSOC S R
MNHOC239 HGSOC S R
MNHOC258 HGSOC S
MNHOC271 HGSOC S S
























MNHOC232 HGS/ HGE OC
MNHOC241 LGSOC VS
MNHOC109 LGEOC S






MNHOC182 MC R R





MNHOC9 not classified S
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In collaboration with Dr Deborah Wilsker of the Frederick National Laboratory for Cancer 
Research (MD, USA), who set up a multiplex immunofluorescent (IF) assay to stain and 
quantify RAD51 foci in FFPE tumours (Wilsker et al., 2019), we performed the 
quantification of RAD51 foci in our TMA. 
RAD51 nuclear foci, along with β-catenin (as tumour tissue marker), were evaluated through 
immunofluorescence (IF). Only tumours positive for β-catenin, with at least 2900 nuclei 
available for the analysis, an intact tissue and specific fluorescent signal were included in 
the analysis. With these criteria, 37 different PDXs and 5 control tissues (i.e. human EOC 
samples, murine EOC, murine ovarian tissue) were analysed. More than 2500 images were 
acquired with confocal microscopy and the analysis was performed with Definiens image 
analysis software, reporting the percentage of cells per core having ≥5 RAD51 foci per 
nucleus (figure 4.13, A). The results showed that 98% of the samples had less and 2% of 
RAD51 positive cells (figure 4.13, B), even removing the cut-off of 2900 nuclei available 
for the analysis, the results did not change. In addition, we observed a great variability of 
RAD51 positive cells in the two cores of the same PDXs. 
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Figure 4.13 RAD51 foci at baseline in EOC-PDXs  
A) Representative images of MNHOC18 and the pipeline of software analysis. MNHOC18, 
core a, expresses 0.6% of RAD51 positive cells (≥5 foci per nucleus). B) Baseline expression 
of RAD51 foci in the tumour cores analysed in the TMA with at least 2900 nuclei per core 
available for the analysis. Data are expressed as the % of nuclei with ≥5 foci per nucleus per 
core. For almost all of the PDXs, two different cores were available for the analysis.  
 
Considering the response to DDP and olaparib and dividing the PDXs into the three 
categories: resistant, sensitive and very sensitive, the % of cells positive for RAD51 foci was 
not different among the three groups, as shown in figure 4.14 (A, DDP response; B, olaparib 
response). In detail, the group of DDP R PDXs expressed an average of 0.463 ± 0.155 (mean 
± SD) (n=3) RAD51-foci positive cells, PDXs DDP S 0.336 ±0.175 (n=12) and PDXs DDP 
VS 0.380 ±0.110 (n=8) (one way ANOVA, p=0.444) ; while PDXs OLA R had 0.504 ±0.210 
(n=5) RAD51-foci positive cells, OLA S 0.41 RAD51-foci positive cells (one sample, 
MNHOC271) and OLA VS had 0.230 ±0.075 (n=4) (p=0.112). 
Figure 4.14 RAD51 foci expression at the basal level and response to therapy 
A) The upper histogram shows the % of nuclei expressing ≥5 RAD51 foci (mean, SD) in the 
PDXs analysed, divided into three groups based on their response to DDP therapy: resistant 





















































































































































% of nuclei expressing ≥5 RAD51 foci (mean, SD) in all the PDXs analysed, clustered for their 
response to olaparib (Ola R, resistant; Ola S, sensitive; Ola VS, very sensitive). 
 
4.3.2 Evaluation of RAD51, BRCA1 and γH2AX nuclear foci in geminin 
positive FFPE EOC-PDX tumours 
Recently, an assay has been set up evaluating RAD51 foci in FFPE tumour samples 
specifically in cells in S/G2 phase of the cell cycle (where HR takes place), using geminin 
(GEM) as a marker of cellular proliferation, and it has been reported that low % of 
RAD51+/GEM+ cells in tumours predict sensitivity to olaparib in a panel of breast cancer 
PDXs (Castroviejo-Bermejo et al., 2018a; Cruz et al., 2018). Applying this protocol to our 
EOC-PDXs, we analysed and scored the % of proliferating cells positive for RAD51 foci. 
We also considered and analysed the expression of BRCA1 foci and γH2AX foci in GEM+ 
cells, as markers for BRCA1 activity, and DNA DSB and apoptosis, respectively. 
As detailed in Materials and Methods, for all the three proteins, we considered positive cells 
those were ≥5 RAD51 foci per nucleus were observed (figure 4.15, representative images). 
Only geminin positive cells were considered and at least 100 geminin positive cells had to 
be counted. The cut off of 10% RAD51+/GEM+ cells discriminated between RAD51 
positive and negative tumours (Castroviejo-Bermejo et al., 2018a), while the cut off for 
BRCA1 and for γH2AX were respectively 35% (based on the median of positive cells in the 
entire xenobank) and 25% (Castroviejo-Bermejo et al., 2018a).  
The % of positive cells among the PDXs varied from 0% to 78% for RAD51 (mean 26% ± 
SD 0.23, median 26%) (figure 4.15, A), from 0% to 100% for γH2AX (mean 69% ± SD 
0.22, median 74%) (figure 4.15, B), and from 0% to 93% for BRCA1 foci (mean 39% ± SD 
0.3, median 35%) (figure 4.15, C).  
Differently from what observed in breast cancer PDXs, in EOC-PDXs several cells showed 
a pan-γH2AX staining in the nucleus, besides  
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cells with γH2AX foci, suggesting a higher degree of apoptosis and basal DNA damage 
compatible with the higher chromosomal instability of this malignancy (Cancer Genome 
Atlas Research Network, 2011; Tamura et al., 2020).  
We observed that 9 out of 10 PDXs BRCA1 mutated were also negative for BRCA1 foci 
expression, except MNHOC125 which displayed 51% of positive cells for BRCA1 foci 
(figure 4.15, C). 
Figure 4.15. Percentage of cells positive for both nuclear foci and geminin in all 
the PDXs studied  
RAD51 foci (panel A), γH2AX foci (panel B) and BRCA1 foci (panel C) have been 
quantified by IF co-staining with geminin, marker of S/G2 cell cycle phase. Each bar 
represents the % of cells evaluated in each tumour, having ≥5 foci and positive for geminin. 
In the histogram C relative to BRCA1 foci, * red bars indicate BRCA1 mutated PDXs. Dashed 
lines are the cut-off that divide tumours in negative (% of positive cells lower than the 
threshold) or positive. On the right, representative IF images of different PDXs; nuclei are 
stained in blue (DAPI), geminin in green (FITC) and foci in red (m-Cherry). White arrows 




We explored the correlation between RAD51 and BRCA1 and we observed a positive 
correlation between RAD51 and BRCA1 foci (Spearman correlation index 0.656, p<0.0001, 
n=35), where tumours with low number of RAD51 positive cells mainly displayed low 




Figure 4.16 Correlation between RAD51 and BRCA1 foci  
Distribution of RAD51 and BRCA1 foci in the EOC-PDXs and linear regression.  
 
We studied the correlation between RAD51 and BRCA1 foci expression and the response to 
therapy. In figure 4.17 are reported the % of RAD51+/GEM+ cells (figure 4.17, A) and the 
% of BRCA1+/GEM+ cells (figure 4.17, B) in the FFPE PDXs divided for their sensitivity 
to DDP in the three groups of response. We did not find any correlation with DDP response 
and the % of RAD51+/GEM+ cells (Kruskal-Wallis test p=0.486) (figure 4.17, C), not even 
clustered PDXs in RAD51 positive (positive have >10% of RAD51 positive cells) or 
negative tumours (Jonckheere-Terpstra test p=0.3164). The correlation between the % of 
BRCA1+/GEM+ cells vs DDP response was also not significant considering the expression 
of foci in continuous (Kruskal-Wallis test p=0.1245) (figure 4.17, D), while reach the limit 
of significance considering tumour positive vs negative (positive have >35% of BRCA1 
positive cells) vs DDP response (Jonckheere-Terpstra test p=0.040). 


























Figure 4.17 RAD51 and BRCA1 foci positive cells and response to DDP treatment in 
FFPE EOC-PDXs  
The histograms show the % of positive cells for RAD51 (A) and BRCA1 foci (B) among the PDXs 
studied and clustered for their response to DDP (light blue= very sensitive; pink= sensitive; orange= 
resistant). The box plots on the right show that no correlation has been found between the distribution 
of RAD51+/GEM+ and BRCA1+/GEM+ cells and DDP response.  
 
However, the % of RAD51+/GEM+ and BRCA1+/GEM+ cells significantly associated with 
olaparib response. Indeed, tumours very sensitive to olaparib showed the lowest % of 
RAD51+/GEM+ positive cells and BRCA1 positive cells than PDXs resistant to olaparib 
(figure 4.18, A-B). In particular, the association between the % of RAD51+/GEM+ positive 
cells and olaparib response was significant (Kruskal-Wallis test p=0.011) (figure 4.18, C), 
also when considering tumours in RAD51 positive/negative (Jonckheere-Terpstra test: 
p=0.0047). The association between BRCA1+/GEM+ positive cells and olaparib response 
was also significant (Kruskal-Wallis test p=0.0144) (figure 4.18, D), even dichotomizing 





















































































































































































































































































































Figure 4.18 RAD51 and BRCA1 foci positive cells and response to olaparib treatment 
in FFPE EOC-PDXs  
The histograms show the % of positive cells for RAD51 (A) and BRCA1 foci (B) among the PDXs 
studied and clustered for their response to olaparib (light blue= very sensitive; pink= sensitive; 
orange= resistant). The box plots show the positive correlation between RAD51 positive cells (C) 
and BRCA1 positive cells (D) and olaparib response, where very sensitive tumours to olaparib 
significantly express lower positive cells. 
 
4.3.3 Discussion III 
In this section, we explored the role of RAD51 and BRCA1 foci as potential biomarkers able 
to predict HRD status and response to therapy in FFPE EOC-PDXs tumours. We studied 
also the presence of γH2AX foci, markers of DNA DSB and apoptosis, as indicator of the 
level of endogenous damage. Preclinical evidence support a strong, quantitative correlation 
between γH2AX foci and DNA DSB, including the ones induced by genetic factors such as 
DNA repair genes mutations (Rothkamm et al., 2015). However, in our PDXs, we observed 
a diffuse expression of γH2AX foci in tumour cells and nuclei completely damaged, showing 
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corroborating published data suggesting that EOC is characterized by a high degree of 
chromosomal instability (Yu et al., 2006).  
The induction of RAD51 nuclear foci as biomarker of HR deficiency was firstly described 
by Graeser et al. studying breast cancer biopsies after neoadjuvant chemotherapy (Graeser 
et al., 2010). The induction of RAD51 foci has been correlated with the ability of cells to 
repair damage through HR (Ceccaldi et al., 2016; Wilson et al., 2018). However, this method 
suffers from a poor clinical translatability, because it is not always possible to have fresh 
tumour specimens or FFPE biopsies at basal and after drug treatment.  
We used two different IF-based methods to evaluate RAD51 foci as surrogate marker of HR 
in FFPE biopsies at the baseline, without the need to induce DNA damage. The first method 
quantified nuclei expressing at least 5 foci in all the tumour cells of FFPE TMA, while the 
second method also quantified nuclei expressing at least 5 foci but only in 
proliferating/geminin positive cells within the FFPE tumours, and it has been described to 
predict olaparib response in breast cancer PDXs (Castroviejo-Bermejo et al., 2018a; Cruz et 
al., 2018).  
We were able to detect and quantify RAD51 nuclear foci in FFPE ovarian PDXs tumour 
specimens at baseline (not treated condition). To do this, it is of pivotal importance to use a 
very sensitive microscope and to be able to establish a discriminating cut off and 
experimental conditions to have reproducible and reliable results. In addition, we 
demonstrated that considering only proliferating cells in S/G2 phase of the cell cycle 
(GEM+) is a determinant factor for RAD51 positivity to be correlated with olaparib 
response. Indeed, the IF of the total number of tumour cells positive for RAD51 foci was not 
able to predict olaparib response. This could be due to different reasons: technical and non-
technical. The setup of imaging acquisition by confocal microscope and of the software that 
automatically analyses all the images, is important to avoid loss of information. For instance, 
the condition to establish whether a cell is positive for RAD51 foci is the presence of at least 
5 foci in the nucleus. An automatic acquisition has the advantage of reproducibility, but 
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when the number of foci is low, it may generate false negative results, as probably happened 
during the analysis of our TMA, where the number of cells expressing at least 5 foci is very 
low than in the same PDXs analysed directly by the operator with a good fluorescent 
microscope during the second test. On the other hand, the analysis made by the operator can 
suffer from other issues, such as inter-operator reproducibility and the impossibility to 
analyse rapidly a great number of samples. While, another technical issue could be related 
with the use of different primary antibodies anti-RAD51 used in the two tests (Castroviejo-
Bermejo et al., 2018a; Cruz et al., 2018; Wilsker et al., 2019) that could not have the same 
specificity. The third factor could be related to the identification of RAD51 foci only in the 
subgroup of proliferating tumour cells, which is in line with the fact that HR acts during 
S/G2 phases of the cell cycle. So, the expression of RAD51 foci in proliferating cells should 
directly depend from HR activation.  
The number of RAD51 foci in geminin positive cells determined by IF test significantly 
correlated with olaparib response of the PDXs studied, but not with DDP, suggesting that 
platinum anti-tumour activity may be the result of a sum of different factors that need to be 





4.4 FOCUS ON NER AND BER PATHWAYS AND RESPONSE TO 
PLATINUM THERAPY 
Platinum agents represent the standard therapeutic option for many solid tumours, included 
EOC. Looking at the mechanism of action of platinum compounds, these drugs mainly 
determine DNA adducts, which can be repaired or not by the cancer cells determining the 
anti-tumour activity of the drug. Besides HR, which is the DNA repair pathway most 
involved in the resolution of ICLs, also NER and BER play crucial roles, particularly 
involved in the resolution of DDP-induced DNA adducts (Slyskova et al., 2018). For these 
reasons, we explored the role of some determinant genes and proteins involved in the NER 
and BER pathways in determining the response to DDP in our EOC-PDXs. The proteins we 
studied were DNA polymerase β (POLB) and ERCC1. The latter has been investigated both 
as a single protein and conjugated with XPF, because the formation of ERCC1/XPF complex 
can be considered a readout of NER activity (Kirschner and Melton, 2010). 
4.4.1 Relationship among ERCC1, XPF, POLB and ERCC1/XPF complex 
expression levels in the xenobank 
These experiments have been performed using the TMA available in our laboratory and we 
analysed 52 EOC-PDXs included in the TMA.  
A descriptive analysis is reported in table 4.11, which summarises ERCC1 and POLB 
protein levels expressed as IHC score, the number of ERCC1/XPF complexes per nucleus 
detected by proximity ligation assay (PLA), and ERCC1, XPF and POLB absolute number 
of mRNA copies normalized quantified by RT-PCR in all the PDXs and in the subgroup of 




Table 4.11 Descriptive analysis of ERCC1 and POLB IHC, ERCC1/XPF foci (PLA) 
and ERCC1, XPF and POLB mRNA expression levels in the EOC-PDXs studied 
Legend: n: number of samples; SD: standard deviation; Min-Max: range; missing= number of PDXs were 
the data is not available. 
 
POLB and ERCC1 protein expression has been determined by IHC using primary antibodies 
reported in other published studies (Alvisi et al., 2020; Arbogast et al., 2011; Friboulet et al., 
2013b). IHC analyses have been done in collaboration with Prof Eugenio Scanziani, an 
expert pathologist. The calculated IHC score is based on signal intensity and the percentage 
of positive cells (as detailed in Materials and Methods). The ERCC1 IHC score assigned to 
the analysed PDXs has been found ranging from 0 (negative signal) to a maximum of 3.5 
(median 1.3, mean 1.4 ± SD 0.9) (figure 4.19, D), while POLB ranges from 0 to 12 (median 
6, mean 5.5 ± SD 4.2) (figure 4.19, E). For ERCC1, some samples showed a cytoplasmic 
staining, much lower than the nuclear, which likely reflects the presence of one of the four 
isoforms of ERCC1 (the isoform 203), not involved in the NER and reported to be 
cytoplasmic (Friboulet et al., 2013b). Only the nuclear stain was considered for this analysis 
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Min - Max 0.0 - 3.5 0.0 - 12.0 0.9 - 8.8 0.2 - 3.1 0.0005 - 0.009 0.004 - 0.1619
Missing 3 1 3 16 16 16















Min - Max 0.0 - 3.5 0.0 - 12.0 0.9 - 8.8 0.2 - 3.1 0.0009 - 0.0090 0.0040 - 0.1619
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Figure 4.19 ERCC1 and POLB proteins expression on the TMA visible in IHC  
A) Representative image of the FFPE-TMA including the 52 EOC-PDXs under study, stained 
with antibody anti-ERCC1 (Santa Cruz Biotechnology, sc-10785). Magnification 2X. B) 
Representative MNHOC506, ERCC1 positive sample (IHC score= 3.25). ERCC1 dots are 
present both in the cell nucleus and in the cytoplasm. Magnification 20X, brightfield 
microscopy. C) Representative MNHOC182, POLB positive sample (IHC score=12). 
Magnification 40X, brightfield microscopy.  D-E) Distribution of ERCC1 and POLB IHC 
score assigned to each EOC-PDXs analysed. The IHC score is based on the antibody signal 




ERCC1/XPF complexes have been detected and quantified in 49 PDXs by proximity ligation 
assay (PLA), a technique used to detect proteins which closely interact and that has been 
previously reported to be applied to ERCC1/XPF, which are visible as nuclear foci (Friboulet 
et al., 2013b; Kuo et al., 2018) (figure 4.20, A-B). We quantified the average number of 
ERCC1/XPF foci per nucleus expressed in the PDX tumours, present in duplicate in the 
TMA, evaluating at least three different areas in each core. ERCC1/XPF complexes were 
expressed at different levels ranging from 0.9 to 8.8 foci per nucleus (figure 4.20, C). 
 
Figure 4.20 ERCC1/XPF protein complexes detected by PLA in IHC in FFPE 
EOC-PDXs  
A) Negative control. PLA was done without primary antibodies. It is possible to observe nuclei 
counterstained with Nuclear Fast Red (pink nuclei). B) The same FFPE EOC-PDX sample 
after PLA technique. ERCC1/XPF foci are visible as violet dots within epithelial cancer cells 
nuclei (pink nuclei). Magnification 40X, brightfield microscopy. C) Mean of ERCC1/XPF 




We analysed different correlations between ERCC1 and POLB IHC score, ERCC1/XPF foci 
number per nucleus and ERCC1, XPF and POLB mRNA number of copies (table 4.12). The 
ERCC1 IHC score positively correlated with the XPF mRNA (p>0.0001) and ERCC1/XPF 
foci number (p=0.05), but interestingly, not with ERCC1 mRNA.  
As regards ERCC1/XPF complex, all the PDXs expressed ERCC1/XPF foci per nucleus 
(median 4.9; mean 5.0 ± SD 2; range: 3.6-6.3) and no differences among the various EOC 
subtypes (p=0.392) could be observed. Besides ERCC1 IHC score, ERCC1/XPF foci 
number significantly correlated POLB IHC score (p<0.0001). XPF and ERCC1 mRNA both 
correlated with POLB mRNA (p=0.02 and p=0.05, respectively).  
The same correlations have been then repeated in the high grade EOC-PDXs and in this 
subgroup were maintained for the correlations between POLB IHC score and ERCC1/XPF 
foci number (p>0.0001) and ERCC1 IHC score and XPF mRNA (p>0.0001).  
Table 4.12 Correlations between ERCC1 and POLB IHC score, ERCC1/XPF foci and 
ERCC1, XPF and POLB gene expression data in the EOC-PDXs under study 
Legend. In each box: first line reports the Spearman correlation index, the second line is the p-














-0,01 -0,11 0,04 1
0,96 0,53 0,82
34 35 35 36
0,65 0,11 0,32 0,15 1
< 0,0001 0,54 0,06 0,4
34 35 35 36 36
0,14 0,17 0,09 0,32 0,4 1
0,43 0,33 0,6 0,05 0,02



















4.4.2 Analysis of ERCC1, XPF, POLB and ERCC1/XPF complex as 
possible predictive biomarkers for platinum response in EOC-PDX TMA 
The pharmacological response to DDP was available for 25 of the PDXs under study, 
including 10 very sensitive, 12 sensitive and 3 resistant high grade PDXs, in which we 
focused for this analysis. ERCC1 IHC score did not significantly associate with DDP 
response (Kruskal-Wallis p=0.847) (figure 4.21, A), neither did the POLB IHC score 
(Kruskal-Wallis p=0.664) (figure 4.21, B). 
Figure 4.21 ERCC1 IHC score, POLβ IHC score and DDP response in high grade 
EOC PDXs  
A) Distribution of ERCC1 IHC score in PDXs very sensitive (n=10), sensitive (n=12) and 
resistant (n=2) to DDP. B) Distribution of POLB IHC score in PDXs very sensitive (n=9) 
sensitive (n=12) and resistant (n=3) to DDP. The box plots express data as mean ± standard 
deviation. p-value (not statistically significant) is reported above the two box plots.  
 
In addition, ERCC1/XPF foci number per nucleus has not been found differently 
expressed among the three groups of DDP response (Kruskal-Wallis p=0.909) (figure 
4.22, A), neither when we tried to consider ERCC1/XPF foci number in very sensitive vs 




Figure 4.22 ERCC1/XPF foci number per nucleus and response to DDP in high 
grade EOC-PDXs 
A) Distribution of ERCC1/XPF foci per nucleus in the three groups of response to DDP: very sensitive 
(n=10), sensitive (n=10) and resistant (n=3). B) Distribution of ERCC1/XPF foci per nucleus in the 
PDXs clustered in two groups of response to DDP: very sensitive (n=10) vs sensitive and resistant 
(n=13). The box plots express data as mean ± standard deviation. p-value (not statistically significant) 
is reported above the two box plots.  
 
Our preliminary hypothesis that the number of ERCC1/XPF foci expressed at the basal level 
in the tumour could be a readout of the NER activity and thus, a determinant for platinum 
response, has not been proved by these data.  
To clarify these results, we tested whether DDP treatment could affect the formation of the 
functional complex ERCC1/XPF in cancer cells using a cell line model. A2780 ovarian 
cancer cells were treated with cytotoxic doses of DDP and cells were fixed at different time 
points after drug exposure. We could detect and quantify the ERCC1/XPF nuclear foci in 
untreated cells (at the baseline) and observed a significant increment of the foci number per 
nucleus in cells 24 hrs and 48 hrs after DDP treatment at the dose of 10 μM (drug IC50 of 
A2780) (p=0.03 and p=0.02, respectively) (figure 4.23). We also treated A2780 cells with 
the DDP dose of 20 μM, but ERCC1/XPF were not significantly augmented even if a trend 
towards increment was observed (p=0.12 at 24 hrs; p=0.18 at 48 hrs) (figure 4.23). The lack 
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of significant increment of foci number at the higher dose of DDP could be explained by the 
enhanced number of apoptotic nuclei observed already 24 hrs after treatment.  
 
Figure 4.23 Detection by IF and quantification of ERCC1/XPF foci per nucleus 
in A2780 ovarian cancer cells at the baseline and after DDP treatment  
A) IF picture of ERCC1/XPF nuclear foci (green dots, FITC, in blue nuclei, DAPI) expressed 
in untreated A2780 cells. B) Expression of ERCC1/XPF foci at 24 hrs and 48 hrs post-DDP 
treatment at 10 μM dose (IC50) and 20 μM. C) Quantification of ERCC1/XPF number of foci 
per nucleus in untreated A2780 cells (black bar) and after DDP treatment with 10 μM and 20 
μM, and fixed at two different time points (different shadows of grey bars). Histograms show 
the average number of ERCC1/XPF foci and standard deviation of three replicates, where at 
least 50 nuclei in different tumour areas have been quantified. Unpaired t-test was used to 
compare untreated vs treated cells at different conditions. * p≤0.05. 
 
4.4.3 Discussion IV 
Besides the 50% of high grade ovarian cancer patients who harbour HR defects associated 
with the extreme sensitivity to DDP and PARPi therapy, it has been reported that 4-8% of 
cases have mutations or promoter hypermethylation in NER genes (Konstantinopoulos et al., 
2015), which associated with response to platinum treatment and might explain the different 
therapeutic response to platinum agents and PARPi sometimes observed (Ceccaldi et al., 
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2015; Mouw et al., 2015). The role of HR and NER in supporting the antitumour effect of 
DDP has been proved in preclinical experiments (Damia et al., 1996; Tavecchio et al., 2008) 
and in the clinic, where patients with NER or HR deficiency were associated with long-
lasting response to chemotherapy and increased PFS and OS respect those with NER and 
HR proficient (Ceccaldi et al., 2015; Mouw et al., 2015). An increase in NER and BER 
activities in tumours was described to associate with DDP resistance (Bergoglio et al., 2001; 
Caiola et al., 2015; Damia et al., 1996; Wang et al., 2019). However, the clinical validation 
of these results was difficult for different reasons: the choice of valid biomarkers able to 
associate DNA repair activity and DDP response, the choice of the technique used, as well 
as intra-tumour and intra-patient heterogeneity (Friboulet et al., 2013a; Macerelli et al., 
2016).  
ERCC1 is one of the most studied NER players as a determinant of therapy response and 
prognostic marker, but contrasting results have been reported in different solid cancers  
(Rubatt et al., 2012; Steffensen et al., 2014, 2009) and its role is still to be clarified. DNA 
POLB is a protein involved in different DNA repair pathways, mainly BER, NER and FA, 
and high levels of POLB have been associated with resistance to DDP, possibly explained 
by the capacity to bypass DDP induced intra-strand crosslinks allowing  cell replication 
(Bergoglio et al., 2001), and it was observed in in vitro non-small cell lung cancer cells 
overexpressing POLB, that the pharmacological inhibition of the protein could revert the 
DDP resistant phenotype of the cells (Caiola et al., 2015). Based on this evidence, we studied 
the role of ERCC1 and POLB as potential predictive biomarkers for DDP response in a 
platform of EOC-PDXs, considering their gene expression levels, as well as protein levels 
and the functional complex ERCC1/XPF by PLA. Surprisingly, we did not find significant 
correlation between ERCC1 protein and its mRNA levels, but only between ERCC1 and 
XPF mRNA (p<0.0001). A possible explanation for the lack of correlation between ERCC1 
mRNA and protein expression may be explained by the fact that the ERCC1 mRNA 
evaluated included all the four isoforms, while in IHC we only considered the nuclear 
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staining, where the isoform 203 is not localized. This could also explain the lack of 
association between ERCC1 protein and DDP response of high grade PDXs that has been 
observed, as well as the contrasting results present in literature, and pinpoints the necessity 
to find alternative approaches to validate biomarkers (Olaussen and Postel-Vinay, 2016). 
With this aim, we studied the expression by PLA of ERCC1/XPF functional complex, a 
limiting step for NER activity during the resolution of DDP adducts (Friboulet et al., 2013a, 
2013b). We detected the complex expressed at the baseline in all the PDXs analysed, but the 
value of ERCC1/XPF foci per nucleus did not associate with DDP response in the high grade 
EOC-PDXs. As we observed in vitro that ERCC1/XPF complex amount significantly 
increased after DDP treatment, we may hypothesize that the up-regulation of ERCC1/XPF 
could be a better predictor for NER activity, rather than its basal expression, similar to 
RAD51 foci induction upon DSBs for HR, which indicates HR proficiency (Graeser et al., 
2010; Waks et al., 2020). In fact, ERCC1 higher levels have been also observed in HGSOC 
biopsies after neoadjuvant chemotherapy compared with primary untreated tumours, 
suggesting an up-regulation of ERCC1 after treatment, even if the number of observations 
was small (Scurry et al., 2018). Another possible reason is that DDP response to therapy is 
the results of a sum of mechanisms, included NER, which differently contribute to determine 
the antitumor activity of treatment, and maybe a combinatorial approach might be more 
indicative.  
Regarding POLB, we did not observe a significant correlation between mRNA, protein and 
DDP response, but we found a significant correlation between POLB protein and 
ERCC1/XPF foci per nucleus (p<0.0001). BER and NER pathways are both involved in the 
repair of DDP-induced DNA lesions, so this correlation may suggest that these two pathways 











Despite recent improvements in surgical and pharmacological therapy achieved in the 
treatment of EOC, this malignancy remains the deadliest gynaecological tumour in the 
Western countries (Bray et al., 2018). Vague symptoms in the early phases of the disease 
and the lack of effective screening methods allow 75% of cases to be diagnosed at an 
advanced/metastatic stage (FIGO III/IV), when the chances of surviving are lower (Reid et 
al., 2017). The third major clinical impediment causing the low survival of EOC patients is 
the high incidence of relapsing tumours resistant to platinum-based chemotherapy, which 
occurs in two-thirds of patients (Bowtell et al., 2015; Lheureux et al., 2019b). Platinum-
based chemotherapy is the cornerstone of systemic therapy in the treatment of EOC, which 
is generally, initially very sensitive to platinum agents, i.e. carboplatin and cisplatin 
(Galluzzi et al., 2012; Lheureux et al., 2019b). These compounds are alkylating agents that 
exert their cytotoxic effect mainly forming DNA-platinum adducts, such as inter and intra-
strand crosslinks between purine bases (Chaney et al., 2005; Dasari and Tchounwou, 2014). 
DDP-induced DNA damage is repaired by several DNA repair pathways, involving different 
proteins and cooperating with each other to repair the lesions: NER, BER, TLS, MMR, FA 
and HR. The great susceptibility to platinum therapy observed in high grade ovarian cancers 
is in part due to the presence of defects in proteins involved in these pathways, which 
enhance the anti-tumour activity of DNA damaging agents and led us to hypothesize that, at 
the contrary, increased DNA repair activity could be associated with resistance to therapy. 
Half of HGSOC harbours alterations in HR (i.e. BRCA1/BRCA2 germline or somatic 
mutations, BRCA1 hypermethylation, mutations in other HR genes), which impairs HR 
function, a condition named BRCAness phenotype (Konstantinopoulos et al., 2015; Lord and 
Ashworth, 2016; Turner et al., 2004).  
The introduction of PARPi revolutionized the therapeutic strategies of EOC and potentially 
of all the solid tumours with a BRCAness phenotype. In fact, PARPi were found in synthetic 
lethality with BRCA1/BRCA2 mutated cancer cells (Bryant et al., 2005; Farmer et al., 2005).  
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Numerous preclinical and clinical studies have then established that PARPi therapeutic 
potential exceeds germline BRCA1/BRCA2 mutated tumours, and may potentially involve 
all the HRD tumours (Mirza et al., 2016a; Pilié et al., 2019; Pujade-Lauraine et al., 2017). 
Unfortunately, with the widespread use of PARPi, cases of acquired resistance have been 
reported in the clinic. Resistance to platinum and PARPi therapy, in a contest lacking valid 
therapeutic alternatives, is a critical and unmet clinical issue. There is the need to both 
elucidate the determinants of drug resistance and identify predictive biomarkers of response.  
With this background, the aim of my thesis was to study the role of different DNA repair 
pathways, genes and proteins in response to DDP and olaparib and to find potential 
biomarkers and functional assays able to predict the response to therapy in in vivo EOC 
models. 
The use of suitable and robust preclinical models is of pivotal importance in translational 
cancer research and in the Department of Oncology, where I undertook this PhD, a collection 
of more than sixty ovarian cancer PDXs is available. These in vivo models well recapitulate 
the biological features of the original patient tumour, are stable after several in vivo passages, 
and in aggregate, represent the complex clinical tumour heterogeneity and molecular 
diversity of EOC. In fact, all the histotypes of EOC are represented (80% are high grade 
serous and/or endometrioid tumours, as in the clinic) and pharmacologically the PDX 
xenobank shows a wide range of response to olaparib and DDP (Ricci et al., 2014). The 
pharmacological characterization of the PDXs to DDP and olaparib, allowed their 
classification into three categories based on their response to therapy: very sensitive, 
sensitive and resistant based on well-established parameters that fulfilled the response to 
chemotherapy observed in the clinic, and that could also be applied to orthotopic models. 
The pharmacological characterization has permitted the use of this PDX platform to study 




I contributed to the characterization of the PDX platform for the mutational profile, 
observing that all the HGOC models carry TP53 mutations, as described in the literature 
(Ahmed et al., 2010; Cancer Genome Atlas Research Network, 2011; Cole et al., 2016). 
Then, I focused on DNA repair genes, which are the object of my thesis, evaluating the 
mutational status of HR, FA and DDR genes. I observed that 11 out of 33 PDXs had BRCA1 
mutations, and 2 PDXs were mutated in BRCA2, while non-pathogenic or unknown 
mutations were observed in the other HR genes (i.e. PALB2, FA genes, ATM, ATR). In order 
to explore the HRD condition in our PDXs, not only the mutational profiles of HR and FA 
genes were characterized, but also epigenetic alterations that frequently occur in HGOC, 
such as the hypermethylation promoter status of BRCA1 and FANCF (D’Andrea, 2003; 
Konstantinopoulos et al., 2015), as well of other NER and MMR genes. Different CpG 
islands-enriched promoter regions have been evaluated in the genes of interest with two 
techniques, pyrosequencing with pre-custom primers and MS-PCR with primers designed 
ad hoc, already reported in literature (Sabatino et al., 2010; Ter Brugge et al., 2016). We 
also verified that the expression levels of the genes analysed were effectively reduced in the 
PDXs found hypermethylated, confirming BRCA1 hypermethylation status in 8% of the 
PDXs evaluated with MS-PCR, while few PDXs have been found hypermethylated in 
FANCF, ERCC1 and MLH1 promoter regions with reduction of gene expression. No 
correlation between XPA hypermethylation status and gene expression was found, 
suggesting that probably the regions considered were not those involved in the regulation of 
gene transcription. 
In order to deepen the study of DNA repair and response to therapy, I evaluated in the 
xenobank the expression of a wide panel of DNA repair genes involved in different DNA 
repair pathways. Genes were variably expressed in all the PDXs and no difference was 
observed among the different histotypes, even if this analysis suffered from the fact that 
some histotypes (mucinous, clear cells and low grade serous) were under-represented. 
Analysing the correlations between the single genes, it was observed that genes belonging  
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to the same pathway correlated with each other (i.e. FA genes). Interestingly, CDK12, a 
cyclin-dependent kinase described being mutated in 3% of HGOC (Konstantinopoulos et al., 
2015) and a transcriptional regulator of several DNA repair genes, correlated with the 
expression of PALB2, 53BP1 and XPF (p<0.05). These data were also corroborated in two 
different TCGA datasets, supporting a role of CDK12 as transcriptional regulator of DNA 
repair gene expression.  
CDK12 also emerged as one of the four genes found significantly associated with DDP 
response in the HGOC PDXs, and in particular, DDP resistant PDXs expressed higher levels 
of CDK12, XPF and PALB2 (p<0.05) compared with sensitive and very sensitive PDXs. 
Conversely, USP28 was more highly expressed in the very sensitive than in resistant HGOC 
PDXs (p<0.05). The biological significance of these correlations needs to be proven. 
However, we could corroborate the prognostic values of CDK12 in the TCGA dataset, where 
patients with a residual tumour < 2cm, but higher levels of CDK12 mRNA, had a worse 
prognosis compared with those expressing low CDK12 levels.  
Regarding olaparib, none of the 21 genes whose expression levels were established in the 
xenobank significantly correlated with olaparib response, even in the subgroup of HGOC 
PDXs. Currently, the presence of germline BRCA1/BRCA2 mutations is one of the 
biomarkers used in the clinical trials to predict response to PARPi therapy. However, 
because PARPi sensitivity mostly relies on HR defects, as well as for platinum agents, 
platinum sensitivity itself has been considered a surrogate marker for HRD and another 
clinical biomarker of PARPi response (Franzese et al., 2019; Konstantinopoulos et al., 2020; 
Rafii et al., 2017). Looking at the PDX platform response to DDP and olaparib, we have 26 
PDXs characterized for both drugs, and among them all the olaparib responsive tumours are 
also sensitive to DDP (n=8) and all the DDP resistant tumours do not respond to olaparib 
(n=8). However, not all the DDP very responsive tumours are also responsive to olaparib 
(n=5). These data showed a low concordance between cisplatin and olaparib response 
(Cohen’s k= 0.33), suggesting that the response to DDP is a poor predictive factor for 
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olaparib response in our PDXs. Moreover, PDXs with pathogenic mutations in 
BRCA1/BRCA2 are very sensitive/sensitive to DDP, but two out of 6 are resistant to olaparib, 
suggesting that the mechanisms underlying DDP response do not always overlap with 
mechanisms that determine olaparib response, as already described (Ceccaldi et al., 2015). 
Preclinical and clinical evidence suggested that PARPi could be effective in a wider range 
of tumours than those BRCA mutated, including BRCAness tumours, whose identification 
requires methods evaluating multiple molecular events. For this reason, we tested 10 PDXs 
with a genomic-based test, the HRDetect assay, in collaboration with Dr Nik Zainal. Her 
group set up an algorithm, based on five distinct HR-associated mutational signatures 
captured by whole genome sequencing, and elaborated a score indicative of HR deficiency 
(>0.7) or HR proficient status (<0.7) (Chopra et al., 2020; Davies et al., 2017). 5 PDXs had 
an HR score >0.9, and two of them harboured BRCA1 mutations, another showed BRCA1 
promoter hypermethylation, while currently, we do not know the cause for which the other 
two PDXs were classified as HRD. 
We wanted to verify if the HRD status could predict response to both DDP and olaparib 
response. To this aim, we considered HRD PDXs the ones with a HR score >0.7 and/or 
BRCA mutated. Based on these criteria, a significant association between HRD status and 
DDP response (p<0.05) and olaparib response (p<0.05) could be observed corroborating the 
evidence on the role of the HR status as a determinant of the response to these drugs 
(Konstantinopoulos et al., 2015). 
Relapsing patients with acquired resistance to therapy require functional assays to establish 
the effective DNA repair activity of the tumour to possibly predict response to therapy and 
ultimately, to direct patients to therapeutic alternatives. In fact, the available tests for the 
determination of HDR status (i.e. Myriad and Foundation Medicine’s assays) evaluate 
“genomic scars” based on genomic footprints, that have been accumulating during the 
historical evolution of the tumour and do not catch the determinants of response in “real-
time”, such as revertant mutations that restore HR proficiency; this likely explains their low 
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predictive capacity, proven in clinical trials where they were used (Coleman et al., 2017; 
Mirza et al., 2016b; Pellegrino et al., 2019). 
Starting from these considerations, we explored two possible DNA repair functional 
readouts: the evaluation of RAD51 foci as a surrogate marker of HR activity and 
ERCC1/XPF complex in IHC as surrogate markers for NER. Their quantification in our 
PDX platform was then correlated with both DDP and olaparib sensitivity.  
The induction of RAD51 foci after DNA damage has been generally considered a readout of 
a competent HR repair and indeed these tests have been correlated with HR activity and 
response to neoadjuvant and PARPi therapy in breast and ovarian fresh tumours or primary 
cultures or FFPE biopsies, collected close to therapy administration (Graeser et al., 2010; 
Mukhopadhyay et al., 2010; Shah et al., 2014). However, recently, a method able to quantify 
RAD51 foci and to predict the response to olaparib has been published, which does not 
require the induction of DNA damage (Castroviejo-Bermejo et al., 2018a; Cruz et al., 2018). 
In fact, in this method the number of RAD51 foci was evaluated in tumour cells geminin 
positive, indicating cells in the S/G2 phase of the cell cycle, where the HR repair takes place. 
We tried two different approaches. We quantified the basal expression of RAD51 foci 
(minimum 5 foci per nucleus) in all the β-catenin positive cancer cells of PDX tissues 
included in a TMA. The imaging acquisition was performed with a confocal microscope and 
the analysis by dedicated software. In this condition, neither of the evaluable PDXs 
expressed more than 2% of cells positive to RAD51 foci and there was also a great variability 
between the duplicates available for each PDX in the TMA. We did not find any significant 
correlation between RAD51 foci quantified with this method and response to therapy. In 
parallel, we applied on FFPE PDXs tumour specimens the method described by Cruz et al., 
where RAD51 foci were quantified only in proliferative/geminin positive cancer cells and  
the evaluation was performed by the operator with a fluorescent microscope. Geminin is a 
pan nuclear protein expressed during the S/G2 phase of the cell cycle, so, we evaluated the 
RAD51 foci only in the subgroup of proliferating cells, where the HR is effectively active. 
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γH2AX nuclear foci have been quantified to verify the presence of endogenous damage, and 
our PDXs showed high levels of γH2AX foci, in accordance with the genomic instability, 
which is a hallmark of EOC (Prat et al., 2018; Vanderstichele et al., 2017). Besides RAD51 
foci, also BRCA1 foci have been quantified following the same criteria, as an additional 
marker of HR status. We quantified the % of positive cells in the PDXs analysed (those with 
≥5 foci per nucleus and geminin +), and then we divided tumours in RAD51 or BRCA1 
positive or negative, based on the % of positive cells quantified in the tumour (i.e. RAD51 
positive tumours had ≥10% of RAD51+/GEM+ cells; BRCA1 positive tumours had ≥35% 
of BRCA1+/GEM+ cells). We then correlated the expression of positive cells with DDP and 
olaparib response (analysis in continuous), as well as the correlation between tumours 
classified as RAD51 and BRCA1 positive/negative and response to therapy (analysis per 
trend). We found that low positivity for RAD51 and BRCA1 foci predicted response to 
olaparib, but not to DDP, both in continuous and in trend analyses. These data confirmed the 
importance of evaluating RAD51 foci in the subgroup of proliferating cells with sensitive 
techniques. In addition, our results demonstrated that this test does not predict the response 
to DDP. The fact that the % of RAD51+/GEM+ cells was not able to predict DDP response, 
suggests that the analysis of foci alone is not sufficient to capture the complexity of DDP-
induced DNA damages, whose repair does not involve only HR, but many other pathways 
(Enoiu et al., 2012; Rocha et al., 2018; Slyskova et al., 2018; Wang et al., 2011). 
Considering the importance of BER and NER pathways in the repair of DNA damage caused 
by platinum agents (Galluzzi et al., 2014; Martin et al., 2008; Slyskova et al., 2018), we tried 
to elucidate the role of POLB, ERCC1 and XPF in response to DDP. These proteins are 
among the most studied effectors of these two DNA repair pathways, even if their predictive  
role in DDP response has been reported to be contrasting (Alvisi et al., 2020; Steffensen et 
al., 2014, 2009). We evaluated these three factors as mRNA and protein expression levels 
and, for the first time, we analysed the expression of the active ERCC1/XPF complex, a 
heterodimer acting as endonuclease, whose activity is a critical step in the NER pathway, in 
215 
 
relation with DDP response. Again, the complex was quantified at baseline, not treated 
conditions, in all the PDXs available in the TMA. Its quantification was performed using the 
proximity ligation assay (PLA), a technique able to identify the presence of two proteins 
forming a complex. The levels of ERCC1, XPF and POLB (both mRNA and protein) were 
not associated with DDP response; in addition, neither the ERCC1/XPF complex expression 
could predict the sensitivity to platinum treatment. These latter negative data could be 
partially explained by the fact that an induction of ERCC1/XPF complex was found after 
treatment of cells in vitro with cytotoxic doses of DDP suggesting that ERCC1/XPF 
induction could be a better biomarker of DDP response.  
All the experiments described in this thesis were done using all the PDXs samples we have 
available in our xenobank, which currently represents one of the largest collections of EOC-
PDXs described in literature. However, we are consciousness that our statistical analyses 
suffered from the lack of preliminary tests aim to determine the sample size necessary to 
yield a certain power for a test, given a predetermined Type I error rate α. This aspect will 
necessary be taken in consideration in the future experiments aimed to validate the results 
obtained until now, in order to ameliorate the experimental design and to enforce the power 
of the study.  
At present, there is an urgent need for biomarkers and functional assays able to predict the 
response to therapy of EOC patients and our xenobank represents a valid tool to perform 
preclinical experiments aimed to elucidate the role of potential biomarkers and to test new 
predictive assays. For the first time, we evaluated the predictive potential of RAD51 foci 
expressed in untreated FFPE EOC-PDXs, in relation with olaparib response, confirming 
previous data reported in breast cancer models (Castroviejo-Bermejo et al., 2018b). These 
results need to be corroborated using FFPE biopsies of patient tumours and could be easily 
evaluated in the clinical setting by using standardized techniques. Unfortunately, it was not 
able to predict DDP response.  
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It will be certainly interesting in the near future to set up other functional assays to be used 
as predictive biomarkers as these better represent the DNA repair capacity of the tumour 
cells. Recently, the fiber assay, that evaluates the replication fork stability, has been 
associated with carboplatin response in HGSOC organoids (Hill et al., 2018). However, this 
assay also suffers from the fact that live cells are needed and it cannot be applied in FFPE 
tumour samples.  
DNA repair is an important determinant of tumour response to chemotherapy, but it is not 
the sole determinant. In addition, ovarian carcinomas present unique and highly variable 
combinations of copy number aberrations and different cancer clones and it could be that a 
single IHC analysis could be insufficient to capture the complexity of tumour response to 
therapy. More specific methodologies, such as single-cell multi-omics and parallel 
deconvolution of the mutational and epigenetic traits of individual cancer cells (Marusyk et 
al., 2020) and the setting up of liquid biospies through out the entire patients clinical history 
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